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Abbreviations 
ACCESS  A Case Control Etiologic Study of Sarcoidosis 
ADR  adverse drug reaction 
Ag  antigen 
AIP acute interstitial pneumonia 
ANCA  anti-neutrophil cytoplasmic antibody  
ANF  antinuclear factor 
APC  antigen presenting cell  
BAL  bronchoalveolar lavage 
BALF  bronchoalvealar lavage fluid 
BHL  bilateral hilar lymphadenopathy 
BMI  body mass index 
BS  buccal swab 
BTNL2  butyrophiline-like 2 
CARD15  caspase recruitment domain 15 
CI  confidence interval 
CNS  central nervous system 
COP cryptogenic organizing pneumonia 
COX2  cyclooxegenase-2 
CR1  complement receptor 1 
CT  computed tomography 
CTD-ILD connective tissue disease-associated interstitial lung disease 
CV  variation of confidence 
CXR  chest X-ray 
CYP  cytochrome P450 
CYP1A2  cytochrome P450 1A2  
CYP2C9  cytochrome P450 2C9  
CYP2C19  cytochrome P450 2C19  
CYP2D6  cytochrome P450 2D6  
CYP3A4  cytochrome P450 3A4  
CYP3A5  cytochrome P450 3A5  
DAH  diffuse alveolar hemorrhage 
DBS  dried blood spot 
DI-ILD  drug-induced interstitial lung disease 
DIP desquamative interstitial pneumonia 
DLCO  diffusing capacity for carbon monoxide 
DNA  deoxyribonucleic acid 
EDTA  ethylenediaminetetraacetic acid 
EM  extensive metabolizer 
FDA Food and Drug Administration 
FEV1  forced expiratory volume in one second 
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FRET  fluorescence resonance energy transfer 
FVC  forced vital capacity 
Hb  hemoglobin 
HLA  human leukocyte antigen 
HP hypersensitivity pneumonitis 
HRCT  high resolution computed tomography 
Ht  hematocrit 
HT  heterozygote 
IFN-γ  interferon-gamma 
IL  interleukin 
ILD  interstitial lung disease 
IM  intermediate metabolizer 
INR  international normalized ratio 
IPF  idiopathic pulmonary fibrosis 
LAM lymphangioleiomyotosis 
LD  lactate dehydrogenase 
LIP lymphocytic interstitial pneumonia 
LTA  lymphotoxin alpha 
MHC  major histocompatibility complex 
MT  mutation 
MTHFR  methylenetetrahydrofolate reductase 
MTX  methotrexate 
MUMC  Maastricht University Medical Centre 
NE  norepinephrine 
NSIP  non-specific interstitial pneumonia 
ODV  O-desmethylvenlafaxine 
OR  odds ratio 
PAP pulmonary alveolar proteinosis 
PCR  polymerase chain reaction 
PM  poor metabolizer 
RA  rheumatoid arthritis 
RB-ILD respiratory broncheolitis 
RFI respiratory functional impairment 
RFLP  restriction fragment length polymorphism 
SD  standard deviation 
SNP  single nucleotide polymorphism 
SNRI  serotonin-norepinephrine reuptake inhibitor 
SSO sequence specific oligonucleotides 
SSP sequence specific primers 
TDM  therapeutic drug monitoring 
TGF-β  transforming growth factor beta 
Th1  T-helper cell 1 
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TLR2  Toll-like receptor 2 
TNF-α  tumor necrosis factor alpha 
TPMT  thiopurine methyltransferase  
UM  ultra-extensive metabolizer 
US  United States 
UV  ultra violet 
VEGF  vascular endothelial growth factor 
VKORC1  vitamin K epoxide reductase complex 1 
vs versus 
WASOG  World Association of Sarcoidosis and Other Granulomatous 
diseases 
WT  wild type 
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Introduction 
Interstitial lung diseases 
Interstitial lung diseases (ILD) are a rapidly growing and increasingly complex 
component of clinical practice. They represent a group of heterogeneous 
disorders that diffusely involve the lung parenchyma. The term ’interstitial‘ was 
originally applied to these disorders because they are associated with 
thickening of the alveolar septum. The ’interstitium‘ is that part of the alveolar 
structures bounded by the alveolar epithelial and endothelial basement 
membranes. The normal alveolar interstitium is composed of connective tissue 
components (e.g. collagen, elastic fibers, mesenchymal cells), and 
inflammatory and immune effector cells (monocytes/macrophages and 
lymphocytes). Generally, ILD involve alveolar epithelial and endothelial cells as 
well. In addition, although these diseases primarily attack the alveolar 
structures (inflammation and fibrosis), many also involve airways, arteries and 
veins.1,2 ILD can lead to diffuse remodelling and architectural damage to 
normal lung tissue and progressive loss of lung function.  
Although idiopathic pulmonary fibrosis (IPF) and sarcoidosis are the two most 
common forms of ILD encountered in clinical practice, well over 100 different 
types of ILD have been identified on the basis of clinical presentation, 
radiographic findings, and histopathologic examination.3-5 The patient’s age, 
cigarette-smoking status, and gender will provide useful clues. IPF for example 
is almost always an adult disorder, typically occurring in patients over 60 years 
of age. Patients with idiopathic non-specific interstitial pneumonia (NSIP) of the 
fibrotic variety are usually younger than 60 years of age. Although pulmonary 
sarcoidosis can manifest in the elderly patient, it is more common in young 
adults and middle-aged people. Respiratory bronchiolitis associated with ILD 
(RB-ILD) is seen almost exclusively in cigarette smokers, but it can occur in 
both men and women of all ages. In contrast, the very rare disorder 
Lymphangioleiomyomatosis (LAM) occurs exclusively in women of childbearing 
age.  
A detailed occupational history and changes in domestic environment are also 
essential, as it may lead to identification of a specific inhalation cause or trigger 
for ILD. At-risk occupations for ILD include miners (pneumoconiosis); 
sandblasters and granite workers (silicosis); dental workers (dental workers’ 
pneumoconiosis); welders, shipyard workers, pipe fitters, electricians, and 
mechanics (asbestosis); farm workers, poultry workers, bird fanciers, and bird 
breeders (hypersensitivity pneumonitis); and workers in aerospace, nuclear, 
computer, and electronics industries (berylliosis). History of existing, persistent 
and/or altered environmental ‘fibrogenic’ factors at home, the workplace, in 
automobiles or frequently visited facilities/homes or hobbies such as exposure 
16⏐Chapter 1 
to birds, moulds, woodworking, use of sauna and hot tubs are often ignored 
but equally important and may provide a useful clue for specific diagnosis and 
management of hypersensitivity pneumonitis.6  
An overview of the different diseases, also known collectively as ILD, is shown 
in Table 1.1. 
 
Table 1.1 Interstitial Lung Diseases (ILD). 
ILD of known causes Drug-Induced (DI-ILD)* 
 Asbestos 
 Beryllium 
 Radiation Fibrosis 
 Silicosis 
 Infection 
Idiopathic interstitial pneumonia (IIP) Idiopathic Pulmonary Fibrosis (IPF) 
 non-IPF IIP:  
 • Familial Pulmonary Fibrosis 
 • Desquamative Interstitial Pneumonia (DIP) 
 • Acute Interstitial Pneumonia (AIP) 
 • Non-specific Interstitial Pneumonia (NSIP) 
 • Cryptogenic Organizing Pneumonia (COP) 
 • Lymphocytic Interstitial Pneumonia (LIP) 
 • Respiratory Bronchiolitis (RB-ILD) 
Granulomatous ILD Sarcoidosis 
 Histiocytosis-X 
 Hypersensitivity Pneumonitis (HP) 
Other Diffuse Alveolar Hemorrhage (DAH) 
 Connective Tissue Disease-associated ILD  
(CTD-ILD) 
 Eosinophilic Pneumonia 
 Lymphangioleiomyomatosis (LAM) 
 Pulmonary Alveolar Proteinosis (PAP) 
 Wegener’s granulomatosis and other vasculitidies 
* the ILD with bold typeface will be addressed in the coming chapters. 
 
Drug-induced interstitial lung disease 
Drug-induced interstitial lung disease (DI-ILD) is the most common form of 
drug-induced respiratory disease. The drugs involved not only include 
prescribed and over-the-counter-drugs, but also illicit drugs, herbs, alcohol, 
and dietary ingredients.7-10 An ever increasing number of drugs can produce or 
reproduce variegated patterns of naturally-occurring infiltrative lung 
disease.7,9,11 Although, only in a limited number of cases drugs unequivocally 
have been identified as cause, it is important to acknowledge the potential role 
of medication in the development of drug-induced ILD.7,12 This is due to the 
severity of the potentially irreversible damage to the lungs and the 
improvement that is often easily achieved by stopping administration of drugs. 
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Rational treatment of drug-toxicities in cases where the mechanism of toxicity 
is known is common clinical practice. However, often the connection with drug-
use and the development of related inflammatory damage or idiosyncratic 
toxicities is hard to recognize and objectify, especially in those cases using 
multiple drugs.13 Furthermore, the list of drugs involved has grown rapidly over 
the last decades. An example of a drug-induced ILD, in this case caused by 
nitrofurantoin, is shown in Figure 1.1. For a list of the most important 
categories of substances which can cause respiratory problems with some 
examples see Table 1.2, and also www.pneumotox.com for an extensive 
overview of drugs known to be able to damage the respiratory system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  A                                                        B   
Figure 1.1 Chest X-ray (A) showing a diffuse interstitial pattern and a high resolution CT-scan (B) 
demonstrating thickened septa and patchy ground-glass opacities of a patient with drug-
induced interstitial lung disease associated with nitrofurantoin. 
 
 
Table 1.2 Summary of the categories of substances known to cause respiratory problems with 
some examples of the possible causative agents. 
Drugs* (illicit) Biomolecules Blood/Stem-cells Herbs/Dietary  
   supplements 
Miscellaneous 
Amiodarone Interferons Retinoic acid Ephedra Talc 
Cocaine Immunoglobulins Blood products Comfrey Silicone 
Methotrexate Anti-thymocyte  
   globuline 
Stem-cell  
   transplantation 
Germander Mineral oil 
Nitrofurantoin  Blood transfusion Aristolochic acid  
Methadone     
Oral anticoagulants     
*see appendix for a complete list of drugs and other substances involved, sorted by CYP enzymes. 
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Diffuse alveolar hemorrhage 
Diffuse alveolar hemorrhage (DAH) can be a fulminant and often fatal bleeding 
complication, but can also occur as an almost sub-clinical condition with a 
pneumonia-like manifestation. DAH results in accumulation of iron in the lungs 
and, in turn, iron causes oxidative stress and inflammation. It has been 
suggested that oxidative damage plays a role in the pathophysiology of various 
diseases.14 It is important to prevent or recognize DAH at an early stage to 
avoid irreversible damage. Particularly, in critically ill patients with unexplained 
infiltrates, DAH should be considered. DAH events can occur as a result of 
over-anticoagulation due to coumarin sensitivity, resulting in a relative vitamin 
K deficiency. It can also occur as a result of the ingestion or inhalation of so-
called super-warfarines, (illicit) drugs or toxic fumes.15-18 An example of a lung 
with DAH is shown in Figure 1.2 and the histological aspect is illustrated in 
Figure 1.3A. At present, the diagnosis of DAH is often made by observing an 
increased percentage of siderophages (iron-positive macrophages, >20%) in 
bronchoalveolar lavage fluid (BALF), indicated with Perl’s staining, as shown in 
Figure 1.3B.19  
 
  
 
   
          B            A          C 
 
 
Figure 1.2 Chest X-ray (A) and high resolution CT-scan (B/C) of a patient suffering from diffuse 
alveolar hemorrhage (DAH) showing widespread ground-glass attenuation. 
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 A                                                       B 
  
Figure 1.3 Histological appearance (A) of diffuse alveolar hemorrhage (DAH). Acute phase of DAH: 
alveolar walls with interstitial oedema, congested capillaries, and hyaline membranes 
with regenerating alveolar epithelium underneath. Perls’ stained bronchoalveolar lavage 
(BAL) fluid cells (B; dark grey=positive). 
 
Sarcoidosis 
Sarcoidosis is a systemic granulomatous disorder of unknown cause, 
characterized by the presence of noncaseating granuloma, see Figure 1.4 for a 
schematic presentation of granuloma formation.20,21  
Sarcoidosis occurs throughout the world, affecting all genders, races and ages. 
However, several studies demonstrated a peak incidence of the disease 
occurring in individuals ranging between 25–55 years of age, with a greater 
presence of men in the under 40-years of age category.22,23 Epidemiologic 
studies regarding the incidence, prevalence, and mortality rates of sarcoidosis 
are difficult because of the highly variable disease presentation24 and the lack 
of a known etiology. Regional variabilities due to race and gender, as well as 
phenotypic variability, further confound epidemiological measurements. 
Involvement of the lungs or intrathoracic lymph nodes is clinically evident in 
90% of the symptomatic patients during their disease and up to 30% show 
spontaneous remission.25 In 10-30% of the patients the disease becomes 
chronic, what can result in significant lung function impairment.26,27 The 
diagnosis of sarcoidosis is often one of exclusion of other diseases and involves 
biopsies and chest X-rays (CXR) or high resolution computed tomography 
(HRCT) scans. Five stages of the radiographical abnormality were recognized: 
stage 0 (normal CXR), stage I (bilateral hilar lymphadenopathy [BHL]), stage II 
(BHL and parenchymal abnormalities), stage III (parenchymal abnormalities 
without BHL), and stage IV (end stage lung fibrosis), see also Figure 1.5.28 An 
acute form of sarcoidosis is the so-called Löfgren’s syndrome with distinct skin 
(Erythema nodosum) and lung (CXR stage I) presentation. 
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Figure 1.4 A schematic presentation of granuloma formation in sarcoidosis. 
  Ag=antigen; APC=antigen presenting cell; IFN-γ=interferon-gamma; IL=interleukin; 
Th1=T-helper 1; TNF-α=tumor necrosis factor alpha; TGF-β=transforming growth factor 
beta (adapted from Moller29). 
 Hypothetical model of the pathogenesis of sarcoidosis. An antigen induces antigen-
specific, Th1-mediated granulomatous inflammation with production of Th1 cytokines 
(IFN-γ, IL-2). Granuloma formation is set in motion by activated macrophages and 
T-cells along with other effector cells (e.g. fibroblasts) under the regulatory influence of 
local cytokine production. Removal of the antigen allows TGF-β to downregulate the 
immune response. 
 
 
Although the specific trigger of sarcoidosis is still unknown, there appear to be 
some pre-requisites to develop the condition. The first being predisposition, the 
second is exposure and the third circumstances. The (genetic) predisposition 
appears to be not dependent upon a single gene and/or polymorphism, for in 
TNF-α 
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several studies a range of different polymorphisms have been investigated and 
found to have an influence on the contracting or progression of the disease.30-36 
In Table 1.3 an overview is presented of some of the most common 
polymorphisms and triggers that have been associated with sarcoidosis, but up 
until now no single agent or trigger stands out as cause.  
 
Table 1.3 An overview of some of the polymorphisms and triggers that have been associated with 
sarcoidosis. 
HLA TNF various triggers/jobs/exposure 
DRB1*03 TNF-α G-308A BTNL2 G16043A health care workers 
DRB1*1501 TNF-α G-238A BTNL2 G16071A firefighters/fumes 
DQB1*0602 TNF-α C-857T CARD15 C2104T teachers/chalk 
  CARD15 A1761G insecticides/pesticides 
  CR1 C5507G molds/(agricultural) dust/clay 
  VEGF C813T manmade fibers 
   bacteria 
   metals (e.g. aluminum, zirconium) 
   talc 
 
 
  
 
 
 
 
 
                                                   A 
 
 
 
 
 
 
 B                                C                                 D                               E 
 
 
Figure 1.5 Chest X-ray (CXR) stages 0-IV: radiographic appearances of sarcoidosis. 
 (A) Stage 0 (5-15%): normal chest radiograph; (B) Stage I (45-65%): bilateral hilar 
lymphadenopathy (arrows), without evidence of interstitial lung disease; (C) Stage II 
(30-40%): both lymphadenopathy and parenchymal abnormalities (nodular and 
reticulonodular opacities); (D) Stage III (10-15%): parenchymal infiltration without hilar 
lymph node enlargement (reticulonodular infiltrates); (E) Stage IV (15-25%): obvious 
interstitial abnormalities with fibrotic lesions. 
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Polymorphisms 
The human DNA comes with faults (mutations) that can influence the function 
of a protein or enzyme. Mutations are random mistakes and they are called 
polymorphisms whenever the DNA mutation occurs in more than one percent 
of the population. A polymorphism can affect the function of a protein in a 
positive or negative manner, depending on where it is positioned or what its 
effect on the length or amino acid build-up of the final protein is. For example, 
a polymorphism that causes a so-called stop codon in the coding region of the 
protein will produce a truncated protein that almost always has a severely 
altered function or no functionality left at all. Whereas a polymorphism in the 
promoter region of the protein, for instance, can cause a heightened rate of 
production of the protein involved. 
Polymorphisms and, more specific single nucleotide polymorphisms (SNP), can 
be investigated using different PCR methods or detection techniques (e.g. 
restriction fragment length polymorphism (RFLP) using restriction enzymes, or 
real-time PCR assays using fluorescence resonance energy transfer (FRET) or 
hydrolysis probes). In the studies presented in this thesis SNPs were detected 
using melting point analysis with fluorescent hybridization probes using the 
FRET principle. This detection method uses the properties of a donor 
fluorophore that transfers its energy to an acceptor that has to be in close 
proximity (no more than three base pairs apart) in order to accept the energy 
and emit at a different wavelength when returning to its ground state. The 
FRET principle is visually explained in Figure 1.6 and an example of the melting 
curve results obtained when running a FRET assay on a LightCycler® are shown 
in Figure 1.7. In the upper part of Figure 1.7 the lessening of the fluorescence 
signal as the temperature of the samples was raised is clearly visible. This rise 
in temperature (the so-called melting) will cause the probes to be melted off 
their complementary piece of DNA. Moreover, because the distance of the two 
fluorophores in that situation will become more than the required maximum of 
three base pairs, FRET is no longer possible and a reduction of signal is 
apparent (Figure 1.6). As the probes that spans the SNP is complementary, 
either to the wild type DNA or to the SNP one wishes to examine, more heat is 
needed to melt it off when the fit is perfect. So when both alleles 
(heterozygote) are present, one part of the probes will melt off at a lower 
temperature than the other. When applying the first derivative to these melting 
curves, the bottom part of Figure 1.7 is produced and the different melting 
temperatures will be more clearly visible as separate peaks. In the shown 
example the used probe spanning the SNP was complementary to the wild 
type, therefore producing a peak for the mutation at a lower temperature.  
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Figure 1.6 Principle of fluorescence resonance energy transfer (FRET) assays. 
 
 
 
       A 
 
 
 
 
 
 
 
 
 
      B 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Results of a cytochrome 2C19 assay, with melting curves (A) and the first derivative (B). 
MT=mutation (CYP2C19*2/*2), HT=heterozygote (CYP2C19*1/*2), WT=wildtype 
(CYP2C19*1/*1). 
 
Excitation
Excitation
Emission
Non-measured
emission
FRET
Annealing
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Scope and aims of the study 
The aims of the studies presented in this thesis were to investigate several 
polymorphisms and assess their possible role in the cause and course of 
interstitial lung disease (ILD). ILD, especially drug-induced ILD (DI-ILD), can 
occur as a cause of drug(s) or drug-drug interactions. The CYP enzyme family 
plays an important role in the metabolization of all sorts of ingested or inhaled 
xenobiotic substances. In Chapter 2 the possible role of cytochrome P450 
(CYP) enzymes in DI-ILD is reviewed. Chapter 3 describes a simple and 
uncomplicated method to isolate DNA from easy obtainable and patient friendly 
dried blood spot and/or buccal swab samples prior to real-time polymerase 
chain reactions (PCR). The aim of Chapter 4 was to establish whether allelic 
variation in specific CYP polymorphic genes, namely CYP2D6, CYP2C9, and 
CYP2C19, contributes to variability in drug response and unexpected toxicity. 
Therefore, a case-control study was conducted. The cases consisted of patients 
with DI-ILD. Two control groups were used: one group of healthy volunteers 
and one group of patients with idiopathic pulmonary fibrosis (IPF). In Chapter 
5 the role of CYP polymorphisms is further illustrated in the case-report 
describing the therapeutic failure of venlafaxine in a case lacking CYP2D6 
activity. In Chapter 6 it was hypothesized that in patients treated with 
coumarins a serious complication i.e. diffuse alveolar hemorrhage (DAH) may 
be associated with vitamin K epoxide reductase complex 1 (VKORC1) and CYP 
(CYP2C9 and CYP2C19) variant alleles. Clinical information of patients using 
coumarins with at least one episode of DAH was gathered retrospectively 
during a seven year period. The aim of Chapter 7 was to evaluate the 
relationship between the presence of tumor necrosis factor (TNF) 
polymorphisms, human leukocyte antigen (HLA)-DRB1*03 linkage and the 
prognosis of sarcoidosis. In a retrospective case-control study TNF-α G-308A, 
TNF-α G-238A and LTA were genotyped in 625 sarcoidosis patients. These 
patients were classified into patients with persistent disease and patients with 
non-persistent disease using chest X-ray appearances and lung function 
parameters after at least two years of follow-up. The aim of Chapter 8 was to 
assess the association of butyrophilin-like 2 (BTNL2) G16071A with the course 
of pulmonary sarcoidosis and verify association with disease predisposition. In 
addition, the linkage between BTNL2 G16071A and certain HLA-DRB1/DQB1 
types was investigated. In a retrospective case-control study BTNL2 G16071A, 
HLA-DQB1 and DRB1 were typed in 632 sarcoidosis patients. These patients 
were classified into 304 patients with persistent and 328 patients with non-
persistent sarcoidosis using chest X-ray stages after at least two years follow-
up. Finally, in Chapter 9, a summary and the implications of the findings 
presented in this thesis are argued and directions for future research are briefly 
discussed. 
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Abstract 
Background  
Interstitial lung disease and especially drug-induced interstitial lung disease can occur as 
a cause of drug(s) or drug-drug interactions. In this review we summarize the possible 
role of cytochrome P450 (CYP) enzymes in drug-induced interstitial lung disease. 
 
Recent findings  
The CYP enzyme family plays an important role in the metabolization of all sorts of 
ingested, injected or inhaled xenobiotic substances. Although the liver is considered to be 
the major metabolization site of CYP enzymes, in recent years more CYP isoforms have 
been detected in lung tissue. Polymorphisms in these CYP genes can influence the 
metabolic activity of the subsequent enzymes, which in turn may lead to localized (toxic) 
reactions and tissue damage. 
 
Summary  
Drug toxicity can be the consequence of no or very poor enzyme activity, especially if no 
other metabolic route is available. In case of reduced enzyme activity, dose reduction or 
prescribing an alternative drug metabolized by a different, unaffected CYP enzyme is 
recommended to prevent toxic side effects. Therefore, knowing a patient’s CYP profile 
before drug prescription could be a way to prevent drug-induced interstitial lung disease. 
Moreover, it might be helpful in explaining serious adverse effects from inhaled, injected 
or ingested xenobiotic substances.  
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Introduction 
The lungs are a target for a variety of xenobiotic and possible toxic substances, 
because of their large contact surface with both the outside world and 
circulating blood. Air can deliver (mineral) particles or (toxic) fumes and blood 
is the main supplier of most drugs, independent of the way of administration. 
Moreover, they form not only an important first point of contact or barrier, but 
also can act as a metabolization site for certain substances. Drugs can induce 
specific respiratory reactions, or the lungs may be affected as part of a 
generalized response. The most common form of drug-induced respiratory 
disease is drug-induced interstitial lung disease (DI-ILD). The drugs involved 
not only include prescribed and over-the-counter-drugs, but also illicit drugs, 
herbs, alcohol, and dietary ingredients.1-4 An ever increasing number of drugs 
can produce or reproduce variegated patterns of naturally occurring infiltrative 
lung disease, including most forms of interstitial pneumonias, alveolar 
involvement, and, rarely, vasculitis.1,3,5 Although, only in a limited number of 
cases drugs unequivocally have been identified as cause, it is important to 
acknowledge the potential role of medication in the development of DI-ILD.1,6 
This is due to the severity of the potentially irreversible damage to the lungs 
and the improvement that is often easily achieved by stopping administration 
of drugs. Rational treatment of drug-toxicities in cases where the mechanism of 
toxicity is known is common clinical practice. However, often the connection 
with drug-use and the development of related inflammatory damage or 
idiosyncratic toxicities is hard to recognize and objectify, especially in those 
cases using multiple drugs.7 
The aim of this review is to discuss drug-induced respiratory reactions and the 
possible mechanisms involved, focussing on the role of cytochrome P450 (CYP) 
polymorphisms. 
Drugs and lungs 
The diagnosis of DI-ILD primarily rests on the temporal association of exposure 
to drug(s), and the development of respiratory symptoms. It is also clinically 
challenging, especially when trying to find predictors for the possibility that an 
individual is at risk for developing such a reaction, and moreover, in avoiding 
re-challenge with the trigger. For an overview of drugs known to be able to 
damage the respiratory system see www.pneumotox.com. In some cases the 
evidence that reactions in the lungs are drug-induced is circumstantial.1 A 
straightforward interpretation is hampered when the damage is irreversible or 
when the symptoms aggravate after stopping drug administration. Thus, the 
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diagnosis of DI-ILD is mainly one of exclusion and requires the meticulous 
ruling out of all other possible causes.  
The variability in drug response among patients is multi-factorial, including 
extrinsic factors like environmental aspects and also genetic and intrinsic 
factors that affect the disposition (absorption, distribution, metabolism and 
excretion) of a certain drug (Table 2.1). The existence of large population 
differences with small intra-individual variability is consistent with inheritance 
as determinant of drug response; it is estimated that genetics can account for 
20-95% of variability in drug disposition and effects, see also Figure 2.1.8 
 
Table 2.1 Factors influencing drug metabolism. 
Environment Smoking 
Diet 
Alcohol 
Inhalation of (toxic) fumes 
Extrinsic factors 
Drug use Prescribed drugs 
Illicit drugs 
Over the counter drugs 
Herbal supplements 
Concomitant drugs 
Demographic Gender 
Age 
Race 
Intrinsic factors 
Disease Disturbed kidney excretion function 
Diminished liver blood perfusion 
Changed metabolic function 
Genetic factors  Polymorphisms in genes encoding for metabolic enzymes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Drug response in a population. 
 Patients with the same diagnosis and treated with the same medication. Most patients 
react well (white), some of the patients do not respond to the therapy (grey) and some 
react with adverse reactions or toxicity (black). 
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Two metabolization routes (phase I and phase II reactions) are responsible for 
the transformation of the majority of xenobiotic substances, with the purpose 
of facilitating elimination from the body. Phase I reactions, performed mainly 
by CYP enzymes, involve hydroxylation, reduction and oxidation while in phase 
II reactions glucuronidation, sulfation, acetylation or methylation take place. 
The risk of developing DI-ILD and clinical patterns vary, depending on a variety 
of host and drug factors. Several different xenobiotic-metabolizing CYP and 
phase II enzymes are present in the human lung, possibly contributing to in 
situ activation. Metabolism also affects the biological activity of the drug. 
Mostly, the biological activity of the parent drug is superior to that of the 
metabolite, but there are several exceptions. Sometimes CYP metabolism yields 
very toxic metabolites, e.g. acetaminophen, benzo[a]pyrene or 
carbamazepine.9 Occasionally, drugs may cause the formation of reactive 
oxygen species by uncoupling of the electron transport of the CYP system. 
These metabolites or reactive oxygen species may damage vital cellular 
components, such as proteins, lipids or DNA.  
CYP enzymes 
The most common DNA variations in the human genome are called single 
nucleotide polymorphisms (SNPs). The presence of certain SNPs can result in a 
less functional enzyme and a subsequently changed, i.e. slower, metabolization 
for certain drugs. SNPs in the CYP genes are one of the key factors known to 
cause variation in drug response between individuals.2,3,7-11 In recent years 
more CYP enzymes were detected within lung tissue. Local metabolization, or 
rather the lack of metabolization in some cases, might explain adverse 
reactions and subsequent tissue damage in the lungs.2,10,12-14  
With the widespread possibility to determine the genetic profile of the CYP 
enzymes, their metabolic capacity can be determined. Patients can be divided 
into ultra-extensive (UM), extensive (EM), intermediate (IM) or poor 
metabolizers (PM).15  
The most important CYP enzymes for drug metabolism are CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, and CYP3A5. This review will focus on clinical 
relevance and prevalence of CYP polymorphisms that are also important in 
relation to the lungs (Table 2.2).  
The completion of the sequence of the human genome revealed the presence 
of 115 human CYP genes: 57 active and 58 pseudo-genes.16 The CYP enzymes 
are a superfamily of hemoproteins found in a wide range of different organs 
and tissues.9,17-21  
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Table 2.2 CYP distribution and metabolic activity in the liver and presence in lung tissue. 
CYP % Distribution % Metabolic activity Presence in the lung 
3A 30 55 +++ 
2C 20 10 ++ 
1A2 13 2 + 
2E1 7 1.5 +++ 
2A6 4 1.5 +++ 
2D6 2 30 ++ 
 
 
CYP proteins are conveniently arranged into families and subfamilies on the 
basis of percentage amino acid sequence identity.22 Figure 2.2 illustrates an 
example of CYP enzyme nomenclature, see also www.cypalleles.ki.se for an 
overview of human CYP allele nomenclature. The CYP isoenzymes in families 
1-3 are responsible for 70-80% of all phase I-dependent metabolism of 
clinically used drugs and also participate in the metabolism of a large number 
of xenobiotic substances.23-25 
Substances (medicines or other compounds) that are metabolized by CYP 
enzymes are called substrates. Inhibitors can reduce the action of a 
cytochrome, while so-called inducers can enhance the metabolism of a specific 
CYP enzyme. 
The metabolic capacity of the different CYP enzymes is also defined as low 
affinity/high capacity or high affinity/low capacity. The CYP2D6 enzyme is, like 
CYP2C9 and CYP2C19, defined as a high affinity/low capacity, which implies 
that these CYP enzymes prefer to metabolize specific substrates at a low 
concentration. As the concentration of a medicine increases, the metabolism 
can possibly spill over to CYP3A4 and CYP1A2, which are low affinity/high 
capacity enzymes. 
Several CYP enzymes, important for metabolism in the liver, but also in the 
lungs, will be discussed in detail. 
 
 
 
 
 
 
 
 
Figure 2.2 An example of the nomenclature of CYP enzymes. 
 The fully functional allele is indicated with *1, whereas the variant alleles are indicated 
with higher allele numbers and result in an aberrant functioning enzyme. 
C Y P 3 A 5 *3
Family
Subfamily
Isoenzyme
Allele
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CYP1A2 
Until recently, CYP1A2 was assumed to be present exclusively in the liver, but 
with more sensitive techniques available it has been detected in other tissues, 
including the lungs.9,12,13 Sixteen variant alleles, not counting the 20 isotypes of 
the *1 allele, have been identified to date. The metabolic activity of CYP1A2 
consists primarily of hydroxylating and demethylating compounds through 
oxidative metabolism. Substrates for CYP1A2 metabolism are, e.g. caffeine26, 
theophylline, and naproxen.27 Used in combination with an inhibitor, grapefruit 
juice for example, serum levels of substrates may increase, with toxicity and 
adverse drug reactions (ADRs) as a possible result.28 Induction of the CYP1A2 
metabolism can be achieved by cruciferous vegetables such as Brussels 
sprouts, broccoli or cabbage, and charbroiled foods (burned meats). Another 
important inducer of CYP1A2 is tobacco smoke.29 
CYP1A2 is a low affinity/high capacity enzyme in contrast to CYP2D6, CYP2C9, 
and CYP2C19 in the metabolism of many drugs.30 Gender differences have 
been found in the Chinese population, with men having more CYP1A2 activity 
compared with women.31  
CYP2C9 
Of the CYP2C family, CYP2C9 is considered to be the most important isoform, 
being the largest contributor and responsible for the metabolic clearance of up 
to 15% of all drugs (among which a host of clinically important drugs such as 
NSAIDs, oral anticoagulants, and angiotensin II blockers) undergoing phase I 
metabolism.32 Most of the CYP2C9 activity in terms of drug metabolism takes 
place in the liver, but it is found in various other tissues.33 To date, 34 variant 
alleles of the CYP2C9 enzymes have been identified and Lee et al.34 determined 
that two of these CYP2C9 variant alleles, *2 (430T) and *3 (1075C), were 
found in 35% of the Caucasians. These CYP2C9 variant alleles are present 
much less frequently in African-Americans and Asians (about 2% and 5%, 
respectively).35 Patients with CYP2C9*2 or CYP2C9*3 variant alleles require 
lower doses of drugs metabolized by CYP2C9, because of the reduced activity 
of these common variants.36 
The only clearly recognized inducer of CYP2C9 is rifampicin. Moreover, in the 
case of concomitant rifampicin use, serum levels of drugs metabolized by 
CYP2C9 have been shown to reduce, by induction. In the case of e.g. warfarin 
use, this can lead to not enough anticoagulation and in turn could cause 
thrombotic events.37 
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CYP2C19  
CYP2C19 is found in many tissues, but predominantly in the liver were it 
accounts together with CYP2C9, for approximately 20% of the total CYP 
activity. Until recently, 26 different variant alleles for CYP2C19 were identified.38  
The prevalence of CYP2C19 enzyme polymorphisms differs significantly 
between ethnic groups. For example, the PM phenotype occurs in 2-6% of 
Caucasians, 10-20% of Africans, and in 15-30% of Asians.39,40 Variant alleles of 
CYP2C19 lead to reduced or no enzyme function. Determining the metabolizer 
phenotype may also help in the case of treatment with drugs that rely on 
CYP2C19. Rifampicin has been identified as an inducer of both CYP2C19 and 
CYP2C9.41 Other drugs (anti-convulsants and steroids) that typically induce 
other CYP enzymes may also induce CYP2C19, but to a lesser extent than 
CYP2C9 and CYP3A4.42 
CYP2D6 
Although CYP2D6 represents only 1-2% of the liver CYP isoenzymes by weight, 
it takes care of some 30% of its metabolic activity (Table 2.2).43,44 Next to its 
important role in the liver’s drug metabolism, CYP2D6 is also found in many 
other tissues, including the lungs.45,46 For many drugs, especially psychotropic 
drugs, CYP2D6 is considered a high affinity/low capacity enzyme, which implies 
that CYP2D6 will preferentially metabolize drugs at lower concentrations.47  
Until recently, 75 different variant alleles for CYP2D6 were identified. There are 
ethnic differences in the distribution of EMs, PMs, and UMs. PMs are present in 
approximately 5-14% of Caucasians.48,49 Bradford50 indicated that Asians, 
Pacific Islanders, Africans and African Americans have a higher percentage of 
reduced-function or non-functional CYP2D6 (40-50%) than do Caucasians 
(26%). UMs carry a duplication of a fully functional CYP2D6 allele which results 
in higher CYP2D6 enzyme levels. Due to these higher CYP2D6 enzyme levels, 
UMs require a higher daily dose to obtain a therapeutic drug blood level. UMs 
are generally rare representing 1-3% of the Caucasian population.51 
CYP2D6 is the main metabolic enzyme for a whole range of (psychotropic) 
drugs and the presence of a less functional enzyme can have serious treatment 
consequences or lead to severe ADRs.52,53 
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CASE: A 43-year-old female presented with a non-productive cough and dyspnoea. The chest 
X-ray (CXR) and high resolution CT-scan (Figure 2.3A) showed coarse reticular opacities indicative 
of ILD. She used metoprolol for her hypertension, flecainide as an antiarrhythmic, and fenfluramide 
for obesity. Bronchoalveolar lavage fluid (BALF) showed an increased number of cells, 
predominantly lymphocytes, and the presence of plasma cells and foamy alveolar macrophages 
(Figure 2.3B), indicative of hypersensitivity pneumonitis or DI-ILD. Lung biopsy specimens 
demonstrated non-specific interstitial pneumonia (NSIP) of the cellular type. The patient’s clinical 
condition deteriorated and artificial respiration was required for 6 weeks. She was treated with 
prednisone and fenfluramine was stopped. Hereafter, the clinical condition improved spectacularly 
and the CXR abnormalities resolved completely. Four years later, the patient’s initial complaints 
returned. Again, the CXR showed the earlier reported reticular opacities and BALF analysis 
revealed the aforementioned signs of DI-ILD. To date, dexfenfluramine was started six weeks prior 
to this admission. The first clinical deterioration was not recognized as DI-ILD related to 
fenfluramine. The second deterioration appeared after starting dexfenfluramine as adjuvant 
therapy for her obesity. At that time, a role for (dex)fenfluramine was assumed in the 
development of pneumonitis. In addition genotyping revealed a CYP2D6*1/*3 heterozygote 
variant. She used metoprolol and flecainide on a regular base. When another drug metabolized by 
the CYP2D6 system was added she deteriorated. Therefore, the use of various drugs metabolized 
by the same affected enzyme should be avoided, for this may result in significant accumulation of 
these drug(s), leading to toxic serum levels and severe side effects. Avoiding those drugs or dose 
reduction appeared to be beneficial in this patient and protected her from similar adverse effects 
until now. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 (A) High resolution CT-scan; (B) Foamy alveolar macrophage. 
 
 
Table 2.2 CYP distribution and metabolic activity in the liver and presence in lung tissue. 
CYP % Distribution % Metabolic activity Presence in the lung 
3A 30 55 +++ 
2C 20 10 ++ 
1A2 13   2 + 
2E1   7      1.5 +++ 
2A6   4      1.5 +++ 
2D6   2 30 ++ 
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CYP3A4 
To date, 20 CYP3A4 allelic variants have been identified. CYP3A4 is considered 
to be one of the most contributing CYP enzymes in all phase I drug 
metabolizations. In the liver the CYP3A enzymes make up about 30% of all 
CYPs present, but take care of about 55% of the metabolism. CYP3A4, 
together with CYP3A5, are considered to be the major forms present. 
Whenever the concentration of a substrate increases beyond the capacity of 
the main metabolizing CYP enzyme, the metabolism can spill over to CYP3A4, 
which is a low affinity/high capacity enzyme.  
The most common variant in the 5’-untranslated region is CYP3A4*1B, which is 
strongly associated with increased CYP3A5 expression in a study by Wojnowski 
et al.54 and also associated with enhanced CYP3A4 expression.55 Allelic 
frequencies range from 0% in Asians to 4-10% in Caucasians and 48-80% in 
African-Americans.56 Inducers of CYP3A4 are e.g. rifampicine, carbamazepine, 
phenobarbital, and St. John’s Wort. Grapefruit juice, amiodarone and 
verapramil are some of the possible inhibitors of CYP3A4.4 
CYP3A5 
CYP3A5, together with CYP3A4, is one of the most contributing CYP enzymes, 
but not so much in the Caucasian population. For the homozygous 
CYP3A5*3/*3 variant, which is a less functional enzyme, is the more prevalent 
genotype in the Caucasian population. Moreover, in Caucasians the frequency 
of the CYP3A5*3 allele is about 90-95% and of the functional CYP3A5*1 allele 
only about 10%.57,58 In Asians the CYP3A5*3 allelic frequency is about 75% 
and about 35% in African-Americans.58 In all CYPs the term ‘wild type’ stands 
for the most prevalent and fully functional (*1/*1) enzyme, CYP3A5 being the 
exception to the rule. As a consequence, an individual who possesses one or 
two CYP3A5*1 alleles, needs a higher (two to threefold) maintenance dose of 
medicines metabolized by CYP3A5, such as i.e. the immune modulator 
tacrolimus.59  
Until recently, 11 different CYP3A5 allelic variants have been found. 
Furthermore, contrary to the situation in the liver, in the lungs CYP3A5 is the 
main CYP3A form expressed.20 
Discussion 
Many prescribed drugs are effective in only 25-60% of the patients (Figure 
2.1).60 Therefore, it is also important to determine co-factors in drug 
metabolism, as depicted in Table 2.1. A disadvantage of drug development is 
the fact that most drugs are tested in a standardized population, which rules 
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out severe toxicity and will not always predict drug interaction(s). Also, in a lot 
of trials multiple drug prescription or intake is not taken into account. 
Moreover, in many cases genetic metabolic differences, like the presence of 
one or multiple polymorphisms in CYP enzymes, can make it difficult to predict 
therapeutic drug reactions.  
Although in most cases the clinical consequences may be minor, the impact can 
be enormous for patients receiving medicines with a narrow therapeutic index, 
due to either, sub-therapeutic drug levels, or (severe) ADRs, or increased 
mortality rates. For the latter this was established in a recent study about 
tamoxifen use and CYP2D6 polymorphisms.52 An example of CYP poly-
morphisms and subsequent lung involvement is shown in another recent study, 
in which the link between CYP2C9 and VKORC1 SNPs, the prescription of oral 
anticoagulants and the occurrence of diffuse alveolar hemorrhage (DAH) was 
established.61 Patients with CYP2C9*2 and/or CYP2C9*3 variant alleles require 
up to 61% lower maintenance doses of warfarin because of the reduced 
enzyme activity of these common variants.36 A common serious ADR in these 
patients, therefore, can be over-anticoagulation, resulting in (life threatening) 
bleeding complications, such as DAH. 
Furthermore, in a case-control study it was found that 91.5% of patients with 
DI-ILD had at least one of the studied CYP2D6, CYP2C9 or CYP2C19 variant 
alleles compared with 70.5% (p<0.001) of healthy volunteers. DI-ILD 
appeared to be associated with the presence of at least one variant CYP allele.2 
These and other studies support the potential usefulness of personalized 
medicine by genotyping aiming to improve efficacy, tolerability and drug 
safety.25,62 
Different patient categories should be tested for CYP polymorphisms: elderly 
patients with many drugs for different diseases, patients using drugs with a 
small therapeutic range and patients with unexplained side effects. Although 
the genotypic profile does not always predict the phenotypic expression, the 
interaction profile between different drugs can be estimated by computer 
models. Starting with a lower dose or using a medicine that is metabolized by 
another enzyme or route is often a way to prevent ADRs and reduce 
interactions. In addition, the best way to check the effect is to measure serum 
levels of the drug and its metabolites, the so called therapeutic drug monitoring 
(TDM). However, therapeutic serum levels of many drugs are not available or 
expensive to ascertain. In organ transplantation medicine, TDM together with 
CYP genotyping is already daily practice and can be cost effective, because of 
the high costs and the small therapeutic range of the immunosuppressive 
medication used.59,63  
Nevertheless, genotyping should be considered to identify patients that might 
be at risk of severe toxic responses to environmental, pharmacological, herbal 
remedies and/or nutritional stimuli, in order to guide appropriate individual 
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dosage(s).25 Nowadays, DNA material for genotyping can be easily obtained 
and patients do not even have to go to hospital for sample drawing.64 Both 
clinical and genetic risk stratification (pharmacogenomics) may lead to more 
accurate prevention of drug-induced damage in the future.11,25 However, 
further research is needed to explore the clinical relevance. 
Conclusion 
An ideal situation would be the introduction of a genetic medical passport for 
each patient to achieve a system in which therapeutic drug monitoring will be 
standard clinical practice. In this manner the incidence of ADRs and related 
medical consumption will decrease, which in the end will lead to a better 
pharmacotherapy for patients and reduced healthcare costs. To achieve this, a 
multi-disciplinary approach will be necessary to individualize pharmacotherapy 
on the basis of the pharmcogenetic profile.  
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Abstract 
Background 
Several commercial DNA isolation kits are available for extracting genomic DNA from 
whole blood samples, but these procedures require quite some hands-on time and are 
rather expensive. An alternative technique could be dried blood spot (DBS) sampling, 
with which DNA isolation is faster, cheaper and logistics are easier. We have developed a 
non-commercial DBS method and examined whether the quality and quantity of DNA, 
isolated from DBS and noninvasively obtained buccal swab (BS) samples, was 
satisfactory. 
 
Study design  
DNA isolation from EDTA blood samples and blood spots on filter paper were compared 
after DNA isolation with a column method and two different DBS methods. BS samples 
were obtained by rubbing a sterile, dry cotton swab against the inside of the subject’s 
cheek. In addition, the quantity of the obtained DNA was measured and melting curve 
analyses of five cytochrome P450 and three ATP-binding cassette polymorphisms were 
performed with real-time PCR FRET assays to establish the quality of the obtained DNA 
from both the DBS and BS samples. 
 
Results  
In all cases the genotype results corresponded completely. Moreover, the derivative 
melting curves of the DNA samples obtained from the capillary blood and BS were 
comparable and highly reproducible. The mean DNA concentrations measured were 
16.0 ng/μl (12.6-19.4 ng/μl) and 70.2 ng/μl (57.3-83.1 ng/μl), respectively, for DBS and 
BS samples (p<0.001).  
 
Conclusion  
The DBS DNA isolation appears to be a useful alternative for the commercially available 
DNA isolation kits and an extremely useful method to discriminate between genotypes. 
This expands the possibilities of this quick and easy DNA isolation procedure. In 
particular, the noninvasive BS sampling method appeared to be a good alternative to 
invasive sampling methods. 
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Introduction 
Pharmacogenetics, the study of the role of inheritance in the individual 
variation in drug response, is still a growing field and it is gaining more 
importance in the treatment and investigation of the cause of certain diseases, 
symptoms and adverse drug reactions (ADR). The promise of 
pharmacogenetics lies in its potential to identify the right drug and dose for 
each patient. Even though individual differences in drug response can result 
from the effects of age, sex, disease or drug interactions, genetic factors also 
influence both the efficacy of a drug and the likelihood of an adverse reaction 
occurring.1-3 There is an increasing number of examples in which 
pharmacogenetic studies have indicated that a genetic test prior to treatment 
may be useful either for setting the individual dose or making a decision to use 
a particular drug.4-6 Therefore, genetic testing of individuals, specific patient 
groups and possibly their family members or genotyping prior to prescribing 
certain drugs is becoming more important. The materials used for genotyping 
are mostly ethylene diamine tetra-acetic acid (EDTA) whole blood obtained by 
venous sampling and tissue samples. However, both require an invasive 
sampling method and for a number of subjects, this can be a reason to refrain 
from signing up to an investigation or trial. 
Several commercial DNA isolation kits are available for extracting genomic DNA 
from EDTA whole blood samples. To obtain DNA from whole blood, 
commercially available DNA isolation procedures, require approximately one 
hour hands-on time of a technician and are rather expensive (approximately 
€4.00 per isolation). Simplification of the standard DNA isolation procedures by 
the dried blood spot method (DBS) might be advantageous. DBS sampling has 
already become common practice for newborns. Over the past decade many 
applications have been reported for both qualitative and quantitative screening 
of metabolic disorders.7 Possible advantages of genotyping with DBS are: 
1. The patient does not have to leave home and no phlebotomist is necessary. 
2. Genotyping results are known when the patient visits the clinician and the 
clinician can take these results into account when he prescribes (other) drugs. 
3. Transport is easy and there is a decrease in transport costs because only an 
envelope with the DBS of the patient is required. 4. Lower isolation costs and 
faster handling: DNA isolation with DBS is rapid, simple and no expensive DNA 
isolation kits are necessary. 
Previously, the usefulness of DBS genotyping has been described.8,9 However, 
a non-commercial method for DNA isolation with DBS in association with 
pharmacogenetics has not yet been reported in literature. In the present study 
a new non-commercial DBS method was developed for isolating DNA from 
capillary blood and this method is validated versus a standard commercial 
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available DNA isolation kit and also compared to an already existing extraction 
method for DBS described by Fischer et al.10 
The aim of this study was also to test if the same DNA isolation protocol as 
applied to DBS could be used for isolating DNA from noninvasive buccal swab 
(BS) samples. Subsequently, the DNA quality and quantity of the BS samples 
were compared with the obtained DBS samples. Real-time PCR melting curve 
analyses were performed and DNA yields were measured using UV 
spectrometry. Additional storage tests were performed in order to ascertain 
whether delays in sending the sample to the laboratory or rather time from 
acquiring the BS sample to isolation, had an influence on the final result. 
Moreover, establishing the turnaround time and storage conditions required to 
avoid problems allows storage recommendations to be provided for the patient 
to follow. 
Materials and methods 
Samples and materials 
EDTA whole blood samples and blood spots on filter paper made from the 
same samples were obtained from 106 Chinese renal transplant recipients and 
isolated by using 200 μl EDTA whole blood with a column method QIAamp 
blood mini kit, (Qiagen, Leusden, The Netherlands) according to 
manufacturer’s instructions and the DBS method developed by our lab. 
Additionally, DNA was isolated from 10 samples obtained from healthy 
volunteers using the column method for EDTA blood and simultaneously 
obtained finger prick blood was isolated using the DBS method described in this 
study and the one described by Fischer et al.  
Furthermore, another 100 DBS samples were collected by finger prick from 
healthy volunteers to examine our DBS method in clinical practice. When using 
the DBS method capillary blood can be obtained by a finger prick by the 
patients themselves. The drop of blood is spotted on filter paper (Whatman® 
Schleicher and Schuell, code 903 (2992), Whatman®, Dassel, Germany).  
Buccal swabs were obtained by thoroughly rubbing a sterile, dry cotton stick 
(Copan plain swab sterile plastic applicator rayon tipped, ref 155C, Copan, 
Brescia, Italy) twice up and down against the inside of the individual’s cheek on 
the one side of the mouth. One DBS and one BS sample were collected at the 
same time from 25 healthy volunteers, resulting in a total of 25 DBS and 25 BS 
samples to examine the two sampling methods that could be used in clinical 
practice. In addition, the samples were isolated according to our DBS protocol.  
After obtaining 12 BS samples per individual from a total of five healthy 
volunteers for a storage test, four swabs from each subject were kept at room 
temperature, four were put in a refrigerator, and four in a freezer. The BS 
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samples kept at room temperature were isolated at day 1, 3, 5, and 7 after 
sampling. The samples kept at 4–8°C were isolated at 1, 2, 3, and 4 weeks and 
the BS samples stored at -20°C were isolated at 1, 2, 3, and 4 months after 
sampling. 
The DNA concentrations of the samples were measured on the NanoDrop® 
ND-1000 UV Spectrophotometer (Witec AG, Littau, Switzerland).  
Written informed consent for participation in this study was obtained from all 
subjects. 
DNA isolation 
EDTA whole blood samples, capillary DBS and BS samples were collected. In 
the laboratory, after drying for ½ h a 3 mm paper disk was cut out from the 
blood spot sample with a puncher (Harris Uni-core™) or the tip was cut off the 
cotton stick. In addition, the 3 mm bloodstained paper disk or the cotton tip 
was placed into a cup, 500 μl sterilized Milli-Q water (Millipore B.V., 
Amsterdam, The Netherlands) was added and vortexed three-times for 5 s 
each. The water was pipetted off. After adding 200 μl 10% Chelex® 100 
solution (Bio-Rad Laboratories, CA, USA), the cup was placed in a water bath 
at 95°C for 30 min. Finally, this DNA solution was pipetted into a new cup and 
the DNA was ready for use.  
With the method described by Fischer et al.10 the 3 mm disk is placed in an 
Eppendorf™ cup and washed twice with 1 ml of phosphated-buffered saline-
0.1% Tween during 10 min with shaking. After transferring the disk to a 2 ml 
screw-cap cup and adding 200 μl 5% Chelex-100 solution (Sigma-Aldrich 
Chemie B.V., Zwijndrecht, The Netherlands), the cup is placed in a water bath 
at 60°C for 30 min, followed by 30 min in a water bath boiling at 100°C. 
Genotyping 
A total of five previously described cytochrome P450 (CYP) and three ATP-
binding cassette (ABCB1) polymorphisms were performed in this study, using 
real-time PCR fluorescence resonance energy transfer (FRET) assays (TIB 
MOLBIOL, Berlin, Germany), namely: CYP3A4-V A-392G, CYP3A5*3 A6986G, 
CYP2C9*2 C430T, CYP2C9*3 A1075C, CYP2C19*2 G681A, CYP2C19*3 G636A, 
CYP2D6*3 2549delA, CYP2D6*4 G1846A, ABCB1 C1236T, ABCB1 G2677T/A, 
and ABCB1 C3435T.11-15 The single nucleotide polymorphisms (SNPs) were 
genotyped by examining the melting curves from the aforementioned FRET 
assays using the LightCycler® (Roche Diagnostics, Basel, Switzerland). 
For comparison an EDTA sample, isolated on the MagNA Pure Compact (Roche 
Diagnostics), was genotyped within the same run as the DBS and BS samples. 
Furthermore, a heterozygote plasmid sample supplied with the primer/probes 
sets of each assay and a negative water control were analysed within each run. 
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Statistical analysis 
The paired t-test was used to compare the two sampling methods. 
Melting curves were generated by the LightCycler® and its software/integration 
program calculates melting temperature(s) for each detected peak. 
Statistical analyses were performed with SPSS 15.0 (SPSS. Inc., IL, USA) for 
Windows. A p-value of less than 0.05 (two sided) was considered to indicate 
statistical significance. 
Results 
After analysing the melting curves obtained by real-time PCR FRET assays for 
the different DNA isolation methods, the results obtained with the DNA 
extracted with the column method were in complete concordance with the 
results of the DNA isolated with our DBS method. Additionally, the DNA 
isolation with the QIAamp blood mini kit and the two DBS methods performed 
for 10 healthy volunteers were also completely in concordance. Genotyping 
with the DNA isolated with our DBS method for the 100 healthy volunteers 
gave also satisfactory melting curves.  
Although analysis of the column and previously described DBS DNA isolation 
methods were performed for five different real-time PCR FRET assays, an 
overview of the results is only given for the CYP3A5 A6986G polymorphism. 
Melting of a sample homozygous for the CYP3A5 6986G allele produced a 
melting peak at approximately 57.1°C±0.1 (mean±2 SD) and 57.3°C±0.2, and 
the CYP3A5 6986A allele gave a melting peak at approximately 62.3°C±0.2 and 
62.5°C±0.5, for respectively the QIAamp blood mini kit and our DBS DNA 
isolation method. Heterozygous samples contained both type of targets and 
thus generated both peaks. In addition, for heterozygous samples (n=40), the 
difference between the two melting temperatures (5.2°C±0.1) had a coefficient 
of variation (CV) of respectively 0.64% and 1.24%.  
Hence, the derivative melting curves of the commercial DNA isolation method 
and our DBS method were highly reproducible and can therefore be used 
perfectly for discrimination between the CYP3A5*1 and CYP3A5*3 allele, which 
is illustrated in Figure 3.1. The results of the other real-time PCR FRET assays 
were similar to the results presented for the CYP3A5 A6986G polymorphism. 
An issue that may be of importance when the DBS method is used for DNA 
isolation is a possible contamination risk. Because it is likely that the filter 
paper used will be contaminated before and/or after the blood spot is actually 
on the filter paper. Therefore, we examined whether the DBS DNA isolation 
procedure is robust enough to discriminate the blood spot of the patient from 
the contamination caused by rubbing vigorously over respectively the dry filter 
paper, the dry filter paper before adding a blood spot and the dried blood spot 
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on the filter paper. In the cases with the blood sample only the genotypes of 
the patients were seen and in the case of the no blood blank disk, no signal 
was found, which implies that there is no disturbing influence when the filter 
paper is contaminated by hands before or after adding the blood spot on the 
filter paper.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Examples of melting curves from DNA isolated with the QIAamp blood mini kit from 
EDTA whole blood, and the dried blood spot method from capillary blood. 
 Genotyping of the A6986G polymorphism of the CYP3A5 gene with allele specific 
fluorescent probes by derivative melting curve plots using DNA samples isolated with the 
QIAamp blood mini kit (A) and with our dried blood spot DNA isolation method (B).  
 The -dF2/dT derivative melting curves are read in channel 2 for the detection of the 
CYP3A5 fragment. The derivative melting curves is plotted for a similar sample 
homozygous for the 6986G (CYP3A5*3/*3) allele (Tm 57°C); a similar heterozygous 
sample (Tm 57°C (CYP3A5*3) and 62°C (CYP3A5*1)) and a similar sample homozygous 
for the 6986A (CYP3A5*1/*1) allele (Tm 62°C). 
 
 
The DNA concentrations of the DBS and BS samples resulted in mean concen-
trations of 16.0 ng/μl (12.6-19.4 ng/μl) and 70.2 ng/μl (57.3-83.1 ng/μl), 
respectively (p<0.001) obtained using our isolation method. As a comparison, 
the samples isolated using the dried blood spot method previously described 
by Fischer et al.  resulted in a mean concentration of 17.5 ng/μl 10
(12.8-22.2 ng/μl) for these DBS samples (Figure 3.2).  
The derivative melting curves of the DNA samples obtained from capillary blood 
and BS samples were comparable and highly reproducible for all SNPs studied. 
As a representative example, the melting results of the CYP2C9*2 C430T SNP 
are hereby presented below. Melting of a sample homozygous for the 430T 
allele produced a melting peak at approximately 50.6°C±0.4 and 50.7°C±0.4 
for a BS and a DBS sample, respectively. In a sample homozygous for the 
430C allele a melting peak was obtained at approximately 59.5°C±1.2 and 
59.6°C±1.3, respectively, for a BS and a DBS sample. Heterozygous samples 
contained both type of targets and therefore generated both melting peaks, 
with a mean±2 SD difference of 9.6°C±0.4 and 9.5°C±0.7 for the BS and DBS 
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samples, respectively. An overview of all the melting temperature ranges for 
the SNPs investigated, stratified per sample type, are listed in Table 3.1. 
Genotyping confirmed the results demonstrating the same amount of peaks at 
the same melting temperatures and concurrent results were obtained for the 
DBS and BS sample types per subject for the CYP3A4-V, CYP3A5, CYP2C9, 
CYP2C19 and CYP2D6 SNPs that were investigated (Table 3.1). An EDTA 
sample, isolated with the QIAamp blood mini kit, was also analyzed in the 
same run to illustrate and compare the height and position of the melting 
curves of the different sample types. A representative example of a FRET 
melting curve analyses is shown for the CYP2C9*2 assay in Figure 3.2. 
Furthermore, we investigated the stability of the BS samples obtained using a 
plain cotton swab under different storage conditions. When kept at room 
temperature, the performed FRET assays gave only a weak signal that was 
difficult to interpret, or no signal at all, after isolating the swabs after a 7-day 
period. In contrast, when isolating the BS samples at day five all the samples 
still performed well. Storage at 4-8°C extended that period to one month, 
whereas storing the BS samples at -20°C gave good results up until at least 
four months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Mean DNA quantities, isolated with two different DBS DNA isolation protocols, using 
capillary blood DBS and BS samples. 
 1: DBS sample isolated using our method 
 2: DBS sample isolated using the method described by Fischer et al.10 
 3: BS sample isolated using our method 
 BS: Buccal Swab; DBS: Dried Blood Spot. 
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Table 3.1 Overview of melting temperatures±2 standard deviations per sample type for the 
CYP450 SNPs examined and isolated with our dried blood spot method. 
CYP450 SNP Tm BS (°C) DBS (°C) Expected Tm (°C) 
CYP2D6 *3 2549delA Tm1 NA NA 52.1±0.4 
  Tm2 58.8±0.6 58.8±0.6 59.4±0.2 
 *4 G1846A Tm1 57.7±1.2 58.0±1.9 58.2±0.2 
  Tm2 65.2±1.5 66.9±1.8 66.4±0.8 
CYP2C9 *2 C430T Tm1 50.6±0.4 50.7±0.4 50.5±0.2 
  Tm2 59.5±1.2 59.6±1.3 60.4±1.0 
 *3 A1075C Tm1 50.1±0.2 50.2±0.2 50.2±0.3 
  Tm2 NA NA 59.4±0.1 
CYP2C19 *2 G681A Tm1 49.3±1.0 49.0±1.0 49.3±0.1 
  Tm2 55.4±1.2 55.2±0.8 56.1±0.1 
 *3 G636A Tm1 54.0±0.6 54.2±0.2 54.1±0.2 
  Tm2 NA NA 61.4±0.2 
CYP3A4-V A-392G Tm1 NA NA 50.1±0.4 
  Tm2 58.5±0.8 58.6±0.3 58.8±0.4 
CYP3A5 *3 A6986G Tm1 57.6±0.2 57.5±0.2 57.4±0.2 
  Tm2 NA NA 62.6±0.2 
BS: Buccal Swab sample; CYP450: Cytochrome P450; DBS: Dried Blood Spot sample; Expected Tm: 
Positive control, a plasmid sample; NA: Not available; Tm: Melting temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 An example of completely concurrent CYP2C9*2 melting curves of an EDTA blood 
sample, a DBS sample and a BS sample. 
 Positive control  
 EDTA sample      ──────  
 DBS sample 
 BS sample 
 Negative control  ──────     
 The positive control is a heterozygote plasmid sample, supplied with the primer/probes 
of each assay. The negative control is sterile water (no peaks). 
 BS: Buccal Swab; DBS: Dried Blood Spot; EDTA: Ethylenediaminetetraacetic acid. 
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Discussion 
A large difference was found for labour time and costs between the QIAamp 
blood mini kit and our DBS method: it took approximately one hour and €4.00 
per blood sample to isolate DNA from EDTA whole blood with the QIAmp mini 
blood kit while DNA isolation with the DBS method takes about 45 min hands-
on time and less than €2.00 per capillary blood sample. Moreover, there was 
also a significant difference when comparing the two DBS methods, not so 
much in costs, but in hands-on and total time. The method described by 
Fischer et al.10 takes about one hour more before DNA is obtained. 
Furthermore a Tween/phosphate-buffered saline solution is necessary for 
washing the DBS. For DBS samples, there was virtually no difference in DNA 
yield between the isolation method previously described by Fischer et al.10 and 
the one described in this study. Moreover, an advantage of our method is that 
the use of chemicals is minimal, except for a 10% Chelex solution, and it has 
an incubation time of only 30 min.  
Although the amount of blood required for this DBS DNA isolation is less, an 
invasive finger prick is still required to obtain capillary blood. Another restriction 
of this DBS method can be the sometimes relatively low amount of DNA 
obtained from the blood spots.  
Combined with the noninvasive BS as a sampling method, this provides a 
patient friendly and easy way of obtaining DNA samples that can be used for 
genotyping. Especially when conducting a large trial including family members, 
the BSs can be sent by post. Furthermore, attending the hospital in order to 
have a blood sample drawn would no longer be necessary. The sending by post 
and not having to travel to a hospital are advantages that also apply to DBS 
samples. However, when using that sampling method there is still the need to 
draw blood. The noninvasive nature of a BS sample combined with the other 
benefits implicate that there are even fewer drawbacks and people will be more 
motivated to participate.  
We used plain sterile swabs that are readily available and cheap (approximately 
€0.10 each) to investigate if buccal-cell collection and subsequent isolation 
would work. Isolation with our method only takes 30 min in a water bath, and 
adding preparation and pipetting time, the procedure is completed well within 
an hour and with minimal chemical use and cost. On the other hand, 
commercially available saliva collection methods (up to approximately €18.00 
per collection vial) currently being used in most community-based studies 
require an additional kit to isolate DNA, and all at considerably higher costs. 
The obtained BS samples, when using plain sterile cotton swabs, should be 
isolated within five days from the time of sampling to prevent loss of signal 
when performing melting curve analyses. The fact that we did not get a signal 
in the cases that were a week old was a strong indication that amplification of 
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the desired fragment was no longer possible and DNA degradation was 
present. Whenever isolation within five days time is not possible, the BS 
samples can be stored for up to a month at 4-8°C or for up to at least four 
months at -20°C prior to isolation. Therefore, amending the instructions to the 
patient to include: ’Store in the refrigerator when you are not able to send it off 
by mail the same day‘, is an important addition that will improve the final 
result.  
After isolation, the ready to use DNA solution (approximately 150 μl per 
isolation), when pipetted off the Chelex and transferred into a new vial, can be 
stored at 4-8°C or at -20°C for more than one year. 
Conclusion 
The DNA isolation method described appeared to be extremely useful for the 
different sampling procedures (capillary blood and BS). Furthermore, it is able 
to isolate DNA with less hands-on time, is less invasive for the patient, and 
saves transport expenses and DNA isolation costs. Comparison of our DBS 
method to another non-commercially available DBS method resulted in similar 
DNA yields, less use of chemicals and it was less time consuming. All these 
advantages make our DSB method very useful in clinical practice.  
Moreover, it appeared to be a useful alternative for commercially available DNA 
isolation kits. The DNA yields of BS samples were considerably higher 
compared with the yields of DBS samples. For DNA isolated from BS samples 
could be used perfectly to distinguish genotypes or polymorphisms. This 
expands the possibilities of this quick and easy DNA isolation procedure. 
Especially, the noninvasive BS sampling method appeared to be a good and 
patient friendly-alternative to invasive sampling methods. 
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Abstract 
Background 
Drug-induced pulmonary toxicity is a serious and expanding problem with often unknown 
aetiology. Many drugs are metabolized by cytochrome P450 (CYP) enzymes. 
To establish whether allelic variation in CYP polymorphic genes contributes to variability 
in drug response and unexpected toxicity. 
 
Study design 
A case-control study was conducted. The cases consisted of patients with drug-induced 
interstitial lung disease (DI-ILD; n=59). Two control groups were used: one group of 
healthy volunteers (n=173) and one group of patients with idiopathic pulmonary fibrosis 
(IPF; n=110). 
 
Results  
Of the patients with DI-ILD 91.5% (54/59) had at least one of the studied variant genes 
compared with 70.5% (122/173, p<0.001) of the healthy volunteers and 69.1% 
(76/110, p<0.001) of the IPF patients. The percentage of individuals with one or more 
variant CYP genes was higher in DI-ILD group. Odds ratios were significantly increased 
and ranged from 3.25 to 40.8, indicating a significant association between the 
development of DI-ILD and the presence of one or more variant CYP genes. 
 
Conclusion  
DI-ILD appeared to be associated with the presence of at least one variant CYP allele. 
This study supports the potential usefulness of personalized medicine by genotyping 
aiming to improve efficacy, tolerability and drug safety. 
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Background 
One may view the lung as bathed in two dissimilar environments: inhaled air 
and circulating blood. Both can carry noxious substances that may inflict 
damage to the lung. Air can deliver noxious particles and blood is the main 
supplier of most drugs, independent of the route of administration, and adverse 
respiratory reactions may follow by the most unlikely routes. Drugs can induce 
specific respiratory reactions, or the lungs may be affected as part of a 
generalized response. The most common form of drug-induced respiratory 
disease is diffuse interstitial lung disease (ILD). The drugs involved not only 
comprise prescribed and over-the-counter-drugs, but also illicit drugs, herbs, 
alcohol and ingredients of the diet. The list of compounds involved has grown 
rapidly over the last decades.1,2 Although drugs have been unequivocally 
identified as the cause in only a limited number of cases, it is important to 
acknowledge the potential role of medication in the development of ILD. This is 
due to the severity of the potentially irreversible damage to the lungs and the 
improvement that is often easily brought about by stopping administration of 
the drug involved. 
The diagnosis of drug-induced ILD (DI-ILD) primarily rests on the link between 
drug intake and the subsequent development of respiratory symptoms. In 
some cases, the evidence that reactions in the lung are drug-induced is 
circumstantial. A straightforward interpretation is hampered when the damage 
is irreversible or when the symptoms are aggravated after stopping drug 
administration. Rechallenging the patient with the drug involved is frequently 
unethical and dangerous. Sensitive and specific tests are lacking. The key to 
diagnosis is a high clinical acuity.2 All medication needs to be recorded and 
reviewed meticulously. 
The molecular mechanism involved in the development of DI-ILD is still 
enigmatic. Inflammation initiated by drugs, drug metabolites or drug-induced 
free radical generation processes has been implicated.3 There is also emerging 
evidence for a role of genetic factors in the development of ILD such as 
differences in gene expression profiles between pulmonary fibrosis (IPF) and 
hypersensitivity pneumonitis.4,5 
Cytochrome P450 (CYP) single nucleotide polymorphisms (SNPs) are one of the 
key factors known to cause a variation in drug response between individuals.3, 
6-9 CYP is a super family of microsomal enzymes that metabolize various 
endogenous compounds and xenobiotics, including most drugs. Through CYP 
metabolism the chemical structure of drugs is changed, in general facilitating 
elimination of the drug from the body.3,7  
The risk for development of DI-ILD and clinical patterns vary depending on a 
variety of host and drug factors.2 Several different phase I xenobiotic-
metabolizing CYP and phase II enzymes (i.e. conjugation enzymes including 
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several transferases) are present in the human lung, possibly contributing to in 
situ activation.10-14 Metabolism also affects the biological activity of the drug. 
The biological activity of the parent drug is usually superior to that of the 
metabolite, but there are several exceptions. Sometimes CYP metabolism yields 
very toxic metabolites, for example, with paracetamol (acetaminophen), 
benzo[a]pyrene and carbamazepine.14 Occasionally, drugs may cause the 
formation of reactive oxygen species by uncoupling of the electron transport of 
the CYP system.15 These metabolites or reactive oxygen species may damage 
vital cellular components, such as proteins, lipids or DNA.16 This might be the 
cause of clinically relevant drug-induced pulmonary toxicity.12,17,18  
Recently, we reported two cases of patients with interstitial pneumonia who 
developed cardiac failure following treatment with venlafaxine.19 In both cases, 
a strong relationship between the development of the patients’ illness and the 
initiation of venlafaxine treatment was identified. Furthermore, members of the 
CYP family are involved in the metabolism of venlafaxine. Therefore, we 
hypothesized that genetically or environmentally induced inter-individual 
differences in the expression of pulmonary biotransformation enzymes such as 
CYP may form the basis for, or contribute to, the risk of DI-ILD.2,10,13,14  
The aim of this study was to establish whether variation in CYP genes 
contributes to variability in individual drug response and toxicity. Therefore, the 
presence of the most clinically relevant variants of CYP genes (CYP2D6, 
CYP2C9 and CYP2C19 variants) was compared in a population of patients with 
DI-ILD with the presence of these variant genes in a population of patients 
with IPF and one of healthy volunteers. 
Materials and methods 
Setting and study population 
The study was conducted as a case-control study. Between 2002 and 2006, 
575 bronchoalveolar lavages (BAL) were performed on patients referred to the 
department of Respiratory Medicine of the Maastricht University Medical Centre 
(MUMC), Maastricht, The Netherlands, suspected of a non-infectious or 
infectious disorder. Out of these 575 cases, 51.1% appeared to have an 
infectious disorder, 17.8% had diffuse alveolar haemorrhage and 31.1% an 
ILD. Of this latter group, 59 (10.2%) met the criteria of DI-ILD. All of the 59 
patients were Caucasian, used multiple drugs for various indications and did 
not have a history of any pulmonary disorder. The clinical presentation of drug-
induced pulmonary toxicity varied. Besides pulmonary symptoms, some 
patients (n=7; 12%) showed signs of other toxicity such as skin, cardiac and 
gastrointestinal involvement. The diagnosis DI-ILD was established by clinical 
presentation including dyspnoea and hypoxia, diffuse interstitial features on 
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chest X-ray and a high-resolution CT scan as well as a BAL fluid (BALF) profile 
compatible with DI-ILD, excluding an infectious cause.2,20,21 A lung biopsy was 
performed in 20% (n=12) of the patients. Clinical records were reviewed 
carefully and present and past drug use was documented. After reviewing the 
drug use of all DI-ILD patients, the most important groups appeared to be 
antihypertensive medication, β-adrenergic receptor antagonists, anti-arrythmic 
agents, antidepressants and anticoagulants. Every DI-ILD patient used a 
combination of at least two or more of these drugs. Withdrawal of the 
suspected causative drug(s) led to a favorable outcome in 75% of the patients, 
including an improvement of the respiratory symptoms, lung function test 
results, especially the diffusing capacity, and the chest X-ray abnormalities. In 
25% of cases the damage was irreversible. Subjects were genotyped 
retrospectively for CYP polymorphisms and the drug(s) which are metabolized 
by the CYP enzymes that show genetic polymorphisms were identified. 
 
The first control group consisted of 173 healthy Caucasian volunteers, recruited 
for method validation, who did not use medication nor had any relevant 
medical history, especially no history of pulmonary complaints.22 All healthy 
volunteers were hospital employees. This healthy volunteer control group was 
also used to establish the distribution of allele variants in the general 
population. 
 
The second control group consisted of 110 Caucasian patients with IPF, known 
at our out-patient clinic and collected during the timeframe of this study, who 
also used medication for various indications. This group was selected as a 
control group, for it was expected that drug use did not play a substantial role 
in the pathogenesis of this disease. The diagnosis IPF was based on consistent 
clinical features, radiographic findings and BALF analysis results. According to 
the international consensus a biopsy was obtained from 50% of the IPF group, 
which confirmed the diagnosis histologically as being usual interstitial 
pneumonia.23 Clinical records were reviewed carefully and present and past 
drug use was documented. All IPF patients used one or more drug(s). For the 
DI-ILD group as well as for the IPF group it was checked whether the drugs 
used were metabolized by polymorphic CYP enzymes.  
The study was performed in accordance with the Declaration of Helsinki and its 
amendments. The protocol was approved by the local Medical Ethics Board of 
the MUMC. Written informed consent for participation in this study was 
obtained from all subjects. 
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Genotyping 
DNA was obtained from all subjects by using venous EDTA anti-coagulated 
blood and isolating with a High Pure PCR Template Preparation Kit (Roche 
Diagnostics, Mannheim, Germany) according to the manufacturer’s 
instructions. 
In this study, genotyping was carried out for the following CYP allelic variants: 
CYP2C9*2 C430T, CYP2C9*3 A1075C, CYP2C19*2 G681A, CYP2C19*3 G636A, 
CYP2D6*3 2549delA, and CYP2D6*4 G1846A. For genotyping the 
CYP2C9*1,*2,*3 and CYP2C19*1,*2,*3 SNPs, real-time PCR Fluorescence 
Resonance Energy Transfer (FRET) assays were performed using the CYP2C9 
and CYP2C19 Mutation Detection Kits (Roche Diagnostics, Mannheim, 
Germany). The CYP2D6*1,*3 and *4 SNPs were genotyped using FRET assays 
(TIB MOLBIOL, Berlin, Germany) as described by Stamer et al.24 and Müller et 
al.25 on the LightCycler® (Roche Diagnostics, Mannheim, Germany)  
Statistical analysis 
Statistical analyses were performed with SPSS 15.0 (SPSS. Inc., Chicago, IL, 
USA) for Windows. In order to evaluate the association between the presence 
of pulmonary disease and the presence of CYP polymorphisms, odds ratios 
(ORs) with corresponding 95% confidence intervals (CI) were calculated. 
Actual allele distributions were compared against the expected frequencies 
calculated, using the Hardy–Weinberg equilibrium. Deviations from Hardy–
Weinberg equilibrium were analysed using the chi-square test. A p-value of 
<0.05 (two sided) was considered to indicate statistical significance. A 
Bonferroni correction, to adjust for multiple comparisons, was applied were it 
was appropriate (p<0.01, indicating statistical significance). 
Results 
A summary of the characteristics of the DI-ILD, IPF and healthy volunteer 
population is shown in Table 4.1.  
The subjects in the healthy volunteers group were younger than the subjects in 
the other two populations and used no medication. The age difference had no 
influence on the distribution of genetically variant genes, however, it does 
indicate that (multiple) drug use increases with age. The IPF control patients 
did use (multiple) drugs, but to a lesser extent than the DI-ILD patients. Table 
4.1 also shows that of the patients in the ILD group, substantial larger 
percentages were receiving drugs that are metabolized by a polymorphic CYP 
enzyme system. For example, of the 43 patients who received a drug that 
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should be metabolized by CYP2D6, 73% had a genetic polymorphism that 
would be likely to influence their ability to metabolize drugs efficiently. 
 
Table 4.1 Baseline characteristics of the drug-induced interstitial lung disease (DI-ILD), idiopathic 
pulmonary fibrosis (IPF) and healthy volunteers (HV) populations. 
Characteristic DI-ILD IPF HV 
Subjects (no.) 59 110 173 
Male/female (no.) 28/31 62/48 78/95 
Age (mean/range (y)) 65.4/21-87 63.3/27-89 38.5/19-59 
Percentages of above populations taking one or more drugs metabolized by CYP polymorphic enzymes:
CYP2D6 73 18 0 
CYP2C9 52 19 0 
CYP2C19 88 17 0 
CYP=cytochrome P450. 
 
 
The percentages of individuals having one of the studied individual 
polymorphisms (CYP2D6, CYP2C9 and CYP2C19) or combinations in DI-ILD, 
healthy volunteer and IPF control patient groups, respectively, are shown in 
Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Percentage of individual and combinations of cytochrome P450 (CYP) polymorphic genes 
in individuals with drug-induced interstitial lung disease (DI-ILD, n=59), idiopathic 
pulmonary fibrosis (IPF, n=110) and healthy volunteer (HV, n=173) groups. * p<0.05. 
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The genotype distribution for the three groups in this study showed that all 
results were generally consistent with the Hardy-Weinberg equilibrium (Table 
4.2, upper panel, expected values not shown).26-29 One exception was the 
CYP2D6 polymorphism of the healthy volunteer group, in which a small but 
significant deviation from the Hardy-Weinberg equilibrium was observed 
(p<0.01). Fewer heterozygotes (45 actually present in the healthy volunteer 
group versus 56 expected, calculated using the Hardy-Weinberg equilibrium) 
and more homozygotes (13 versus 7) were found. However, the allele 
frequencies in both control groups (healthy volunteers and IPF patients) were 
comparable with those in the reference populations from the literature (Table 
4.2, lower panel).26,27,29 
 
Table 4.3 presents the results from the analyses that compared the proportions 
of persons with one ore more variant genes that express the polymorphic CYP 
enzymes between DI-ILD patients and both control groups. The proportion of 
persons without any allelic variants was only 8.5% among DI-ILD cases versus 
30.9% and 29.5% in IPF patients and healthy volunteers. Furthermore, it 
appeared that there was a higher prevalence of combinations of variant genes 
within the DI-ILD patients compared with the IPF patients and healthy 
volunteers (Table 4.3, upper panel). Subjects without any CYP variant genes 
within the DI-ILD group and healthy volunteer group were used as reference 
group for the calculation of ORs associated with the presence of one or more of 
the studied genetic polymorphisms. Strong and significant associations were 
found comparing the prevalence of CYP2D6 and CYP2C19 genetic variants in 
DI-ILD patients with those of the healthy volunteers. The ORs calculated were 
5.80 (95% CI: 2.17-15.4, p<0.001) for CYP2D6, 3.25 (95% CI: 1.18-8.86, 
p=0.026) for CYP2C9 and 6.47 (95% CI: 2.35-17.7, p<0.001) for CYP2C19, 
respectively (Table 4.3). For the combined genotypes with variant CYP alleles, 
significant ORs were found of 4.91, 14.0, 6.80 and 40.8 (Table 4.3). 
Similar results were found comparing the prevalence of variant CYP genes in 
DI-ILD patients with the IPF control patients. These analyses, as shown in 
Table 4.3, also resulted in significant associations between the development of 
DI-ILD and the presence of CYP genetic variants. 
The percentage of DI-ILD patients having a CYP variant gene and receiving one 
or more drug(s) metabolized by a polymorphic CYP enzyme was 87% (47/54), 
compared with only 16% (12/76) of the IPF patients. 
Table 4.4 lists the (suspected) causative drugs, the CYP enzymes involved in 
the metabolism of the mentioned drugs, the number of DI-ILD patients 
involved (with and without variant CYP genes) and also shows which of the 
variant forms of CYP genes were found. The last column lists the number of 
literature references mentioned on www.pneumotox.com, concerning the 
stated causative drug in relation to lung disease. 
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Table 4.4 List of potentially causative drugs and the cytochrome P450 (CYP) genes and variant 
genotypes expressing enzymes involved in their metabolism. 
Causative drug 
 
CYP genea 
 
Allelic variants present 
 
Drug+ 
variant geneb
No variant gene+ 
inhibitorc 
Literatured 
 
Acenocoumarol 2C9 *1/*2 *2/*3     5 7  4 
 2C19 *1/*2 *2/*2     8 2  4 
Acetaminophen 2D6 *1/*4      2 2  11 
 2C9 *1/*2 *2/*3     2 1  11 
Amiodarone 2D6 *1/*4 *1/*3 *3/*4 *4/*4   8 7  276 
 2C19 *1/*2      6 9  276 
Amitriptyline 2D6 *1/*4      2   4 
 2C19 *1/*2      1   4 
Captopril 2D6 *3/*4      1 1  27 
Carbamazepine 2C9      1  53 
Carvedilol 2D6 *1/*3      1 1  2 
Cotrimoxazol 2C9      1  11 
Cyclophosphamid 2C19 *1/*2      1   65 
Diazepam 2C19 *1/*2      1   
Diclofenac 2C9 *3/*3      1 1  3 
 2C19 *1/*2      1   3 
Fenfluramine 2D6 *1/*3      1   39 
Flecainide 2D6 *1/*3      1   10 
Fluoxetine 2D6 *1/*4 *1/*3     2 1  8 
 2C19 *1/*2      2   8 
Haloperidol 2D6      1  2 
Ibuprofen 2C9 *1/*2      1 1  6 
 2C19 *1/*2      1   6 
Methotrexate       2  117 
Metoprolol 2D6 *1/*4 *4/*4 *1/*3  10 1  2 
Montelukast 2C9 *1/*2      1   6 
Morphine 2D6 *1/*4      1   16 
Naproxen 2C9 *1/*2      1 1  14 
Omeprazol 2C19 *1/*2      4 5  1 
Pantoprazol 2C19 *1/*2 *2/*2     5 2  
Paroxetine 2D6 *1/*4      2 2  2 
Propranolol 2D6 *1/*4 *3/*4     1 1  11 
Ranitidine 2D6 *1/*4      2 1  
 2C19 *1/*2      2 1  
Risperidone 2D6 *1/*4      1   1 
Tamsulosin 2D6 *1/*3 *3/*4     3 1  
Temazepam 2C19 *1/*2 *2/*2     4   
Tramadol 2D6 *1/*4      1   2 
Valsartan 2C9 *1/*3 *1/*2 *2/*3    3 1  3 
Venlafaxine 2D6 *1/*4      2   5 
 2C19 *1/*2      1   5 
a Gene expressing CYP enzyme involved in the metabolism of the drug. 
b Total number of patients with a variant CYP gene receiving the drug. 
c Total number of patients receiving the drug, without a variant CYP gene, but with the drug being 
associated with an inhibition of the CYP enzyme involved in the metabolism of the drug. 
d Total number of articles at www.pneumotox.com referring to the mentioned drug. 
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Discussion 
To the best of our knowledge, this is the first study indicating that DI-ILD may 
be attributable to a reduced metabolic capacity by CYP enzymes. According to 
our results, there seems to be an association between having one or more CYP 
genetic variants that may lead to reduced metabolism, receiving drugs that are 
metabolized inadequately by the affected system and the development of 
DI-ILD. Looking at the ORs, ranging from 3.25 to 40.8, patients with variant 
CYP enzymes appear to be at a substantially greater risk of developing a 
DI-ILD when prescribed multiple drugs. These findings strengthened our 
presumption that inadequate drug metabolism predispose an individual for the 
development of DI-ILD. In 91.5% of the studied DI-ILD patients at least one 
CYP variant gene was present, whereas this percentage was about 70% in the 
control populations. In the DI-ILD group the prevalence of having more than 
one CYP variant gene was also substantially higher. The results support the 
potential usefulness of CYP genotyping in selecting appropriate drugs or 
dosages of drugs and avoiding subsequent serious adverse effects. 
 
CYP isoenzymes have been detected in animal as well as in human lung 
tissues.30 It is generally agreed that the CYP super family of enzymes forms the 
first step in the inactivation and elimination of numerous drugs by oxidation 
and reduction. Considering the fact that bio-activation by CYP enzymes plays 
an important role in human drug toxicity, polymorphisms in the CYP450 
enzyme system may result in large inter-individual variations in the metabolism 
and toxicity of xenobiotics.  
 
Given the ever-increasing number of patients, especially seriously ill and/or 
elderly, who take more than one drug, also often metabolized by the same CYP 
enzyme, the inherent problems of drug-induced toxicity are alarming.31 
Physicians should therefore be alert to the possibility that a drug-induced 
pulmonary reaction may originate from an inappropriate metabolism, especially 
in case of multiple drug use. The results in this study corroborate that 
genotyping a patient before drug initiation could lead to a more tailor-made 
dosing schedule that might protect the patient from the development of serious 
side effects at the start of the pharmacotherapy. Trial-and-error approaches 
could be reduced this way.32 
 
In the present study we focused on CYP polymorphisms. The total ‘genetic 
profile’ of an individual patient should include genes expressing further 
polymorphic enzymes and other proteins involved in drug metabolism and 
response. For example, in the case of azathioprine indication, also used as 
treatment for IPF, testing for thiopurine methyltransferase (TPMT) variants 
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involved in the azathioprine metabolism is advised before starting 
treatment.33-35 In the US, drug labels for azathioprine now include information 
on TPMT polymorphisms and recommend determining patients’ phenotype or 
genotype prior to drug treatment.36 
 
The finding that 87% of the studied DI-ILD patients received one or more 
drug(s) metabolized by an affected CYP metabolism route is consistent with the 
assumption that the interstitial lung reactions were drug-induced and that the 
case group in this study was well defined. In the other cases drug-drug 
interactions may have been responsible for the toxic drug effects or other 
pharmacogenetic factors might be involved, such as reduced TPMT activity 
involved in methotrexate metabolism.37,38 
 
There are an increasing number of examples where pharmacogenetic studies 
have indicated that a genetic test prior to treatment may be useful either for 
setting the individual dose or making a decision to use a particular drug.39 The 
ability to identify individuals who are susceptible to ADRs has the potential to 
reduce the personal and population costs of drug-related morbidity.8 
In this retrospective study, the healthy volunteers used no medication and 
among the IPF group patients used fewer drugs compared with the DI-ILD 
patients. However, this does not imply that the healthy control patients and IPF 
patients are not at risk of developing a drug-induced pulmonary reaction. 
Persons with more than one CYP polymorphism and/or other relevant 
polymorphisms may be susceptible to develop DI-ILD when (multiple) drugs 
are prescribed.9,35,37 To answer the question whether persons with one or more 
of these polymorphisms will develop a DI-ILD, whenever future drug 
prescription is mandatory, needs follow-up. However, since the CYP 
polymorphisms of these patients are already known, this can be taken into 
consideration when prescribing, thus avoiding (possible) adverse drug 
reactions. Moreover, a prospective case-control study deriving both treated 
patients and control patients from one population source of multi-drug users 
would be useful, in order to evaluate the cost effectiveness of the introduction 
of pharmacogenetic testing into routine healthcare. Such studies will help to 
identify factors that increase the risk of unwanted outcomes from drug therapy. 
They will also help to establish in which circumstances genotyping should be 
performed prior to commencing drug treatment and in tailoring drug treatment 
for individual patients.8,9 
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Conclusion 
This study indicates that the presence of CYP variant genotypes appeared to be 
a substantial susceptibility risk factor in the development of drug-induced 
pulmonary adverse events. Therefore, genotyping prior to drug prescription 
may be clinical useful for the prediction and prevention of drug-induced 
pulmonary toxicity, especially in case of multiple drug use, where prior 
genotyping or phenotyping has the potential to contribute to the patients’ 
safety. Both clinical and genetic risk stratification (pharmacogenomics) may 
lead to more accurate prevention of drug-induced damage in the future. 
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Abstract 
Background 
Understanding the mechanisms of drug metabolism and interactions can help to prevent 
side-effects.  
 
Study design 
Not only drug interactions, environmental factors, disease processes and aging are 
factors in the inter-individual metabolic capacity variance, but also genetic factors 
probably play an important role, as is illustrated in the case presented. Besides 
therapeutic drug monitoring, genotyping some important cytochrome P450 (CYP) 
enzymes was of additional value in explaining why the patient developed severe adverse 
effects and, moreover, did not experience any therapeutical effect of venlafaxine.  
 
Results 
Results indicated that the patient was a poor metabolizer for CYP2D6, the most 
important phase I enzyme to metabolize venlafaxine. This corroborates that 
polymorphisms in the CYP gene influence the metabolic activity of the corresponding 
enzymes, thus affecting the subsequent serum drug levels and their metabolites.  
 
Conclusion 
This case highlights the potential benefit of both clinical and genetic risk stratification 
(pharmacogenetics) prior to treatment, either for setting the individual dose or for 
making a decision about using a particular drug. 
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Introduction 
Adverse drug reactions (ADRs) pose a serious medical problem and are an 
important burden on health-care costs.1,2 In general, the recognition of ADRs 
has become an increasingly important area in clinical practice. Clinical 
presentation of ADRs varies and to relate certain reaction with a drug, there 
must be a temporal relationship, appropriate clinical presentation and, ideally, 
improvement with discontinuation of the drug. Drug-induced reactions can 
cause any known pathological pattern. At present, there are no specific tests; 
rechallenge is unlikely to be helpful and is generally regarded to be dangerous. 
Drugs metabolism is influenced by drug-drug interactions, environmental 
factors, disease processes, food and ageing.3 Furthermore, there is increasing 
evidence that interindividual difference in the genetic profile of phase I and II 
enzymes account for a substantial portion of the heterogeneity of the response 
to medication(s) and the development of ADRs.4,5 
Antidepressants are widely used in clinical practice, although the effect is 
debated. Venlafaxine, for example, belongs to a new generation of 
antidepressants being a serotonin (5-HT)-norepinephrine (NE) reuptake 
inhibitor. Venlafaxine and its main active metabolite, O-desmethylvenlafaxine 
(ODV), inhibit the reuptake of both 5-HT and NE with a potency greater for the 
5-HT than for the NE reuptake process. Venlafaxine is metabolized by CYP2D6 
into its main active metabolite ODV and to a lesser extent by CYP3A4 into the 
inactive N-desmethylvenlafaxine, see also Figure 5.1.6-8 The suggested 
therapeutic concentration range lies between 195 and 400 μg/l for the sum of 
venlafaxine and ODV, and depends mainly on the CYP2D6 activity.8,9 Decreased 
CYP2D6 activity increases the risk of side-effects.7  
Side-effects, due to overdosing, cause only mild symptoms in the majority of 
patients. However, severe toxicity is reported with the most common 
symptoms being central nervous system depression, serotonin toxicity, seizure 
or cardiac conduction abnormalities. Although the exact mechanism of injury is 
unclear, total serum concentrations of venlafaxine and its major active 
metabolite ODV of 900 μg/l or more combined are likely to cause toxicity.6,10 
Deaths have been reported following large doses and in combination with other 
medication and alcohol.9,11  
Recently, we reported two cases of interstitial pneumonia with cardiac failure 
developing in patients treated with venlafaxine.12 A strong relationship between 
the development of patients’ illness and the initiation of venlafaxine treatment 
was identified. It was hypothesized that alterations in metabolic drug clearance 
as a result of genetic factors or drug-drug interactions might, in part, be 
responsible for the drug-induced toxicity. Unfortunately, no DNA was available 
of these two cases and therefore CYP variants could not be confirmed. 
However, this observation prompted us to evaluate a possible role of this 
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genetic variant in the presented case. We report a case with a severe 
refractory depression not responding to venlafaxine in which therapeutic drug 
monitoring (TDM) in combination with pharmacogenetics were performed in 
the diagnostic follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Main metabolic pathway of venlafaxine 
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Case report 
A 42-year-old woman was visiting the outpatient hepatology clinic because of, 
since six weeks existing, progressive fatigue, dyspnoea, paresthesias of the 
fingers, hands and legs. She felt agitated and had an elevated heart rate in rest 
of 110 beats per minute. She was known with morbid obesity (body mass 
index [BMI] 46 kg/m2), arterial hypertension, left ventricle hypertrophy with a 
decreased left ventricle ejection fraction (40% of predicted), depression and 
non-alcoholic steatohepatitis. The medication she used is summarized in Table 
5.1. At that time haematological and biochemical laboratory investigations 
revealed no abnormalities. After her last suicide attempt, two months before 
presentation at the outpatient clinic, the psychiatrist started venlafaxine 75 mg 
to treat her depression. As no mental improvement occurred, the venlafaxine 
dose was increased gradually to 225 mg daily, but still no improvement was 
established. Moreover, her mental situation worsened and so did the other 
complaints she presented with at the outpatient clinic. The fore-mentioned 
adverse effects (especially the tachycardia and agitation) coincided the most 
with the side-effects listed for venlafaxine, see also Table 5.1. This prompted 
us to measure the serum venlafaxine level and of its main active metabolite 
ODV which were 1300 μg/l and less than 100 μg/l, respectively, well above the 
recommended combined concentration range of 195-400 μg/l.8 At the same 
time, three common polymorphisms in the CYP genes (CYP2C9, CYP2D6 and 
CYP2C19) were analyzed, as described previously.13 These tests were 
performed to rule out or establish a genetic component. Moreover, the 
genotyping was used to investigate whether venlafaxine was the most likely 
cause for the ADR, or one or more of the prescribed co-medication not being 
metabolized properly by the investigated enzymes. For accumulation of other 
drugs might be causing additional drug-drug interaction problems. A 
homozygote variant of CYP2D6 (CYP2D6*4/*4) was found indicating that no 
functional CYP2D6 enzyme and, therefore, no metabolic activity, was present. 
Furthermore, a heterozygote variant of CYP2C9 (CYP2C9*1/*2) and a wild-
type genotype of CYP2C19 (CYP2C19*1/*1) were found. Mainly the fact that 
the patient appeared to be a poor metabolizer of CYP2D6 substrates explained 
the high toxic serum levels of venlafaxine without the presence of its main 
active metabolite ODV. Venlafaxine was stopped immediately and so was 
metoprolol, also metabolized by CYP2D6, see also Table 5.1.14 Gradually, her 
complaints of agitation, dyspnoea and tachycardia disappeared.  
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Table 5.1 Specifics of the medication and dosages administered at time of presentation.  
Drug and dose Group Main ADR Metabolized by  
Ursodeoxycholic acid  
3 daily dose 300 mg 
Dissolves cholesterol stones Nausea, constipation Not applicable  
Furosemide 
40 mg 
Loop diuretic Hypotension, nausea Glucuronidation 
Metoprolol 
100 mg 
β-blocker Bradycardia, fatigue, 
dizziness, hypotension  
CYP2D6 
Simvastatin 
40 mg 
Lipid-lowering agent Headache, asthenia, 
nausea 
CYP3A4 
Zopiclone 
7.5 mg 
Hypnotic agent Confusion, clumsiness, 
anxiety 
Major CYP3A4,  
minor CYP2C8 
Valsartan 
80 mg 
Angiotensin II receptor 
antagonist 
Headache, dizziness, 
asthenia 
CYP2C9 
Rosiglitazone 
4 mg 
Thiazolidinedione  Headache, fatigue, 
diarrhea 
Major CYP2C8,  
minor CYP2C9 
Pantoprazole 
20 mg 
Proton pump inhibitor Headache, diarrhea, 
anxiety 
CYP2C19 
Venlafaxine 
75 mg to 225 mg 
Serotonin-nor epinephrine 
reuptake inhibitor 
Tachycardia, fatigue, 
agitation, hypertension 
Major CYP2D6, 
minor CYP3A4 
Type of medication (group), main adverse reactions (ADR) and CYP route metabolism is depicted. 
Discussion 
This case highlights the importance of CYP genotyping in combination with 
serum drug monitoring to establish a relationship between ADR and drug 
metabolism. High toxic serum levels of venlafaxine without a detectable 
concentration of its main active metabolite ODV strongly indicated that no 
CYP2D6 enzyme activity was present. This was confirmed by genotyping. The 
complaints with which patient presented herself at the outpatient clinic could 
be attributed to high levels of venlafaxine and were a direct consequence of the 
rate of CYP metabolism.7,15,16 Furthermore, this drug is known to cause 
serotonin-syndrome in some cases.17 The complaints were not related to 
metoprolol, which is also metabolized mainly by CYP2D6, see also Table 5.1. 
Metoprolol, a selective adrenergic beta-1-blocking agent, was prescribed to the 
patient because of hypertension. The drug competes with adrenergic 
neurotransmitters such as catecholamines; resulting in a decreased heart rate, 
cardiac output and blood pressure. Toxic effects include bradycardia, 
hypotension, bronchospasm, and cardiac failure, which were not observed in 
our patient. Another rare side-effect of metoprolol therapy can be depressive 
symptoms, but as the patient was prescribed metoprolol years before the onset 
of the depression, this was unlikely.18,19 A more plausible explanation is the fact 
that patients can also be non-responders to venlafaxine therapy, not linked to a 
certain CYP450 genotype, but in combination with a poor metabolizer the risk 
of a maintained depression and acquiring ADRs is increased substantially.8,20 
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Other more rare ADRs include pulmonary (e.g. interstitial pneumonia) and 
cardiovascular (e.g. agina pectoris, sinus arrythmia) problems and even sudden 
deaths have been reported, suggesting venlafaxine and/or its metabolites to be 
a possible proarrhythmic agent.21-23 Direct toxic effect or hypersensitivity is 
likely to be the mechanism.  
Venlafaxine is mainly metabolized by CYP2D6 and only for a very small amount 
by CYP3A4, see also Figure 5.1.8,24 In particular, CYP2D6 variants may 
manifest phenotypically as poor, intermediate, extensive or rapid 
metabolizers.25,26 Administration of venlafaxine to poor metabolizers places 
them at risk of accumulation of the drug to toxic concentrations.7 Moreover, 
poor metabolizers are more likely to experience ADR.7 Also, co-administration 
of venlafaxine with drugs that inhibit the activity of CYP2D6, such as some 
antiarrhythmic agents, could provoke accumulation of the drug and predispose 
patients to drug-induced damage.27 However, the venlafaxine datasheet states 
that co-prescription of venlafaxine and metoprolol, although it should be 
exercised with caution, poses no problem in a normal situation when checking 
the patient’s blood pressure regularly. 
Genotyping prior to administration of the drug probably prevents unnecessary 
medication for at least six weeks (period needed for evaluating the effect of the 
medication). Furthermore, and possibly even more important, it warns the 
psychiatrist that increasing the dose is no option, since the active metabolite 
will not be formed due to the inappropriate metabolism of venlafaxine. 
Moreover, it exposes the patient to an increased ADR risk, because of 
decreased clearance. The risk for development of drug toxicity, including drug-
induced lung damage and cardiopulmonary effects, differ depending on a 
variety of host (including CYP polymorphisms) and drug factors.23,28 Increased 
serum levels of drugs can be observed, not only after overdose administration 
of the drug, but also because of decreased clearance in some subjects, due to, 
as in this case, an incapability to metabolize or drug-drug interactions.25  
The promise of pharmacogenetics, the study of the relationship between 
variants in a large collection of genes and variable drug effects, lies in its 
potential to identify the right drug and dose for each individual patient.29 Thus, 
genotyping can provide therapeutic and pharmaco-economic benefits and 
should be considered in patients using (multiple) drugs.29,30 The affected 
CYP450 enzyme, causing an inappropriate effect of the antidepressant, can 
also influence other drugs metabolized by the same CYP system. Therefore, 
physicians should prescribe combinations of certain drugs with caution.  
78⏐Chapter 5 
Conclusion 
Introduction of venlafaxine in our patient resulted in tachycardia and agitation 
without improvement of the depressive symptoms. It appeared that the patient 
was a poor metabolizer for CYP2D6, the most important phase I enzyme to 
metabolize venlafaxine. Discontinuation of this drug resulted in resolving of the 
symptoms. This case highlights the potential benefit of both clinical and genetic 
risk stratification (pharmacogenetics) prior to treatment, either for setting the 
individual dose or for making a decision about using a particular drug. To 
minimalize ADRs, genetic screening prior to prescription of certain ‘risk drugs’ 
and TDM during treatment would be an ideal situation. 
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Abstract 
Background 
Diffuse alveolar hemorrhage (DAH) is a life threatening bleeding complication that can 
occur as a result of oral anti-coagulation therapy.  
We hypothesized that in patients treated with coumarins, alveolar hemorrhage is 
associated with vitamin K epoxide reductase (VKORC1) and cytochrome P450 (CYP) 2C9 
(CYP2C9) variant alleles. In addition, in the case of acenocoumarol use, CYP2C19 allelic 
variants also play a role. 
 
Study design 
During a 7-year period patients using coumarins with confirmed DAH were gathered. Out 
of 173 confirmed DAH cases, 75 received oral anticoagulants, and 63 patients (84%) of 
these 75 were included because their DNA was available. For genotyping the CYP2C9*2 
(C430T), CYP2C9*3 (A1075C), CYP2C19*2 (G681A), CYP2C19*3 (G636A), VKORC1 
(G-1639A) and VKORC1 (C1173T) single nucleotide polymorphisms (SNPs), real-time 
PCR’s were performed.  
 
Results 
In 62 (98.4%) out of 63 DAH patients, variant genes were found. In 51 (81.0%) of the 
63 patients VKORC1 allelic variants (20 homozygote and 31 heterozygote) were present. 
In 31 (49.2%) of the 63 DAH cases CYP2C9 variant alleles (three homozygote, 26 
heterozygote, and two compound heterozygote) and in 20 (32.0%) of the 63 patients 
both allelic variants were observed.  
 
Conclusion 
Genotyping of four SNPs for VKORC1 and CYP2C9 polymorphisms is useful in predicting a 
high probability of the occurrence of DAH, in patients on oral anticoagulants. Early and 
timely use of genotyping is recommended to prevent a fatal outcome and to provide a 
safer and more individualized anticoagulant therapy. 
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Background 
Coumarin-based oral anticoagulants act as vitamin K antagonists. They are the 
most commonly prescribed drugs for therapy (such as in venous thrombosis or 
pulmonary embolism) or prophylaxis (as in chronic atrial fibrillation, prosthetic 
heart valves and other cardiovascular diseases) of thromboembolic conditions. 
The primary goal of coumarin administration is to prevent clot formation and its 
expansion while carefully avoiding unintended adverse drug reactions (ADR) 
from over-anticoagulation.1 The effect of the therapy is monitored by the 
prothrombin-time international normalized ratio (INR). An INR of less than 2.0 
is associated with an increased risk of thromboembolism, and an INR of 4.0 or 
more denotes an increased risk of bleeding.2  
One of the bleeding complications occurring in patients receiving coumarins, is 
diffuse alveolar hemorrhage (DAH).3 DAH may be fulminant and lead to death. 
Due to the severe effects of overdosing and the narrow therapeutic window, 
correct management of coumarins is challenging. A safe and effective dose has 
to be determined during the early phase of therapy, and maintenance doses 
need to be adjusted to compensate for changes in patients’ weight, diet, 
disease state and concomitant use of other medication.4 The challenge is 
becoming even more demanding because of the increased use of coumarins 
that is a consequence of the aging of populations in industrialised countries. 
Despite the ability to closely monitor the therapeutic effect of coumarins, by 
means of the INR, there is a relatively high incidence of complications.1 Since 
early treatment of these complications is life-saving and may result in complete 
recovery. Therefore, early diagnosis can be critical. At present the diagnosis of 
DAH is often made by an increased percentage of siderophages (>20%) in 
bronchoalveolar lavage fluid (BALF), indicated with Perl’s staining.5  
Instead of early diagnosis, prevention would of course be much more 
preferable. The relatively high inter-individual drug requirement indicates that 
genetic factors may impact the therapeutic effect of coumarins. The strongest 
predictors of coumarin induced anticoagulant effects appear to be genes 
encoding for the enzyme vitamin K epoxide reductase complex 1 (VKORC1), 
the target of vitamin K antagonists. The enzyme VKORC1 recycles vitamin K 
epoxide to the reduced form of vitamin K, an essential cofactor in the formation 
of active vitamin K dependent clotting factors II (prothrombin), VII, IX, and X 
through γ-glutamyl carboxylation, see also Figure 6.1.6  
Another predictor appears to be cytochrome P450 (CYP) 2C9, the enzyme 
mainly responsible for the metabolism of coumarins.4,7,8 For instance patients 
with the common, functionally defective, *2 and *3 allelic variants of the  
CYP2C9 gene require significantly lower maintenance doses, take longer to 
achieve dose stabilization, and are at higher risk for serious and life-threatening 
bleeding than are patients without these variants.8 
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When using acenocoumarol as an oral anticoagulant, one might even consider 
CYP2C19, although its contribution to the metabolism of acenocoumarol is 
small compared with CYP2C9.9  
This study evaluates the association between the occurrence of DAH in patients 
after initiating coumarin anticoagulant therapy and the presence of VKORC1 
and CYP2C9 allelic variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Interactions in the vitamin K cycle and coagulation. The vitamin K cycle plays an 
important role in the formation of functional vitamin K-dependent clotting factors (FII, 
FVII, FIX, and FX). Within the vitamin K cycle VKORC1 is responsible for the reduction of 
vitamin K epoxide (the inactive form) to vitamin KH2 (the active form) and the target for 
oral anticoagulants. Interactions can occur on several levels: (1) If variant CYP2C9 alleles 
are present, inadequate metabolism of coumarins by the affected CYP enzyme will result 
in more inhibition of VKORC1. (2) If variant VKORC1 alleles are present, the VKORC1 
enzyme will be more sensitive to inhibition by anticoagulants, resulting in over-
anticoagulation. (3) Inhibition of VKORC1 by coumarins will prevent vitamin K epoxide to 
revert back to vitamin KH2, slowing down the vitamin K cycle. This inhibits the formation 
of vitamin K-dependent clotting factors. High levels of coumarins cause over-
anticoagulation. (4) Vitamin K supplementation stimulates the vitamin K cycle, thus 
preventing over-anticoagulation. * indicates antagonism. 
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Materials and methods 
Setting and study population 
Patients who were diagnosed with DAH at the Maastricht University Medical 
Centre (Maastricht, the Netherlands) from 2002 until 2009 were enrolled in the 
study. The inclusion criteria were bronchoalveolar lavage (BAL) performed in 
the diagnostic work-up and confirmed anticoagulant therapy initiated before 
the clinical episode of DAH. During this 7-year period, 1258 BAL analyses were 
carried out, and 252 cases with suspected DAH were identified. BAL was 
performed according to the hospital protocol, as reported previously.10 A total 
of 200 macrophages were counted, the total number of iron-stain (Perl’s 
stain)-positive macrophages were expressed as a percentage of the 200 cells 
counted. A percentage of >20% iron-positive macrophages was considered 
indicative for an alveolar hemorrhage.5 Of the obtained BALF samples, 173 
samples had >20% iron-stain-positive cells. In 75 of these 173 confirmed DAH 
cases, treatment with coumarins had been recently initiated. This study was a 
retrospective evaluation, and DNA was available only in 63 (84%) out of 75 
cases. In 40 of these 63 DAH cases, either genotyping for CYP2D6, CYP2C9, 
and CYP2C19 had been performed previously to evaluate whether there might 
be a drug-induced reaction involved in the observed clinical deterioration, or 
EDTA material was still available. In 23 cases, DNA was isolated from the cells 
in the BALF samples. All remaining samples were genotyped for CYP 
polymorphisms. In addition, for this study, VKORC1 genotyping was performed 
in these 63 DAH cases. 
A control population of 173 healthy, unrelated, Caucasian volunteers was also 
genotyped for the studied single nucleotide polymorphisms (SNPs). 
The study was performed in accordance with the Declaration of Helsinki and its 
amendments. Written informed consent was obtained. The protocol was 
approved by the Medical Ethics Board of the Maastricht University Medical 
Centre.  
Collection of clinical data 
Inpatient and outpatient medical records of these 63 unrelated patients of 
Caucasian origin, presenting with DAH and using coumarins, were reviewed. 
Two patients received phenprocoumol, and the remaining 61 patients received 
acenocoumarol. Routine laboratory tests, chest X-rays, and high-resolution CT 
scans were reviewed in all patients. Appropriate and relevant biopsies were 
also evaluated when available (18 cases).  
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Genotyping 
In addition to the previously determined polymorphisms, VKORC1 genotyping 
was performed.  
DNA was obtained from all subjects by using venous EDTA anticoagulated 
blood or BALF samples and isolated with a High Pure PCR Template Preparation 
Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s 
instructions.  
For genotyping the CYP2C9*2 (C430T), CYP2C9*3 (A1075C), CYP2C19*2 
(G681A), CYP2C19*3 (G636A), VKORC1 (G-1639A), and VKORC1 (C1173T) 
SNPs, three real-time PCR Fluorescence Resonance Energy Transfer (FRET) 
analyses were performed. FRET LightMix® assays (cat.-no. 40-0298-16, 
40-0304-16, and 40-0302-16; TIB MOLBIOL, Berlin, Germany) on the 
LightCycler® (Roche Diagnostics) were used, according to the manufacturer’s 
protocols. These three FRET assays simultaneously determined the two SNPs of 
CYP2C9, CYP2C19 and VKORC1, respectively, in separate capillaries. Each 
assay consisted of a duplex reaction measuring the melting curves of the used 
specific fluorescent probes in two different channels, each with a distinct 
wavelength. Positive (heterozygote, provided with the kit) and negative 
controls were determined with each run.  
Statistical analysis 
Statistical analyses were performed with SPSS version 15.0 software for 
Windows (SPSS Inc., Chicago, IL, USA) for Windows. The chi-square test was 
used to test for statistically significant differences between groups. Odds ratios 
(ORs) with 95% confidence intervals (CIs) were derived from these tables to 
evaluate the strength of associations between genotypes and the DAH event. 
Actual allele distributions were compared against the expected frequencies that 
were calculated, using the Hardy–Weinberg equilibrium. Deviations from 
Hardy–Weinberg equilibrium were analysed using the chi-square test. A 
p-value of <0.05 (two-sided) was considered to indicate statistical significance. 
A Bonferroni correction was applied, if appropriate, to adjust for multiple 
comparisons (p<0.01, indicating statistical significance). 
Results 
The characteristics and summary of relevant clinical data of the studied 
patients (15 females and 48 males) with DAH are listed in Table 6.1. Data 
subdivided on the basis of the presence of the studied polymorphisms did not 
show substantial differences (Table 6.1).  
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The reasons for the patients being on anticoagulants were as follows: atrial 
fibrillation or flutter (n=34); previous myocardial infarction (n=12); chronic 
heart failure (n=7); lung embolisms (n=4); valve replacement surgery (n=4); 
deep-vein thrombosis (n=2). The average dose of the coumarins was low 
(maximum 2 mg/day, with an initial dosing scheme of 6 mg/day for one day, 
then 4 mg/day for one day, and then 2 mg/day or 4 mg/day for two days and 
then 2 mg/day in elderly patients). The INR was above the therapeutic range 
within two weeks after initiation of anticoagulant treatment in all DAH cases 
(median 5.50, with 80% INR >4.00 and 40% INR >6.00). Most of the patients 
had several episodes of an increased INR during the follow-up, were difficult to 
normalize, and had to be kept on lower anticoagulant doses than is standard 
for the general population. Immunological analysis revealed no abnormalities, 
and no underlying systemic diseases were found. The high-resolution CT 
showed wide spread signs of DAH, with patchy bilateral or diffuse areas of 
ground-glass attenuation in all cases. A BAL was performed in all subjects, 
showing hemorrhagic BALF with a markedly positive iron staining (>22%, 
mean 59.3±25.7) and the presence of erythrocytes and pneumocytes type II, 
confirming the diagnosis DAH.10  
The allele frequencies and genotype distribution in the DAH patients were 
determined and compared with the distribution of the same polymorphisms in 
a healthy, unrelated, Caucasian population from our hospital and from 
populations in the literature (Table 6.2).11,12 Allele frequencies and genotype 
distributions of both control populations were in Hardy-Weinberg equilibrium. A 
VKORC1 variant allele was found in 51 of the 63 patients with DAH (81.0%, 
p<0.025). This included 20 homozygotes (AA/TT), including the only two 
patients in our population receiving phenprocoumol, and 31 heterozygotes 
(GA/CT). A CYP2C9 allelic variant was found in 31 of the 63 patients (49.2%, 
p<0.025), including three homozygotes, 26 heterozygotes, and two compound 
heterozygotes. Twenty (32.0%) out of the 63 DAH cases had both VKORC1 
and CYP2C9 allelic variants. In 31 (49.2%) out of these 63 DAH cases, only a 
VKORC1 allelic variant was found. Of the 12 DAH cases without a VKORC1 
allelic variant (GG/CC), five were CYP2C9*1/*2 heterozygotes, four were 
CYP2C9*1/*3 heterozygotes, and two had a compound heterozygous variant 
CYP2C9*2/*3 genotype. The remaining subject had no variant of the studied 
alleles. When comparing patients with controls for the presence of a 
polymorphism (polymorphism present versus no polymorphism), a significant 
difference was found (OR=14.6, 95% CI: 1.96-109.3; p<0.001). Furthermore, 
a CYP2C19 variant allele was found in one third of the DAH cases. In all of 
these patients, this coincided with the presence of a CYP2C9 and/or VKORC1 
allelic variant (Table 6.3).  
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Table 6.2 Allele frequencies and polymorphism distribution in diffuse alveolar hemorrhage (DAH) 
patients compared with healthy volunteers and historical controls. 
 Patients with DAHa Healthy volunteersb Controls from the literaturec 
 
CYP2C9 
(%) 
VKORC1 
(%) 
CYP2C19
(%) 
CYP2C9
(%) 
VKORC1
(%) 
CYP2C19
(%) 
CYP2C911
(%) 
VKORC111 
(%) 
CYP2C1912 
(%) 
No variant allele 50.8 19.0 66.7 61.9 29.5 76.3 64.0 34.0 75.3 
Variant allele  49.2d  81.0e  33.3f 38.1 70.5 23.7 36.0 66.0 24.7 
Alleleg          
        *1 71.4  81.7 79.7  86.4 80.0  86.5 
        *2 15.9  18.3 13.9  13.6 13.5  13.3 
        *3 12.7    0.0   6.4    0.0   6.5    0.2 
         G/C  43.7   52.3   58.5  
         A/T  56.3   47.7   41.5  
a n=63; sex 76.2% male, 23.8% female; age range=20–85 y. b n=173; sex 56.6% male, 43.4% 
female; age range=19–59 y. c For CYP2C9 and VKORC1: n=200; sex 50% male, 50% female; age 
range=18–24 y; For CYP2C19: n=736; sex 82% male, 18% female; age range=18–79 y. d p=0.022 
vs healthy volunteers; p=0.006 vs historical controls. e p=0.021 vs healthy volunteers; p=0.0015 vs 
historical controls. f p=0.024 vs healthy volunteers; p=0.046 vs historical controls. g For CYP2C9: 
*1=wild type, *2=430T, and *3=1075C; for CYP2C19: *1=wild type, *2=681A and *3=636A. 
VKORC1 SNPs are G-1639A and C1173T; genotype G/C is wild type and A/T is variant. 
 
 
Table 6.3 Influences on the coagulation: allelic variants and co-medication in patients (n=63) with 
diffuse alveolar hemorrhage. 
Patient CYP2C9a VKORC1b CYP2C19c Influence of 
no. 
genotype influence genotype influence genotype influence 
co-medication 
(yes/no) 
3 *1/*3 Yes AA/TT Yes *1/*2 Yes 2/1 
1 *1/*2 Yes AA/TT Yes *1/*2 Yes 1/0 
1 *2/*2 Yes AA/TT Yes *1/*1 No 0/1 
1 *1/*3 Yes AA/TT Yes *1/*1 No 1/0 
2 *1/*2 Yes AA/TT Yes *1/*1 No 2/0 
2 *1/*1 No AA/TT Yes *2/*2 Yes 1/1 
3 *1/*1 No AA/TT Yes *1/*2 Yes 2/1 
7 *1/*1 No AA/TT Yes *1/*1 No 3/4 
2 *2/*2 Yes GA/CT Yes *1/*1 No 1/1 
6 *1/*3 Yes GA/CT Yes *1/*1 No 5/1 
4 *1/*2 Yes GA/CT Yes *1/*1 No 3/1 
11 *1/*1 No GA/CT Yes *1/*2 Yes 8/3 
8 *1/*1 No GA/CT Yes *1/*1 No 4/4 
2 *2/*3 Yes GG/CC No *1/*1 No 1/1 
1 *1/*3 Yes GG/CC No *1/*2 Yes 0/1 
3 *1/*3 Yes GG/CC No *1/*1 No 2/1 
5 *1/*2 Yes GG/CC No *1/*1 No 2/3 
1 *1/*1 No GG/CC No *1/*1 No 1/0 
a CYP2C9 SNPs are C430T and A1075C; allele designations: *1=wild type, *2=430T, and *3=1075C. 
b VKORC1 SNPs are -G1639A and C1173T; genotype GG/CC is homozygous wild type and AA/TT is 
homozygous variant. c CYP2C19 SNPs are G681A and G636A; allele designations: *1=wild type, 
*2=681A and *3=636A.  
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The influence of allelic variants and co-medication on the anticoagulation in 
each individual case is summarized in Table 6.3. In about 60% of all the 
patients, co-medication was prescribed that might have influenced the 
coagulation. In only one patient - the one without any variant alleles in the 
VKORC1 or CYP2C9 - the co-medication might have caused the bleeding. In 
this patient, a drug-drug interaction was most likely, with no fewer than four 
drugs (amiodarone, paroxetine, pantoprazole, and clopidogrel), being used that 
could have interacted with the anticoagulant. The drugs prescribed to the 
patients that might have influenced the anticoagulation are listed in Table 6.4. 
Since May 2007, genotyping for the VKORC1 polymorphism, together with the 
earlier described CYP polymorphisms, has been available on request for 
clinicians in our hospital. Subsequently, in the period between May 2007 and 
December 2008, 11 patients with DAH were identified and included in this 
study. In all of these patients, vitamin K supplementation (1 mg/day, orally) 
was started. Out of the 11 patients, 10 responded quite well, recovered, and 
are still alive. Of the 63 studied DAH cases, 37 patients died, primarily because 
of complications related to heart failure in combination with DAH.  
 
Table 6.4 Medication influencing the coagulation in the patients in which this was relevant (n=39). 
Administered co-medication No. of patients 
amiodarone  15 
amitriptyline  1 
aspirin  5 
atorvastatine  7 
carvedilol  5 
clopidogrel  2 
colchicine  1 
esomeprazol  1 
felodipine  1 
fluoxetine  1 
insulin  2 
isoniazid  1 
levothyroxine  1 
nifedipine  1 
omeprazole  5 
pantoprazole  15 
paroxetine  4 
prednisone  8 
ranitidine  1 
rifampin  1 
simvastatin  2 
trimethoprim/sulfamethoxazole  2 
valproic acid  2 
verapamil  2 
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Discussion 
Anticoagulants can cause fatal pulmonary hemorrhage. Barnett et al.13 
reported a case of DAH due to superwarfarin ingestion. More recently, Erdogan 
et al.3 reported a case of DAH associated with coumarin therapy. We described 
a case of DAH in a patient who had malnutrition and was taking antibacterials 
and anticoagulants; at that time, genotyping was not yet available.14 DAH 
results in accumulation of iron in the lungs and, in turn, iron causes oxidative 
stress and inflammation. It has been suggested that oxidative damage plays a 
role in the pathophysiology of various diseases.15 It is important to prevent or 
recognize DAH at an early stage to avoid irreversible damage. Particularly, in 
critically ill patients with unexplained infiltrates, DAH should be considered. 
DAH events can occur as a result of over-anticoagulation due to coumarin 
sensitivity, caused by VKORC1 or CYP2C9 polymorphisms, resulting in a 
relative vitamin K deficiency. Prophylactic administration of vitamin K to 
patients at risk can prevent severe damage.16-18 Just recently, the information 
gathered from genotyping in this study has become available to clinicians. 
Subsequently, vitamin K supplementation (1 mg/day) was initiated in 11 DAH 
cases, resulting in a stabilization of the INR and a positive outcome in 10 of 
these 11 DAH cases. This supports the concept that the use of new 
pharmacogenetic-based dosing schemes and the concomitant application of 
low-dose vitamin K with coumarins will greatly improve coumarin drug 
safety.18,19  
Pharmacogenomics uses the tools of human genetics to tailor medical 
treatment to an individual’s genetic make-up. To this end, phenotypic 
manifestations, a therapeutic outcome, or ADRs are considered in relation to 
the underlying genetic background of a patient.7,20 The identification of the 
molecular target of coumarins, VKORC1, has greatly improved the 
understanding of coumarin treatment and illuminated new perspectives for a 
safer and more individualized oral anticoagulation therapy. Rieder et al.4 
previously demonstrated that the VKORC1 genotype appeared to be the most 
important genetic factor determining variability in coumarin dose; its effect was 
approximately three times higher than that of the CYP2C9 genotype. More 
recently, in line with this, Schwarz et al.16 concluded that the initial variability 
was more strongly associated with genetic variability in the pharmacogenetic 
target of coumarins, VKORC1, than with CYP2C9. 
Variations and SNPs within the translated and non-translated regions of the 
VKORC1 gene have been shown to cause coumarin resistance and sensitivity, 
respectively.21 A frequent SNP within the VKORC1 promoter (G-1639A) has 
been identified as a major determinant of coumarin sensitivity, reducing 
vitamin K epoxide reductase enzyme activity to 50% of wild type (GG=fully 
functional). Homozygous carriers of the VKORC1 -1639A allele (AA) are 
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strongly predisposed to coumarin sensitivity and require lower coumarin 
dosages. However, the link between DAH and the presence of VKORC1 and 
CYP2C9 variant alleles has never been made before.  
To the best of our knowledge, our study is the first one evaluating the 
association between the occurrence of a serious adverse reaction of 
anticoagulant therapy, DAH, and the presence of relevant polymorphisms. We 
found that in 62 (98.4%) of the patients in our study population, a variant 
allele was present. In 81.0% (51/63) of the studied patients, the bleeding 
complication could be explained by the VKORC1 haplotype (61.0% without and 
39.0% with a CYP2C9 allelic variant) alone. As also shown in Table 6.2, only 
19.0% of the patients had no VKORC1 1173T/-1639A variant alleles, compared 
with 29.5% in a healthy volunteer population (n=173) and 34.0% in a 
historical control population (n=200) from the literature.11 In 11 of the 12 DAH 
cases without a VKORC1 variant the CYP2C9 variant allele could explain the 
problems in reaching an appropriate INR. The present CYP2C9 functionally 
defective allelic variant required a 34% lower maintenance dose for the *1/*3 
genotype and a 61% reduction for the *2/*3 genotype, compared with 13% 
for the CYP2C9*1/*2. In the one remaining patient without any variant of the 
alleles studied, the high INR and subsequent DAH event seemed attributable to 
drug-drug interactions. One third of the patients had an extremely high risk as 
they appeared to have both genetic risk factors that are known to stratify 
patients into low dose/high-risk cases.16 Furthermore, the patients with 
VKORC1 and/or CYP2C9 allelic variants present need longer times before dose 
stabilization and are at a higher risk for serious and life-threatening bleeding, 
including DAH, than patients without these variants.8,22 
Our observation confirms that genotyping four SNPs, namely of the VKORC1 
and the CYP2C9 genes, predicts a high risk of overdosing with coumarins 
(warfarin, acenocoumarol, phenprocoumon).23 Although other studies have 
reported a strong linkage disequilibrium between the SNPs in the VKORC1 
gene, our own experience shows that sometimes only one of the examined 
SNPs can display a variant allele.24,25 Accordingly, this implies a potential risk 
factor could be missed if only one SNP is examined. Moreover, in this study, 
the VKORC1 results were obtained in one run, using a reagent combining 
primers and probes for both SNPs, without any extra time or costs. In the case 
of oral anticoagulation with acenocoumarol, genotyping for the *2 (G681A) and 
*3 (G636A) allelic variants in the CYP2C19 gene could be performed. Although 
acenocoumarol is mainly metabolized by CYP2C9 it is also partly metabolized 
by CYP2C19 (Figure 6.1).9 Polymorphisms in this enzyme system could 
therefore present additional anticoagulation problems. In our population, 
however, this polymorphism was of minor importance. All of the subjects with 
a CYP2C19 variant allele (33.3% of all of the patients) also displayed one or 
both of the other two studied polymorphisms.  
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One of the limitations of this study was the fact that DNA was available in only 
63 of the 75 subjects who used oral anticoagulants and were diagnosed with 
DAH. Therefore, conclusions from this case series should be interpreted with 
care, and prospective studies should be conducted to evaluate the cost 
effectiveness of genotyping. Moreover, confirmation of our findings in other 
populations is mandatory. However, the fact that all but one of the included 
patients with DAH demonstrated at least one of the studied genetic defects 
makes the association highly likely. The merits of genotyping before starting 
treatment involving drugs such as coumarins, the effectiveness of which 
depends on genetic variants of CYP2C9 and VKORC1, is still an area of debate 
between regulatory authorities and clinicians. Even though genotyping four 
SNPs is relatively cheap (about $US 200-250 in 2009) and needs to be 
performed only once in a lifetime, until its cost effectiveness is established, one 
could choose to only genotype patients who experience unstable INRs, in order 
to avoid serious complications. Nevertheless, as of August 2007, the US FDA 
issued a recommendation to genotype CYP2C9 and VKORC1 in warfarin 
product labeling, to optimize dosing schedules when prescribing warfarin.24,26 
Furthermore, it is tempting to speculate that by using individualized dose 
adaptation, a significant reduction of bleeding complications, including DAH, 
can be expected, especially in the initial drug-saturation phase.4 
Conclusion 
In all but one of the studied patients with DAH treated with coumarins, an 
association with either a VKORC1 or a CYP2C9 variant allele, or both, was 
found. Early and timely use of appropriate genotyping is important in case of 
coumarin treatment, because of the potential fatal outcome of over-
anticoagulation and the fact that simple vitamin K supplementation can be life-
saving. Therefore, in concordance with the FDA, genotyping of only four SNPs 
for VKORC1 and CYP2C9 allelic variants is recommended in order to provide a 
safer and more individualized anticoagulant therapy.  
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Abstract 
Background 
This study was designed to evaluate the relationship between the presence of tumor 
necrosis factor (TNF) polymorphisms, human leukocyte antigen (HLA)-DRB1*03 linkage 
and the prognosis of sarcoidosis.  
 
Study design 
In a retrospective case-control study, TNF-α G-308A, TNF-α G-238A, lymphotoxin-α 
(LTA) and HLA-DRB1*03 were genotyped in 625 sarcoidosis patients. These patients 
were classified into 298 patients with persistent disease and 327 patients with non-
persistent disease using chest X-ray (CXR) appearances and lung function parameters 
after at least two years of follow-up.  
 
Results 
The TNF-α -308A variant allele was observed in 25.5% of patients with persistent disease 
compared with 44.0% of patients with non-persistent disease. The corresponding odds 
ratio (OR) was 0.43 with a 95% confidence interval (CI) of 0.30-0.61. A strong linkage 
was found between TNF-α G-308A and HLA-DRB1*03 (OR=0.03, 95% CI: 0.02-0.05). 
For TNF-α G-238A and LTA NcoI A252G, there were no statistically significant differences 
in the distribution of genotypes between the groups with and without persistent disease. 
 
Conclusion 
The data indicate that presence of a TNF-α -308A variant allele and HLA-DRB1*03 were 
associated with a favorable prognosis. Because of the strong linkage between TNF-α 
G-308A and HLA-DRB1*03, genotyping of one simple and less expensive TNF-α single 
nucleotide polymorphism can be used to predict the prognosis of pulmonary sarcoidosis 
in clinical practice.  
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Introduction 
Sarcoidosis is a multisystem granulomatous disorder with distinct 
immunopathologic features. The disease is most likely the product of genetic 
susceptibility and an appropriate environmental antigen.1-3 The clinical 
presentation and outcome of sarcoidosis varies considerably. Therapeutic 
options range from no treatment to a variety of therapeutic agents.  
It is well known that the outcome of sarcoidosis varies considerably.4 The 
presence of hilar adenopathy alone5,6 or patients presenting with Löfgren’s 
syndrome more often have a favorable outcome as compared with those with 
parenchymal lung disease.7-9 By contrast, the presence of pulmonary fibrosis is 
associated with chronic disease.5 Pulmonary disease is the most common 
manifestation of sarcoidosis, and pulmonary symptoms are the most common 
reason for treatment.1,3 It is important to identify the patients who are likely to 
have a poor prognosis, to ensure the appropriate individual treatment regimen 
without delay.10 Genetic polymorphisms contribute to clinical phenotypes.6,9,11 
Association of sarcoidosis and class I and II human leukocyte antigens (HLA) 
antigens is well known.3,6,12 Grunewald et al. reported an influence of both HLA 
class I and class II alleles on the disease course in patients with sarcoidosis. 
They found that 76.8% of patients with resolving disease, appeared to be HLA-
DRB1*03 positive, in contrast to only 9.2% of patients with persistent disease.6 
Tumor necrosis factor alpha (TNF-α), a potent pro-inflammatory cytokine that 
plays a pivotal role in inflammatory and immune responses, regulates and 
sustains granuloma formation in sarcoidosis.3 TNF-α production is an innate 
host characteristic that varies between individuals and is associated with 
certain HLA-D receptor (HLA-DR) alleles.13 The TNF gene locus, comprising of 
the TNF-α, lymphotoxin-α (LTA, formerly also referred to as TNF-β) and 
lymphotoxin-β genes, is located in the class III region of the major 
histocompatibility complex (MHC). Genetic analysis has showed a number of 
polymorphisms in these genes and new polymorphisms with potential 
functional consequences.7,14-16 Of genes in the MHC III region, the TNF-α 
polymorphisms have been extensively studied. Several single nucleotide 
polymorphisms (SNPs) are identified in the TNF-α gene. Among these, a 
common polymorphism in the promoter region, a G to A substitution at position 
-308, has been associated with variation of TNF-α production. Especially the 
A-allele of the TNF-α G-308A gene is associated with higher TNF-α serum 
levels and an acute course of sarcoidosis.17 The existence of a strong linkage 
disequilibrium between HLA-DRB1*03 and the TNF-α -308A variant allele has 
been shown.6,9,18 In addition to the TNF-α G-308A polymorphism, others found 
that the TNF-α G-238A and LTA NcoI A252G SNPs were associated with 
variations in TNF-α production and suggested a possible role in the course of 
sarcoidosis.7,8,11,17  
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The aim of the present study was to assess the association among TNF-α 
G-308A, TNF-α G-238A and LTA NcoI A252G variant alleles and clinical 
outcome in sarcoidosis. In addition, the linkage between TNF-α G-308A and 
HLA-DRB1*03 and its influence on disease course in our population was 
studied. 
Materials and methods 
Patients 
From January 2000 to July 2008, 625 consecutive Dutch Caucasian sarcoidosis 
patients, attending the outpatient referral clinic of the Sarcoidosis Management 
Center of the Department of Respiratory Medicine of the Maastricht University 
Medical Centre (MUMC) were included in this study. The time since diagnosis to 
inclusion and/or follow-up for all patients was at least two years. The diagnosis 
was based on a positive biopsy in 71% of cases. In patients with typical 
features of Löfgren’s syndrome and characteristic features of bronchoalveolar 
lavage (BAL) fluid analysis results, no biopsy was obtained. This policy is 
consistent with the World Association of Sarcoidosis and Other Granulomatous 
diseases (WASOG) guidelines.1  
The study was performed in accordance with the Declaration of Helsinki and its 
amendments. The protocol was approved by the Medical Ethics Board of the 
MUMC. Written informed consent for participation in this study was obtained 
from all subjects. 
Collection of clinical data 
Clinical course of patients with sarcoidosis was defined using changes in CXR 
stage and lung function parameters during follow-up. All CXR films were 
graded by a single observer, who was not aware of the clinical data. Five 
stages of the radiographical abnormality were recognized: stage 0 (normal 
CXR), stage I (bilateral hilar lymphadenopathy [BHL]), stage II (BHL and 
parenchymal abnormalities), stage III (parenchymal abnormalities without 
BHL) and stage IV (end stage lung fibrosis).  
For the main analysis, patients were categorized into groups with and without 
persistent sarcoidosis. Persistent disease was defined as worsening of the CXR 
stage to stage II or higher, or remaining at CXR stage II or III, at least two 
years after diagnosis. Non-persistent disease cases were those who remained 
at or regressed to stage 0 or I. 
At inclusion, the forced vital capacity (FVC) and forced expiratory volume in 1 s 
(FEV1) were measured with a pneumotachograph (Masterlab, Jaeger, 
Würzburg, Germany). The diffusing capacity for carbon monoxide (DLCO) was 
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measured by the single-breath method (Masterlab). Values were expressed as 
a percentage of predicted values. The cut-off value for the DLCO, FEV1 and FVC 
was <80% of predicted (≥80% is normal).19 
TNF and HLA typing 
TNF  
DNA was obtained using venous EDTA anti-coagulated blood and isolated with 
a High Pure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, 
Germany) according to the manufacturer’s instructions. 
All patients were genotyped for two TNF-α promoter polymorphisms (G-308A 
and G-238A) and one LTA polymorphism (LTA NcoI A252G, also known as 
lymphotoxin-α, LTA_NcoI, LTA+252, or TNF-β NcoI A329G).20,21 For 
genotyping TNF-α G-308A, TNF-α G-238A and LTA NcoI A252G SNPs, real-time 
PCR Fluorescence Resonance Energy Transfer (FRET) assays (TIB MOLBIOL, 
Berlin, Germany) were performed as described by Bestmann et al.20 on the 
LightCycler® (Roche Diagnostics). The person who performed the analyses was 
blinded to the clinical data that were used for the classification of subjects 
according to disease course. 
HLA 
Genomic DNA was isolated with QIA-AMP kits following the supplier’s protocol 
(Qiagen, Westburg, Leusden, The Netherlands). Concentration and purity of 
DNA samples were measured at 260 nm and 260/280 nm. 
Low-resolution typing of HLA-DRB1 was obtained by Luminex reverse SSO, 
using bead kits from One Lambda (One Lambda, Bethesda, MD) or by PCR-SSP 
using 45 in-house primer mixes as described previously.22 
Statistical analysis 
Statistical analyses were performed with SPSS 15.0 (SPSS Inc., Chicago, IL) for 
Windows. 
Cross tables were used to compare the observed percentages with each 
genotype between groups of patients differing in prognosis. The chi-square test 
was used to test for statistical significant differences between groups. Odds 
ratios (ORs) with 95% confidence intervals (CIs) were also derived from these 
tables to evaluate the strength of associations between genotypes and the 
course of sarcoidosis. Multivariate logistic regression models were used to 
adjust for differences in baseline characteristics between compared groups. A 
p-value of <0.05 (two sided) was considered to indicate statistical significance. 
Deviations from the Hardy–Weinberg equilibrium were analysed using the 
chi-square test. 
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Results 
Patient characteristics of the studied total population and within groups of 
patients with and without persistent sarcoidosis are summarized in Table 7.1. 
Patients with persistent disease more often were male, smoked less often and 
were more frequently treated with corticosteroids. At diagnosis, the percentage 
with CXR stage 0 or I was much lower in patients with persistent disease than 
in the patients with non-persistent disease. Persistent disease was also 
associated with lower mean values of DCLO, FEV1 and FVC at diagnosis.  
 
Table 7.1 Patient characteristics for the total population and sorted by disease persistence. 
  Total population Non-persistent Persistent pa 
  (n=625) (n=327) (n=298) value 
Gender  Female  280 (44.8)  178 (54.4)  102 (34.2)  
 Male  345 (55.2)  149 (45.6)  196 (65.8) <0.001 
Age at diagnosis Year±SD 
(range) 
40.2±11.7 
(12-84) 
40.5±12.6 
(17-84) 
39.8±10.6 
(12-76) 
 
 <40 year  353 (56.5)  185 (56.6)  168 (56.4)  
 ≥40 year  272 (43.5)  142 (43.4)  130 (43.6) 1.00 
Smoking No  556 (89.1)  282 (86.2)  275 (92.3)  
 Yes  68 (10.9)  45 (13.8)  23 (7.7) 0.020 
Time since diagnosis <5 year  154 (24.6)  82 (25.1)  72 (24.2)  
 ≥5 year  471 (75.4)  245 (74.9)  226 (75.8) 0.78 
Corticosteroid use No  281 (45.0)  185 (56.6)  96 (32.2)  
 Yes  344 (55.0)  142 (43.4)  202 (67.8) <0.001 
CXR at diagnosis 0  59 (9.4)  59 (18.1) 0  
 I  188 (30.1)  178 (54.4)  10 (3.4)  
 II  244 (39.1)  65 (19.9)  179 (60.1)  
 III  134 (21.4)  25 (7.6)  109 (36.5) <0.001c 
CXR at follow-up 0  270 (43.2)  270 (82.6) 0  
 I  57 (9.1)  57 (17.4) 0  
 II  142 (22.7) 0  142 (47.7)  
 III  74 (11.9) 0  74 (24.8)  
 IV  82 (13.1) 0  82 (27.5) <0.001d 
DLCOb Mean ± SD 
(range) 
81.2±17.3 
  (23-129) 
86.9±15.1 
(37-129) 
75.0±17.5 
(23-121) 
 
 ≥80%  341 (56.0)  228 (71.9)  113 (38.7)  
 <80%  268 (44.0)  89 (28.1)  179 (61.3) <0.001 
FEV1b Mean ± SD 
(range) 
89.8±21.5 
  (23-140) 
99.8±15.6 
(54-140) 
78.7±21.7 
(23-128) 
 
 ≥80%  439 (72.4)  289 (91.2)  150 (51.9)  
 <80%  167 (27.6)  28 (8.8)  139 (48.1) <0.001 
FVCb Mean ± SD 
(range) 
98.7±19.1 
  (25-152) 
106.0±15.5 
(66-152) 
90.5±19.4 
(25-148) 
 
 ≥80%  509 (84.8)  301 (95.3)  208 (73.2)  
 <80%  91 (15.2)  15 (4.7)  76 (26.8) <0.001 
a Non-persistent versus persistent. b % of predicted (<80% is abnormal). c CXR 0+I versus II+III. 
d CXR IV versus 0+I+II+III. n=number, SD=standard deviation, CXR=chest X-ray, DLCO=diffusing 
capacity of carbon monoxide, FEV1=forced expiratory volume in 1 s, FVC=forced vital capacity. 
Missing: 16/19/25 for DLCO/FEV1/FVC, respectively. All values presented are absolute numbers with 
percentages in parentheses unless otherwise specified.  
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Table 7.2 shows the distribution of polymorphisms for TNF-α G-308A, TNF-α 
G-238A, LTA and HLA-DRB1*03 in patients with and without persistent 
disease. The TNF-α -308A variant allele was more often present in the patients 
with non-persistent disease (44.0%) when compared with patients having 
persistent disease (25.5%). This difference was statistically significant 
(p<0.001). HLA-DRB1*03 was comparable with the TNF-α G-308A with 34.9% 
of patients with non-persistent disease being DRB1*03 positive and of the 
patients with persistent sarcoidosis 13.4% having DRB1*03, see Table 7.2.  
 
Table 7.2 Genotype distributions for the total population and sorted by disease persistence. 
 Genotype Total population Non-persistent Persistent pa 
  (n=625) (n=327) (n=298) value 
TNF-308  GG  405 (64.8) 183 (56.0) 222 (74.5)  
 GA 200 (32.0) 129 (39.4)   71 (23.8) <0.001b 
 AA 20 (3.2) 15 (4.6)   5 (1.7)  
TNF-238 GG  562 (89.9) 290 (88.7) 272 (91.3)  
 GA   63 (10.1)   37 (11.3) 26 (8.7) 0.29 b 
 AA 0 0 0  
LTA AA 281 (45.0) 130 (39.8) 151 (50.7)  
 AG 279 (44.7) 158 (48.3) 121 (40.6) 0.09 b 
 GG   65 (10.3)   39 (11.9) 26 (8.7)  
DRB1*03 Neg 471 (75.4) 213 (65.1) 258 (86.6)  
 Pos 154 (24.6) 114 (34.9)   40 (13.4) <0.001 
a Non-persistent versus persistent. b No variant allele versus variant allele. TNF-308=TNF-α G-308A, 
TNF-238=TNF-α G-238A, LTA=LTA NcoI A252G, DRB1*03=HLA-DRB1*03, GG=wild type for 
TNF-308 and TNF-238, for LTA wild type=AA. All values presented are absolute numbers with 
percentages in parentheses unless otherwise specified.  
 
 
For TNF-α G-238A and LTA there were no statistically significant differences in 
the distribution of genotypes between the groups with and without persistent 
disease; therefore, these polymorphisms were not used for further analysis. 
However, for the LTA there was a trend towards a higher G-allele percentage in 
the group with non-persistent disease (60.2%) compared with the group with a 
persistent course (49.3%). 
In Table 7.3, patients were classified according to genotype distribution and 
next to persistent versus non-persistent disease outcome or HLA-DRB1*03 
presence, alternative clinical parameters for clinical course, such as CXR stage 
and lung function test results are shown. Patients with poor prognosis were 
compared with patients with good prognosis with respect to the distribution of 
the TNF-α -308A variant allele. Those with CXR stage 0 and lung function 
parameters ≥80% represented the group with good prognosis and were used 
as reference. The ORs with 95% CIs were consistently and in most 
comparisons significantly lower than 1, indicating a protective effect of the 
presence of a TNF-α -308A variant allele. Presence of the TNF-α -308A variant 
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allele is associated with good prognosis: in the groups with favorable clinical 
outcome this allele was observed significantly more often than in the groups 
with a less favorable clinical outcome. The OR was 0.43 with 95% CI: 0.31-
0.61. After adjustment for age, gender, corticosteroid use and smoking, the 
odds ratio remained the same: OR=0.43 (95% CI: 0.30-0.61). 
 
 
Table 7.3 Prognosis by genotype distribution of the TNF-α G-308A variant. 
  GG GA AA ORa (95%CI) pa 
  (n=405) (n=200) (n=20) carriage -308A value 
Persistence No  183 (56.0)  129 (39.4)  15 (4.6) 1  
 Yes  222 (74.5)    71 (23.8)    5 (1.7) 0.43 (0.30-0.61) <0.001 
DRB1*03 Pos    18 (11.7)  118 (76.6)    18 (11.7) 1  
 Neg  387 (82.2)    82 (17.4)    2 (0.4) 0.03 (0.02-0.05) <0.001 
CXR stage 0  150 (55.6)  109 (40.4)  11 (4.0) 1  
 I    33 (57.9)    20 (35.1)    4 (7.0) 0.91 (0.51-1.63) 0.75 
 II  105 (74.0)    34 (23.9)    3 (2.1) 0.45 (0.28-0.68) <0.001 
 III  47 (63.5)    25 (33.8)    2 (2.7) 0.72 (0.41-1.23) 0.23 
 IV  70 (85.4)    12 (14.6) 0 0.19 (0.09-0.38) <0.001 
CXR improving No  286 (70.1)  111 (27.2)  11 (2.7) 1  
 Yes  119 54.8)    89 (41.0)    9 (4.2) 1.93 (1.37-2.72) <0.001 
CXR stable No  197 (63.8)  103 (33.3)    9 (2.9) 1  
 Yes  208 (65.8)    97 (30.7)  11 (3.5) 0.91 (0.66-1.27) 0.62 
CXR worsening No  327 (61.3)  186 (34.9)  20 (3.8) 1  
 Yes    78 (84.8)    14 (15.2) 0 0.28 (0.16-0.52) <0.001 
DLCOb Mean±SD  
(range) 
80.3±17.0 
(37-128) 
82.2±18.1 
(23-129) 
89.2±14.9 
(57-121) 
  
 ≥80%  208 (61.0)  116 (34.0)  17 (5.0) 1  
 <80%  188 (70.2)    77 (28.7)    3 (1.1) 0.68 (0.48-0.97) 0.031 
FEV1b Mean±SD  
(range) 
87.6±21.7 
(26-140) 
93.0±20.9 
(23-136) 
100.4±16.1 
(71-128) 
  
 ≥80%  272 (62.0)  149 (33.9)  18 (4.1) 1  
 <80%  122 (73.1)    43 (25.7)    2 (1.2) 0.61 (0.40-0.93) 0.020 
FVCb Mean±SD  
(range) 
97.2±18.9 
(33-152) 
100.6±19.3 
(25-147) 
109.1±15.6 
(83-148) 
  
 ≥80%  320 (62.9)  170 (33.4)  19 (3.7) 1  
 <80%    69 (75.8)    22 (24.2) 0 0.56 (0.33-0.95) 0.031 
a No variant allele versus variant allele. b % of predicted (<80% is abnormal). n=number, OR=Odds 
ratio corrected for age, gender, corticosteroid use and smoking, SD=standard deviation, 
DRB1*03=HLA-DRB1*03, CXR=chest X-ray, DLCO=carbon monoxide diffusing capacity, FEV1=forced 
expiratory volume in 1 s, FVC=forced vital capacity, -308A=TNF-α -308A variant allele, GG=wild type, 
GA=heterozygote, AA=homozygote variant. Missing: 16/19/25 for DLCO/FEV1/FVC, respectively. All 
values are absolute numbers with percentages in parentheses unless otherwise specified.  
 
The OR for the HLA-DRB1*03 positive versus negative cases compared with 
the presence of a TNF-α -308A variant allele was 0.03 (95% CI: 0.02-0.05) 
indicating a strong association. 
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Table 7.3 also shows an increase in mean values of lung function test result 
parameters as the number of A-alleles in the TNF-α G-308A genotype increases 
(e.g. mean % DCLO GG=80.3 < GA=82.2 < AA=89.2).  
In the total population the proportions of patients without or with a TNF-α 
G-308A variant allele were 64.8% (GG) and 35.2% (32.0% GA and 3.2% AA), 
respectively (chi2=0.61, p=0.74). These findings were in accordance with the 
Hardy-Weinberg equilibrium. The observed allele frequencies for all 625 
patients were 80.8% for the TNF-α G-308 and 19.2% for the TNF-α -308A 
allele (p=0.18). The frequency distribution is similar to the distribution reported 
in healthy Dutch controls (75.0% for the G-allele and 25.0% for the A-allele) 
from the literature.23 
Discussion 
In this study, we observed that the presence of a TNF-α -308A variant allele 
had a favorable impact on radiologic evolution and prognosis in sarcoidosis. 
Patients without a TNF-α -308A variant allele had a significantly higher risk of 
developing persistent sarcoidosis with progression to a higher CXR stage and 
worsening of lung function, particularly the DLCO and FVC. Furthermore, the 
existence of a strong linkage disequilibrium between the TNF-α -308A variant 
allele and the presence of HLA-DRB1*03 was confirmed. 
In our current study, the presence of a TNF-α -308A variant allele was 
associated with a lower risk of worsening of the disease. No association 
between the TNF-α G-308A polymorphism and sarcoidosis in general was found 
as all genotype and allele frequencies of the 625 studied sarcoidosis patients 
were in Hardy-Weinberg equilibrium, similar to control populations in literature 
and in concurrence with findings from earlier studies.8,11,23,24 In a meta-analysis 
by Medica et al., it was concluded that the presence of the TNF-α -308A variant 
allele increased the susceptibility to and risk of sarcoidosis by as much as 47%, 
and it was suggested that the polymorphism could be involved in the clinical 
presentation of sarcoidosis.17 
When sorting the sarcoidosis patients into persistent and non-persistent 
categories a clear association did emerge between the absence of the TNF-α 
-308A variant allele and sarcoidosis persistence (OR=0.43, p<0.001). In earlier 
studies, it was found that carriers of the TNF-α -308A variant allele were more 
prone to go through the more acute form (i.e. Löfgren’s syndrome) of 
sarcoidosis with frequent spontaneous remission.8,9,11 This is accordance with 
our finding that presence of the TNF-α -308A variant allele is more prevalent in 
the non-persistent group.  
Categorizing the patients according alternative parameters for clinical course, 
instead of grouping them into patients with persistent and non-persistent 
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disease, also showed strong associations with the distribution of the TNF-α 
G-308A genotype. Looking at the results from this perspective revealed that 
the TNF-α -308A variant allele was absent in the large majority of patients who 
had evolved to CXR stage IV at the end of follow-up (OR=0.19, p<0.001). 
Previous studies are hard to compare with our data as not only sample size and 
characteristics of the participants (ethnicity) displayed significant 
heterogeneity, but sarcoidosis patients were almost always only categorized 
into Löfgren and non-Löfgren patients, and not according to the different CXR 
stages. Therefore, previously no conclusions could be drawn about associations 
or differences in genotype distribution between the various CXR stages.6,8,11 
The categorization according to alternative parameters of clinical outcome also 
showed that the mean lung function test results were worse in the wild type 
(TNF-308 GG) category (Table 7.3). The finding that presence of the variant 
A-allele is strongly and consistently associated with a more favorable 
prognosis, irrespective of the definition of good prognosis, lends support to the 
validity of this association. Moreover, the large sample size in this study also 
makes it very unlikely that the findings are due to chance. 
When examining the selected TNF polymorphisms, only the TNF-α G-308A SNP 
showed significant association with disease progression. The TNF-α G-238A 
polymorphism did not show a different distribution for the non-persistent and 
persistent disease groups. In accordance to others, we observed that presence 
of the LTA NcoI 252G variant allele only tended to be higher in patients who 
did not progress, ruling it out as a prognostic factor.25 In a Japanese 
population, however, as studied by Yamaguchi et al., the A-allele of the LTA 
NcoI A252G polymorphism was found to be a marker for prolonged clinical 
course.26 This is an important reminder of the fact that populations of different 
ethnicity, as in this case Japanese versus Caucasian, can display different 
associations to the same polymorphisms. However, in line with Mrazek et al., 
we also found a slight increased but not statistically significant LTA NcoI 252G 
variant allele presence (34.6%; chi2=1.52, p=0.22 ) in CXR stage I at 
diagnosis compared with CXR stages 0, II and III.7 
In the current study, it was also found that smoking appeared to protect 
against progressing to persistent sarcoidosis, for fewer smokers were present 
in the persistent disease group. This was in accordance with findings from 
earlier studies.27-30  
Interestingly, in our population, men more often showed progression to 
persistent sarcoidosis. It is tempting to speculate that this might be explained 
by the fact that males were more frequently exposed to occupational and/or 
environmental antigenic triggers than females (67.4% versus 31.2%, 
respectively). It is known that these triggers, beside genetic factors, are 
involved in the pathogenic concept of sarcoidosis.3,31,32 
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The frequency of use of systemic corticosteroids was higher in patients with 
persistent disease and may be a confounder for clinical course. However, after 
adjustment for differences in baseline characteristics between the groups with 
persistent and non-persistent disease using multivariate logistic regression, the 
OR associated with the presence of the TNF-α -308A variant allele did not 
change and was still indicative of a halving of the risk of persistent disease.  
In the clinical management of sarcoidosis patients, it is important to identify 
those cases that might have a chance to develop a more severe manifestation 
of sarcoidosis. In those particular cases, treatment aimed at avoiding 
irreversible damage should be started early.33 Corticosteroids are still the first 
drug of choice to treat sarcoidosis in most cases, but it is well known that long-
term use is associated with significant toxicity.33 Since a few years anti-TNF-α 
agents are being used more frequently, especially in chronic cases.10,34 Failure 
of patient response to conventional therapy or the presence of unacceptable 
side effects from other available drugs, especially prednisone, constitute the 
most common reasons for prescribing an anti-TNF-α agent for sarcoidosis.34 
When considering anti-TNF-α treatment it can be very important to have 
information that might be helpful in predicting whether a patient will be a 
responder or non-responder. Studies into responders and non-responders to 
anti-TNF-α therapy have been carried out, e.g. in rheumatoid arthritis (RA) 
patients by Mugnier et al.35 They found that patients without a TNF-α G-308A 
allelic variant were the overall better responders. As shown in the present 
study, patients without a TNF-α -308A variant allele were also more prone to 
develop the persistent form of sarcoidosis. Interestingly, in the infliximab trial 
by Baughman et al., it was found that the patients with a more severe or 
longer duration of (i.e. persistent) pulmonary disease including reduced FVC, 
severe dyspnoea as well as a more impaired quality of life were more likely to 
respond to anti-TNF-α treatment.36 This might suggest that they were most 
likely cases without a variant allele. In accordance to experiences with RA 
patients, it seems to be practical and helpful to monitor sarcoidosis patients 
without a TNF-α G-308A allelic variant early and initiate treatment accordingly. 
So it appears that one simple and less expensive SNP test prior to treatment 
could not only render very useful information about progression. Given that this 
was beyond the scope of this study, future study should evaluate whether a 
single SNP test (TNF-α G-308A) might also be helpful in deciding to start anti-
TNF-α treatment or not. Moreover, when anti-TNF-α treatment is considered 
genotyping TNF-α G-308A may be a useful tool to differentiate between 
responders and non-responders of anti-TNF-α treatment in sarcoidosis. 
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Conclusion 
Our results clearly show that genotyping for the TNF-α G-308A polymorphism 
is helpful in predicting prognosis in sarcoidosis patients. The risk of progressing 
to a more severe pulmonary involvement is higher in the absence of a TNF-α 
G-308A allelic variant and HLA-DRB1*03. Because of the strong linkage 
between TNF-α G-308A and HLA-DRB1*03 genotyping of one simple TNF-α 
SNP is useful in predicting the prognosis of pulmonary sarcoidosis. The findings 
in this study can be used as a base for further clinical validation of the use of 
TNF-α G-308A genotyping to predict the clinical course of sarcoidosis in 
individual patients. Research must continue to depict the role of TNF genes in 
the immunogenetics and clinical management of sarcoidosis.  
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Abstract 
Background 
The aims of this study were to assess the association of BTNL2 G16071A with the course 
of pulmonary sarcoidosis and verify association with disease predisposition. In addition, 
the linkage between BTNL2 G16071A and certain HLA-DRB1/DQB1 types was 
investigated. 
 
Methods 
In a retrospective case-control study BTNL2 G16071A, HLA-DQB1 and DRB1 were typed 
in 632 sarcoidosis patients. These patients were classified into 304 patients with 
persistent and 328 patients with non-persistent sarcoidosis. 
 
Results 
The BTNL2 16071A variant allele was significantly more often present in patients with 
persistent disease (92.4%; 281/304) compared with patients demonstrating a non-
persistent course (86.6%; 284/328); odds ratio (OR)=1.89 with 95% confidence interval 
(CI 95%): 1.11-3.22.  
Furthermore, BTNL2 16071A variant allele carriers have an increased risk (OR=1.85, CI 
95%: 1.19-2.88) to develop sarcoidosis. Moreover, the strong linkage between variant 
allele and HLA-DRB1*15 presence (OR=8.43, CI 95%: 3.02-23.5) was confirmed. 
 
Conclusion 
The presence of a BTNL2 G16071A variant allele almost doubles the risk of progressing 
to persistent pulmonary sarcoidosis, besides increasing the risk to develop sarcoidosis. 
Presumably, these increased risks are due to the strong linkage between BTNL2 
G16071A and DRB1*15. The choice between determining BTNL2 G16071A SNP or the 
HLA-DRB1 type depends on the ability and/or availability to perform either test. 
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Introduction 
Sarcoidosis is a multisystem granulomatous disorder of which clinical 
presentation and outcome vary considerably.1-3 The assumption that genes 
contribute to the etiology of sarcoidosis comes from the observation that 
prevalence and incidence rates of sarcoidosis are different between ethnic 
groups and that the disease tends to cluster in families. Next to family 
clustering, disease clustering in time and place, often with co-workers, was also 
noted.4 Therefore, shared common environmental exposures must be 
considered as well. However, the etiology may not prove to be a single, known 
exposure, and the confirmation of interactions of exposure with genetic 
predispositions would have important implications for the understanding of 
immune responses as well as the pathogenesis of sarcoidosis.4  
In previous studies the association between single nucleotide polymorphisms 
(SNPs) in the butyrophilin-like 2 (BTNL2) gene and the risk to develop 
sarcoidosis has been shown.5-8 The BTNL2 G16071A (rs2076530) 
polymorphism showed the strongest association with sarcoidosis.6 Arnett et al. 
found that the functional BTNL2 reduces proliferation and cytokine production 
from activated T-cells, suggesting a role for BTNL2 as a negative co-
stimulatory molecule with implications for inflammatory disease.9 The A-allele 
of the BTNL2 G16071A polymorphism causes a premature truncation of the 
protein, disrupting insertion in the cell membrane, a necessary process for 
downregulating activated T-cells (Th1).5,10 The truncated protein increases the 
risk of developing sarcoidosis independent of HLA-DRB1 risk alleles.5,6 
However, a possible association with the prognosis of sarcoidosis was not 
investigated. Until now an association with chronic sarcoidosis only has been 
suggested, because of an established strong linkage of the BTNL2 16071A 
variant allele with HLA-DRB1*15 (DRB1*15).6 Association of sarcoidosis and 
class I and II HLA antigens is well known and several studies established the 
risk of progression of sarcoidosis and presence or absence of specific HLA-
types.11-15 In addition, DRB1*15 and the DQB1*0602/DRB1*1501 haplotype in 
particular, was associated with more severe sarcoidosis, whereas DRB1*03 has 
been associated with good prognosis.11,13,16,17  
Pulmonary disease is the most common manifestation of sarcoidosis and 
pulmonary symptoms are the most common reason for treatment.1,18 
Numerous studies have confirmed the utility of chest X-ray (CXR) stages as a 
prognostic guide.1 The presence of hilar adenopathy alone (CXR stage I) is 
usually associated with good prognosis.1,11,19 By contrast, presence of 
parenchymal infiltrates (CXR stages II-IV) is associated with chronic 
disease.1,19 Spontaneous remissions occur in 55-90% of patients with stage I, 
40-70% of patients with stage II, 10-20% of patients with stage III, and in 0% 
of patients with stage IV disease.1 Because of recognized value, CXR staging 
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was used in several studies to categorize sarcoidosis patients into subgroups 
with different pulmonary manifestations.1,20,21 
 
The aims of this study were to assess the association of BTNL2 G16071A with 
the course of pulmonary sarcoidosis and to verify the association with disease 
predisposition. In addition, the linkage between BTNL2 G16071A and certain 
HLA-DRB1/DQB1 types was investigated. 
Materials and methods 
Patients 
From January 2000 to July 2008, 632 consecutive Dutch Caucasian sarcoidosis 
patients, attending the outpatient referral clinic of the ild care center of the 
Department of Respiratory Medicine of the Maastricht University Medical Centre 
(MUMC) The Netherlands, were included in this study. Time between diagnosis 
or inclusion and end of follow-up for all patients was at least two years. 
Diagnosis was in 71% of cases based on a positive biopsy (lung, skin, lymph 
node or liver). In patients with typical features of Löfgren’s syndrome and 
characteristic features of bronchoalveolar lavage (BAL) fluid analysis results 
(including lymphocytosis), no biopsy was obtained.22,23 This policy is consistent 
with the World Association of Sarcoidosis and Other Granulomatous diseases 
(WASOG) guidelines.1  
A control group consisting of 1474 local, healthy, unrelated Dutch Caucasian 
volunteers, hospital workers, and blood or stem cell donors (age: 48.8±10.3 
(21-86); 48.6% female) was used for HLA typing. Out of this control group 200 
samples were randomly selected and typed for the BTNL2 SNP. 
The study was performed in accordance with the Declaration of Helsinki and its 
amendments. The protocol was approved by the Medical Ethics Board of the 
MUMC. Written informed consent for participation in this study was obtained 
from all subjects. 
Collection of clinical data 
At inclusion forced vital capacity (FVC) and forced expiratory volume in one 
second (FEV1) were measured with a pneumotachograph (Masterlab, Jaeger, 
Würzburg, Germany). The diffusing capacity for carbon monoxide (DLCO) was 
measured by the single-breath method (Masterlab). Values were expressed as 
a percentage of predicted values. Missing values for DLCO/FEV1/FVC were 
17/21/26, respectively. The cut-off value for the DLCO, FEV1, and FVC was 
<80% of predicted (≥80% is normal).24 Respiratory functional impairment 
(RFI) was defined as DLCO<80%, FVC<80% or FEV1<80% (percentage of 
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predicted). Patients without RFI were those for whom all three indices were 
normal (≥80%).25  
Clinical course of patients with sarcoidosis was defined using changes in CXR 
stage during follow-up. All CXRs were graded by a single experienced observer, 
who was not aware of the clinical data. Five stages of radiographical 
abnormality were recognized: stage 0 (normal CXR), stage I (bilateral hilar 
lymphadenopathy [BHL]), stage II (BHL and parenchymal abnormalities), stage 
III (parenchymal abnormalities without BHL), and stage IV (end stage lung 
fibrosis).  
For the analysis with respect to prognosis, patients were categorized into 
groups with persistent and non-persistent sarcoidosis. Persistent disease was 
defined as worsening of the CXR stage to stage II or higher, or remaining at 
CXR stage II or III, at least two years after diagnosis. Non-persistent disease 
cases were those who remained at or regressed to stage 0 or I. 
In addition to the categorization into persistent/non-persistent sarcoidosis, CXR 
stages were used combined with lung function test results to classify the 
patients into groups with and without progressive disease. No progression was 
defined as remaining at stage 0, I, II or III or regressing to stage 0 or I. 
Progression was defined as worsening of the CXR stage or remaining at stage 
I, II or III in combination with RFI. 
BTNL2 and HLA typing 
DNA isolation 
DNA was obtained using venous EDTA or heparin anti-coagulated blood and 
isolated with a High Pure PCR Template Preparation Kit (Roche Diagnostics, 
Mannheim, Germany), or with QIA-AMP kits (Qiagen, Westburg, Leusden, The 
Netherlands) according to the manufacturer’s instructions.  
BTNL2 
Patients and controls were genotyped for the BTNL2 G16071A (rs2076530) 
polymorphism using a real-time PCR Fluorescence Resonance Energy Transfer 
(FRET) assay (TIB MOLBIOL, Berlin, Germany) on the LightCycler® (Roche 
Diagnostics). 
HLA 
Low resolution typing of HLA-DRB1 and DQB1 was obtained by Luminex 
reverse SSO, using bead kits from One Lambda (One Lambda, Bethesda, USA) 
or by PCR-SSP, using 45 in-house primer mixes as described previously.26 
High resolution typing of DRB1 and DQB1 was obtained by sequencing exon 2 
and if needed exon 3, as previously described.26,27 Either solid phase 
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sequencing was used as described,27,28 or cycle sequencing was performed 
using Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster 
City, USA). In cases of ambiguous typing, allele specific sequencing was 
performed, using suitable allele specific amplification primers in combination 
with adjusted sequencing primers as described.13 
Statistical analysis 
The chi-square test was used to test for statistical significant differences 
between groups. Odds ratios (OR) with 95% confidence intervals (CI) were 
derived from cross tables to evaluate strength of associations. Multivariate 
logistic regression models were used to adjust for differences in baseline 
characteristics (sex, smoking, and corticosteroid use) between compared 
groups. A p<0.05 (two sided) was considered to indicate statistical significance. 
Deviations from the Hardy–Weinberg equilibrium were analysed using the 
chi-square test. Statistical analyses were performed with SPSS 15.0 (SPSS Inc., 
Chicago, USA) for Windows. 
Results 
Patient characteristics of the total sarcoidosis population and of the subgroups 
with persistent and non-persistent sarcoidosis are summarized in Table 8.1. 
Patients with persistent disease more often were male, smoked less often and 
were more frequently treated with corticosteroids. At the time of diagnosis, the 
percentage with CXR stage 0 or I was much lower in patients with persistent 
disease than in the patients with non-persistent disease. Persistent disease was 
also associated with lower mean values of DCLO, FEV1 and FVC at diagnosis. 
In Table 8.2 an overview of BTNL2 G16071A allele and HLA-DRB1*15 
phenotype frequencies found in our entire sarcoidosis patient group (n=632) 
and in sarcoidosis patients with persistent and non-persistent disease is shown. 
The local healthy Dutch Caucasian control population (n=1474 for HLA and 
n=200 randomly selected out of the total 1474 for BTNL2 G16071A 
establishing that our ‘local’ healthy population did not differ from historic 
controls from literature with the same ethnicity regarding the BTNL2), and 
several patient and control populations taken from the literature, are also listed 
for comparison. 
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Table 8.1 Patient characteristics for the total sarcoidosis population and sorted by disease 
persistence. 
  Total population Non-persistent Persistent pa 
  n=632 n=328 n=304 value 
gender  female 283 (44.8) 177 (54.0) 106 (34.9)  
 male 349 (55.2) 151 (46.0) 198 (65.1) <0.001 
age at diagnosis yr±SD (range) 40.2±11.7 (12-84) 40.5±12.6 (17-84) 39.9±10.7 (12-76)  
 < 40 yr 356 (56.3) 185 (56.4) 171 (56.2)  
 ≥ 40 yr 276 (43.7) 143 (43.6) 133 (43.8) NS 
smoking no 562 (88.9) 283 (86.3) 279 (91.8)  
 yes   70 (11.1)   45 (13.7) 25 (8.2)  0.03 
corticosteroid use no 285 (45.1) 187 (57.0)   98 (32.2)  
 yes 347 (54.9) 141 (43.0) 206 (67.8) <0.001 
CXR at diagnosis 0   66 (10.4)   66 (20.1) 0  
 I 186 (29.4) 172 (52.5) 14 (4.6)  
 II 245 (38.8)   66 (20.1) 179 (58.9)  
 III 135 (21.4) 24 (7.3) 111 (36.5) <0.001b 
CXR at follow-up 0 282 (44.6) 282 (86.0) 0  
 I 46 (7.3)   46 (14.0) 0  
 II 141 (22.3) 0 141 (46.4)  
 III   76 (12.0) 0   76 (25.0)  
 IV   87 (13.8) 0   87 (28.6)  <0.001c 
DLCOd mean±SD (range) 81.4±17.3 (23-129) 87.0±15.0 (37-129) 75.4±17.5 (23-121)  
 ≥80% 353 (57.4) 235 (73.9) 118 (39.7)  
 <80% 262 (42.6)   83 (26.1) 179 (60.3) <0.001 
FEV1d mean±SD (range) 90.2±21.5 (23-140) 100.5±15.3 (54-140) 79.0±21.8 (23-128)  
 ≥80% 448 (73.3) 294 (92.5) 154 (52.6)  
 <80% 163 (26.7) 24 (7.5) 139 (47.4) <0.001 
FVCd mean±SD (range) 99.0±19.1 (25-152) 106.6±15.3 (66-152) 90.7±19.4 (25-148)  
 ≥80% 516 (85.1) 303 (95.6) 213 (73.7)  
 <80%   90 (14.9) 14 (4.4)   76 (26.3) <0.001 
a non-persistent versus persistent. b CXR 0+I versus II+III. c CXR IV versus 0+I+II+III. d % of 
predicted (<80% is abnormal). n=number, yr=years, NS=not significant, SD=standard deviation, 
CXR=chest X-ray, DLCO=diffusing capacity of carbon monoxide, FEV1=forced expiratory volume in 
one second, FVC=forced vital capacity. Missing: 17/21/26 for DLCO/FEV1/FVC, respectively. All values 
presented are absolute numbers with percentages in parentheses unless otherwise specified. 
 
 
 
In the healthy controls the proportions of persons without or with a BTNL2 
16071A variant allele were 18.0% (GG) and 82.0% (44.0% GA and 38.0% 
AA), respectively (chi2=1.39, p=0.24). These findings were in accordance with 
the Hardy-Weinberg equilibrium. 
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Table 8.2 Frequencies of BTNL2 G16071A and HLA-DRB1*15 sarcoidosis patients and controls. 
Population 
 
number 
 
BTNL2 G-allele 
% 
BTNL2 A-allele 
% 
Sarcoidosis patients   632 33.9 66.1 
Non-persistent sarcoidosis   328 36.0 64.0 
Persistent sarcoidosis   304 31.6 68.4 
UK+Dutch patients45   288 33.2 66.8 
German patients5   904 31.4 68.6 
German patients7   210 30.7 69.3 
Local controls   200 40.0 60.0 
Dutch controls41   351 41.2 58.8 
German controls5   427 42.7 57.3 
German controls7   202 38.1 61.9 
UK+Dutch controls45   446 42.6 57.4 
  
HLA-DRB1*15 neg 
% 
HLA-DRB1*15 pos 
% 
Sarcoidosis patients   632 68.2 31.8 
Non-persistent sarcoidosis   328 74.1 25.9 
Persistent sarcoidosis   304 61.8 38.2 
Local controls 1474 77.1 22.9 
Dutch controls46   207 69.1 30.9 
Dutch controls47 2400 74.0 26.0 
Dutch controls48   700 76.2 23.8 
UK controls49   537 78.1 20.9 
 
 
Table 8.3 shows the distributions of the studied BTNL2 polymorphism and HLA 
types in healthy controls, the total sarcoidosis population, and subgroups with 
and without persistent disease or progression. The BTNL2 G16071A 
polymorphism occurs more frequently in the total sarcoidosis population than in 
the healthy local controls (OR=1.85; p=0.007).  
The BTNL2 16071A variant allele was more often present in patients with 
persistent disease when compared with patients having non-persistent disease 
(OR=1.89; p=0.02). After multivariate correction for sex, smoking, and 
corticosteroid use the OR remained similar (OR=1.84, CI 95%: 1.06-3.21; 
p=0.03). The ORs for the subgroups no progression and progression were 
similar to those with and without persistent disease (Table 8.3). 
 
Significant differences with respect to the HLA types DRB1*03 and DRB1*15 
(with or without DQB1*06) were also observed. For the DRB1*15 a 
significantly larger proportion of patients with persistent sarcoidosis was 
positive, 38.2% versus 25.9% in the non-persistent group (OR=1.76; 
p=0.001). The presence of DRB1*15 in combination with DQB1*06 (15Q6 
haplotype) was also associated with an increased risk of poor prognosis: OR of 
1.63 (p=0.006). From all but 60 patients high resolution typing of the 
DQB1*06 allele was available, and presence of the DQB1*0602 allele was 
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associated with poor prognosis: OR=2.36, CI 95%: 1.59-3.49; p<0.001 (data 
not shown).  
 
Table 8.3 Distributions for the controls, total sarcoidosis population, and sorted by disease 
persistence. 
 Type Controls Total 
population 
Odds ratio  
pa 
Non- 
persistent 
Persistent Odds ratio  
pb 
  n=200/1474c n=632 (range) value n=328 n=304 (range) value 
BTNL 71 GG      36 (18.0)   67 (10.6)     44 (13.4)    23 (7.6)   
 GA     88 (44.0) 294 (46.5) 1.85 (1.19-2.88)  0.007d 148 (45.1)  146 (48.0) 1.89 (1.11-3.22)   0.02d 
 AA     76 (38.0) 271 (42.9)   136 (41.5)  135 (44.4)   
DRB1*03 neg 1140 (77.3) 476 (75.3)   215 (65.5)  261 (85.9)   
 pos   334 (22.7) 156 (24.7) 0.89 (0.72-1.11)    NS 113 (34.5)    43 (14.1) 0.31 (0.21-0.46) <0.001 
DRB1*15 neg 1136 (77.1) 431 (68.2)   243 (74.1)  188 (61.8)   
 pos   338 (22.9) 201 (31.8) 1.57 (1.27-1.93) <0.001   85 (25.9)  116 (38.2) 1.76 (1.26-2.47)   0.001 
15Q6 neg 1145 (77.7) 441 (69.8)   245 (74.7)  196 (64.5)   
 pos   329 (22.3) 191 (30.2) 1.51 (1.22-1.86) <0.001   83 (25.3)  108 (35.5) 1.63 (1.16-2.29)   0.006 
a controls versus total population. b non-persistent versus persistent. c 200 healthy, unrelated, Dutch Caucasian 
volunteers for the BTNL2 and 1474 for the HLA typing. d no variant allele versus variant allele. NS=not significant, 
BTNL 71=BTNL2 G16071A (rs2076530), DRB1*03=HLA-DRB1*03, DRB1*15=HLA-DRB1*15, 15Q6=HLA-DQB1*06/ 
DRB1*15 haplotype. All values presented are absolute numbers with percentages in parentheses unless otherwise 
specified. 
 
 
Within the healthy Dutch Caucasian controls who were DRB1*15 positive, 
DQB1*06 was absent in 0.6% (9/1474). In the DRB1*15 positive sarcoidosis 
patients with non-persistent disease a comparable percentage without a 
DQB1*06 (0.6%; 2/328) was found, whereas in the subgroup with persistent 
disease 2.6% (8/304) of the patients possessed a DRB1*15 type without 
bearing a DQB1*06. Within the DRB1*15 bearing group, DQB1*06 showed a 
negative association with progressive disease, but due to the small numbers 
the confidence interval around the odds ratio is very wide. (OR=0.18, CI 95%: 
0.02-1.54; p=0.14). These findings indicate a trend towards an effect of 
DRB1*15 on the course of sarcoidosis independent of DQB1*06. In contrast to 
the DRB1*15 results, the presence of a DRB1*03 allele was associated with a 
good prognosis (OR=0.31; p<0.001).  
The presence of DRB1*15 was strongly associated with the presence of a 
BTNL2 16071A variant allele: OR=8.43 (CI 95%: 3.02-23.5; p<0.001).Within 
the subgroup of patients who were positive for the DRB1*15 (n=201) only 2% 
(n=4) did not possess a BTNL2 16071A variant allele, compared with 14.6% 
(n=63) within the subgroup of DRB1*15 negative patients.  
Possessing neither a DRB1*15 nor the BTNL2 G16071A variant allele compared 
with both the DRB1*15 and a BTNL2 16071A variant allele being present in 
patients displaying persistent disease, resulted in OR=2.61 (CI 95%: 1.45-
4.72; p=0.001) for the DRB1*15/BTNL2 positive haplotype. The OR associated 
with presence of the BTNL2 G16071A in absence of DRB1*15 for persistence is 
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1.53 (CI 95%: 0.88-2.67; p=0.17) and this OR indicates that the effect of the 
BTNL2 is independent of DRB1*15.  
The OR obtained for the combined presence of the 15Q6 haplotype and the 
BTNL2 16071A variant allele were comparable to the results of the DRB1*15 
and BTNL2 16071A variant allele: OR=7.79 (CI 95%: 2.79-21.7; p<0.001). 
The observed association between the presence of DRB1*03 and BTNL2 16071 
A-allele presence was in the opposite direction: OR=0.08, CI 95%: 0.02-0.32; 
p<0.001. Of the subgroup of patients who were positive for the DRB1*03 
(n=156) only 1.3% (n=2) did not possess a BTNL2 16071A variant allele, 
compared with 13.7% (n=65) within the subgroup of DRB1*03 negative 
patients. 
Discussion 
This study is the first that demonstrates that the presence of the BTNL2 
16071A variant allele increases the risk of progressing to more severe and 
persistent pulmonary sarcoidosis. Previously, an association between the 
presence of the BTNL2 16071A variant allele and a susceptibility towards the 
chronic form of sarcoidosis was suggested and an increase in A-allele frequency 
in non-Löfgren patients was observed.7,29 However, the A-allele was not 
considered a risk factor in the progressing of pulmonary sarcoidosis. 
Furthermore, it is confirmed in accordance with others, that the BTNL2 16071A 
variant allele presence almost doubles the risk of developing sarcoidosis. In 
addition, the strong linkage of the BTNL2 G16071A with HLA-DRB1*15 is 
confirmed. This explains why DRB1*15 bearing also is found to be a risk factor 
for disease susceptibility as well as for disease course. 
 
It is well known that the outcome of sarcoidosis varies considerably.30 
Inconsistency exists on how to define severity. The course of sarcoidosis is 
mainly monitored by assessing clinical features and using auxiliary diagnostic 
tests. In the past decade, insight has been provided into the genetic risk for 
sarcoidosis and how the genetic make-up of a patient determines the clinical 
presentation and outcome. Two more provocative studies in sarcoidosis include 
the recognition of the BTNL2 gene as a candidate sarcoidosis susceptibility 
gene5,6 and the identification of mycobacterial catalase-peroxidase as a 
potential sarcoidosis antigen31 that drives granuloma formation.32 The BTNL2 
gene is located close to and in linkage with HLA-DRB1, which in turn is 
implicated in the etiology of sarcoidosis.21,33-35 The BTNL2 G16071A 
polymorphism in particular has been linked with an increased susceptibility risk 
for developing sarcoidosis.5-7 However, other than the suggestion that 
susceptibility might be preferential towards the chronic form of sarcoidosis7, 
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there were no studies done exploring the possibility that BTNL2 G16071A could 
also be associated with an increased risk of progression. In this study it was 
found that possessing the A-allele almost doubles (OR=1.89, CI 95%: 1.11-
3.22) the risk of a persistent course of sarcoidosis. When also using lung 
function test results to categorize the sarcoidosis patients into groups with and 
without progression the OR remains similar (OR=1.75, CI 95%: 1.01-3.04). 
Next to other progression markers, such as DRB1*03 or DRB1*15 
phenotypes11,13,36 or the TNF-α G-308A polymorphism14,37,38, one could argue 
that BTNL2 G16071A does not add much. However, especially in families with 
sarcoidosis patients, this SNP could provide information about the risk of 
developing sarcoidosis and when present, about the course of the disease. 
Moreover, as was found in a study by Coudurier et al. examining a family of 
sarcoidosis patients, the A/A genotype of BTNL2 G16071A can be defined as a 
putative prognosis and/or predictive factor of recurrent and severe sarcoidosis.8 
Therefore, genotyping before developing sarcoidosis in persons with a relative 
with the disease, might give additional information about disease risk and 
course, and can facilitate disease management. Prospective family-based 
studies should be performed to confirm this.  
 
In our study the A-allele of the BTNL2 G16071A also appeared to increase the 
risk of developing sarcoidosis almost twofold, in agreement with results found 
by Valentonyte et al.5 No significant association was established in a study 
performed on other diseases, despite the fact that these were also Th1 
dominated granulomatous diseases similar to sarcoidosis, and a role for MHC 
class II (HLA-DR/DQ) genes was found in these conditions.35,39-44 A possible 
explanation for the lack of a significant association between BTNL2 and 
sarcoidosis in general might be the result of differences in the patient and 
healthy volunteer populations studied. This once again draws the attention to 
the importance of selection and description of the used populations in genetic 
association studies.45,46 In other studies the association between BTNL2 and 
HLA-DRB1/DQB1 was found, but because of the strong linkage disequilibrium 
attributed to HLA-DR/DQ haplotypes.35,47 Indeed, several previous studies in 
other diseases have convincingly and consistently shown association between 
HLA-DRB1 (more specifically the 15Q6 haplotype or DRB1*15) and disease 
susceptibility.48-50  
 
In the present study, the strong linkage disequilibrium for the association 
between DRB1*15 and BTNL2 G16071A was confirmed (OR=8.43, CI 95%: 
3.02-23.5). Moreover, of the DRB1*15 bearing sarcoidosis patients only four 
did not possess a BTNL2 16071A variant allele. Comparing the healthy Dutch 
Caucasian controls (n=1474) with the total sarcoidosis population (n=632) for 
the DRB1*15 resulted in a significant difference indicating an increased risk for 
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developing sarcoidosis when DRB1*15 positive. In addition, an association 
between presence of DRB1*15 and persistent sarcoidosis (OR=1.76, CI 95%: 
1.26-2.47) was established. This was in agreement with results from previous 
studies.5,6,13 This indicates that DRB1*15 positivity can be considered as an 
important factor in both the susceptibility to sarcoidosis and the severity of the 
disease, comparable with the presence of a BTNL2 16071A variant allele. In 
addition, the BTNL2 16071A/DRB1*15 positive haplotype increases the risk of 
a persistent course of pulmonary sarcoidosis almost threefold. However, the 
possibility remains that due to the strong linkage, other functional variations on 
this BTNL2/DRB1*15 haplotype may be the true or additional causal 
determinants.35 Nevertheless, the strong linkage disequilibrium between BTNL2 
and HLA-DR/DQ requires that BTNL2 G16071A should be considered relevant 
to any immune-related disease associated with HLA-DR/DQ.35  
 
Previously, an association of the 15Q6 haplotype with the severity of 
sarcoidosis was found.13 However, because of the rather limited number of 
patients (n=156) and controls (n=418) and the strong linkage disequilibrium 
between DRB1*15 and DQB1*06, it could not be concluded whether the 
association was with either DRB1*15 or with DQB1*06.13 In the present study, 
with an extended number of patients and controls, it was found that the 
number of DRB1*15 bearing individuals without DQB1*06 was nine out of 
1474 for the healthy controls and 10 out of 632 for the patients. Furthermore, 
it was two out of 328 out of the non-persistent group and eight out of 304 out 
of the persistent group. Together with a higher OR observed for the DRB1*15, 
this implicates that typing for HLA-DRB1 and HLA-DQB1 to ascertain the 15Q6 
haplotype does not give any extra information, and that typing for DRB1 is 
sufficient.  
 
In conclusion, the presence of a BTNL2 16071A variant allele was found to be 
associated with an almost twofold increased risk of progressing to more severe 
and persistent pulmonary sarcoidosis in Caucasians. Furthermore, the 
predisposition to develop sarcoidosis was confirmed, as well as the strong 
linkage between the BTNL2 16071A variant allele and DRB1*15 positivity. It 
also became apparent that typing for DRB1 is sufficient because of the lack of 
additional information obtained by typing the DQB1*06, to establish the 15Q6 
haplotype. Whether or not to determine the DRB1 type or test the BTNL2 
G16071A SNP therefore, depends on the ability and/or availability to perform 
either test. Additional research will be necessary to explore the role of these 
findings in the clinical management of sarcoidosis patients. 
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Summary 
Many acute and chronic lung diseases can cause pulmonary fibrosis and are 
commonly referred to as interstitial lung disease (ILD) or diffuse lung disease. 
In most cases the origin of ILD is not known. Genetic predisposition and 
environmental antigens are indicated as risk factors in the majority of these 
ILDs. Several studies have explored the association of genetic polymorphisms 
or the presence of certain variant alleles, with the occurrence and/or 
progression of ILD of unknown etiology.1-7 Moreover, the search for more 
specific ‘markers’ still continues.  
 
The aim of the studies presented in this thesis was to evaluate the clinical and 
prognostic importance of genetic testing in a group of patients with drug-
induced ILD (DI-ILD), a group of patients with oral anticoagulants induced 
diffuse alveolar hemorrhage (DAH), and a group of sarcoidosis patients. All 
these patients were referred to the ild care center of the Maastricht University 
Medical Centre, the Netherlands.  
 
The analyses performed were executed on whole blood samples of drug-
induced ILD, idiopathic pulmonary fibrosis (IPF), and sarcoidosis patients. Of 
patients suffering from diffuse alveolar hemorrhage (DAH) analyses were done 
on whole blood samples and cells present in bronchoalveolar lavage fluid 
(BALF). For the analyses performed on healthy volunteer (HV) groups, whole 
blood and buccal swab (BS) samples were used. In afore mentioned 
populations the value of genotyping cytochrome P450 (CYP) enzymes (i.e. 
CYP2D6, CYP2C9 and CYP2C19) and/or vitamin K epoxide reductase (VKORC1) 
was examined. In sarcoidosis patients, next to tumor necrosis factor alpha 
(TNF-α G-308A) and butyrophiline-like 2 (BTNL2 G16071A), human leukocyte 
antigen (HLA) DRB1 and DQB1 were typed. 
 
 
Chapter 1, the general introduction, presents a summary of various ILDs, with 
an emphasis on drug-induced interstitial lung disease (DI-ILD), diffuse alveolar 
hemorrhage (DAH), and sarcoidosis. Furthermore, the term polymorphism and 
the possible ways in how to detect them are pointed out. In addition, the 
fluorescence resonance energy transfer (FRET) detection method used in this 
thesis is explained more in detail.   
 
In chapter 2 the possible role of cytochrome P450 (CYP) enzymes in ILD, 
especially in drug-induced ILD (DI-ILD) was reviewed. The CYP enzyme family 
plays an important role in the metabolization of a variety of ingested, injected 
or inhaled xenobiotic substances. Polymorphisms in the CYP genes can 
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influence the metabolic activity of the subsequent enzymes, which in turn may 
lead to localized (toxic) reactions and tissue damage. Drug toxicity can be due 
to either absence or to very poor enzyme activity. In case of reduced enzyme 
activity, dose reduction or prescribing an alternative drug metabolized by a 
different, unaffected CYP enzyme is recommended to prevent toxic side effects. 
This is particularly important in multi drug-use. Knowing a patient’s CYP profile 
before drug prescription could prevent drug-induced ILD and other drug-
induced toxicity. Moreover, it might be helpful in explaining serious adverse 
effects from inhaled, injected or ingested xenobiotic substances.  
 
Chapter 3 describes an easy DNA isolation method to be used prior to genetic 
testing. Several commercial DNA isolation kits are available for extracting 
genomic DNA from whole blood samples, but these procedures are time 
consuming and expensive. An alternative technique could be dried blood spot 
(DBS) sampling. With the subsequent simple isolation method DNA isolation is 
faster, cheaper, and logistics are easier. This DBS DNA isolation method, an 
alternative to the commercially available DNA isolation kits, is practical and it 
discriminates between genotypes. It can also be used for buccal swabs 
resulting in good DNA yields and giving completely concurrent results with 
samples isolated using commercial DNA isolation kits. This expands the 
possibilities of this quick and easy DNA isolation procedure, especially in 
combination with the noninvasive patient friendly buccal swab sampling 
method. In addition, buccal swab sampling appeared to be a good alternative 
to invasive sampling methods. 
 
Chapter 4 describes drug-induced pulmonary toxicity, a serious and expanding 
problem. Many drugs are metabolized by cytochrome P450 (CYP) enzymes. To 
establish whether allelic variation in CYP polymorphic genes contributes to 
variability in drug response and unexpected toxicity, a case-control study was 
conducted. The cases consisted of patients with drug-induced interstitial lung 
disease. Furthermore, two control groups were used: one group of healthy 
volunteers and one group of patients with idiopathic pulmonary fibrosis (IPF). 
Of the patients with drug-induced ILD 91.5% had at least one of the studied 
variant genes compared with 70.5% of the healthy volunteers and 69.1% of 
the IPF patients (both p’s<0.001). The percentage of individuals with one or 
more variant CYP genes was higher in the drug-induced ILD group. A 
significant association between the development of drug-induced ILD and the 
presence of one or more variant CYP genes was found. Drug-induced ILD was 
associated with the presence of at least one variant CYP allele. This study 
supports the potential usefulness of ‘personalized’ medicine by genotyping, 
aiming to improve efficacy, tolerability and drug safety. 
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The case presented in chapter 5 illustrates that understanding the 
mechanisms of drug metabolism and interactions may help to prevent side 
effects. The patient was a poor metabolizer for CYP2D6 corroborating that 
polymorphisms in this CYP gene influenced the metabolic activity of the 
corresponding enzymes. In addition, this affected the subsequent serum drug 
levels of venlafaxine and to a much lesser degree metoprolol and their 
metabolites. This achieved that toxic serum levels of venlafaxine were present 
and no active metabolite (O-desmethylvenlafaxine) could be detected. Besides 
therapeutic drug monitoring, genotyping some important cytochrome P450 
(CYP) enzymes was of additional value in explaining why the patient developed 
severe adverse effects. It also helped us to understand why the patient did not 
experience any therapeutical effect of the prescribed venlafaxine. This case 
highlights the potential benefit of clinical and genetic risk stratification 
(pharmacogenetics) before starting treatment. 
 
In chapter 6 diffuse alveolar hemorrhage (DAH) is highlighted. DAH is a 
serious bleeding complication that can occur as a result of, among others, oral 
anticoagulation therapy. This study explored the hypothesis that in patients 
treated with coumarins DAH may be associated with vitamin K epoxide 
reductase complex1 (VKORC1) and cytochrome P450 (CYP) variant alleles in 
CYP2C9, and in case of acenocoumarol use also with CYP2C19 variants. Clinical 
information of patients using coumarins with at least one episode of DAH was 
gathered retrospectively during a seven year period. Out of 173 confirmed DAH 
cases, 75 had received oral anticoagulants and 63 of these 75 (84%) patients 
were included because DNA was available. Of these samples CYP and VKORC1 
single nucleotide polymorphisms (SNPs) were genotyped. In 62 out of 63 DAH 
cases VKORC1, CYP2C9 variant genes, or both were found. This indicates that 
genotyping appears to be useful in predicting a high risk of serious side effects 
related to oral anticoagulant use, including DAH. Consequently, in concurrence 
with the American Food and Drug Administration (FDA), we recommend this 
genotyping, in order to provide a safer and more individualized anticoagulant 
therapy. 
 
Chapter 7 describes a study designed to evaluate the relationship between the 
presence of tumor necrosis factor alpha (TNF-α) polymorphisms and the 
prognosis of sarcoidosis. In a retrospective case-control study TNF-α G-308A, 
TNF-α G-238A and lymphotoxin-α (LTA) were genotyped in 625 sarcoidosis 
patients. These patients were classified into 327 patients with non-persistent 
(regressing to or stable at chest X-ray stage 0 or I) disease and 298 patients 
with persistent disease using chest X-ray appearances and lung function test 
results after a period of at least two years of follow-up. The TNF-α -308A 
variant allele was observed in 25.5% of patients with persistent disease 
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compared with 44.0% of patients with non-persistent disease. Consequently, 
the presence of a TNF-α -308A variant allele is associated with a favorable 
prognosis. Because of the strong linkage between TNF-α G-308A and 
HLA-DRB1*03, genotyping of one relatively simple TNF-α SNP is useful in 
predicting the prognosis of pulmonary sarcoidosis.  
 
In chapter 8 the association between butyrophiline-like 2 (BTNL2) G16071A 
with the course of pulmonary sarcoidosis was assessed and the association 
with disease predisposition was verified in 632 sarcoidosis patients. In addition, 
the linkage between BTNL2 G16071A and certain HLA-DRB1 and HLA-DQB1 
types was investigated. It appeared that the BTNL2 16071A variant allele was 
significantly more often present in patients with persistent disease (92.4%) 
compared with patients having non-persistent disease (86.6%). The presence 
of a BTNL2 16071A variant allele was found to be associated with an almost 
twofold increased risk of progressing to more severe and persistent pulmonary 
sarcoidosis. Furthermore, the predisposition to develop sarcoidosis was 
confirmed, as well as the strong linkage between the BTNL2 16071A variant 
allele and DRB1*15 positivity. It also became apparent that typing for DRB1 is 
sufficient because of the lack of additional information obtained by typing the 
DQB1*06, to establish the 15Q6 haplotype. Whether or not to determine the 
DRB1 type or test the BTNL2 G16071A SNP therefore, depends on the ability 
and/or availability to perform either test. Additional research will be necessary 
to explore the role of these findings in the clinical management of sarcoidosis 
patients.  
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General discussion 
Both genetic and non-genetic information is important in the susceptibility, 
development, cause, and treatment response of diseases. The more we know 
about a patient’s genes and context, the better disease management decisions 
can be made.8 Nevertheless, often the cause of a disease appears to be not 
only associated with a single nucleotide polymorphism (SNP), but is much more 
complicated. Some patients will continue to react unpredictably to therapy 
even though, according to obtained tests results, problems were not expected. 
Extending mapping of transcription factor binding SNPs and structural variants 
associated with transcription factor binding might gather useful information 
about the role of genetics in the phenotypic diversity in humans and provide 
insight into genetic causes of human disease.9,10  
 
The success of modern medicine is partly the result of effective medical 
treatment. Although the overall advantage of many drugs outweighs the side 
effects, substantial costs are still made as a result of complications of drug 
therapy. The variability in drug response among patients is multi-factorial. 
These factors include extrinsic features like environmental aspects or co-
medication, but also genetic and intrinsic factors that affect the disposition 
(absorption, distribution, metabolism and excretion) of individual drugs. The 
existence of large population differences with small intra-patient variability is 
consistent with inheritance as determinant of drug response. It is estimated 
that genetics can account for 20-95% of the variability in drug disposition and 
effects.11 Together clinical and genetic risk stratification (pharmacogenetics) 
may lead to more accurate prevention of drug-induced damage in the future. 
 
In a recent editorial the results of almost ten years after the revealing of a draft 
sequence of the human genome were assessed. Although detailed maps of 
genetic markers of human variation, have facilitated many remarkable 
genomewide efforts to associate known SNPs with disease predisposition, more 
than one decade of genomics will be required to understand the inborn risks of 
most common disorders.8 Nevertheless, reviews that highlight successful 
applications of gene-based medicine might hasten adoption of the beneficial 
changes in medicine that will eventually, if gradually, come from gene-based 
sciences.8 All the same, our increased understanding of the interactions 
between the entire genome and non-genomic factors that result in health and 
disease is paving the way for an era of ‘genomic medicine’.12 
 
There are an increasing number of examples where pharmacogenetic studies 
have indicated that a genetic test prior to treatment may be useful either for 
setting the individual dose or choosing a certain drug.13-18 The ability to identify 
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individuals who are susceptible to adverse drug reactions has the potential to 
reduce the personal and population costs of drug-related morbidity and the 
potential to attribute to the patients’ safety. Especially persons with more than 
one cytochrome P450 (CYP) polymorphism and/or other relevant 
polymorphisms may be susceptible to develop adverse effects, such as drug-
induced interstitial lung disease (ILD), when (multiple) drugs are prescribed.19 
Moreover, other pharmacogenetic factors might be involved, such as those 
involved in methotrexate induced pneumonitis.20-22  
 
One of the major conclusions of this thesis is that genetic screening prior to 
drug prescription may potentially prevent serious adverse effects such as 
diffuse alveolar hemorrhage (DAH) or drug-induced ILD. Another important 
finding is that the results obtained by genetic testing appeared to be useful in 
disease management, because of the prognostic value of the absence or 
presence of specific polymorphisms.  
Polymorphisms in drug-induced lung diseases 
Not only drug interactions, environmental factors, disease processes, and aging 
are factors in the inter-individual metabolic capacity variance, genetic factors 
also play an important role in developing adverse effects in general. 
Considering the fact that bio-(in)activation by CYP enzymes play an important 
role in human drug toxicity, polymorphisms in the CYP enzyme system may 
result in large inter-individual variations in the metabolism and toxicity of 
xenobiotics. The presence of CYP variant alleles adds a substantial susceptibility 
risk factor to the development of drug-induced pulmonary adverse 
events.19,23,24 In the study presented in chapter 6, genetic allelic variants 
appeared to be one of the determinants of variability in sensitivity to 
coumarins. Furthermore, others found that even in patients with stable 
international normalized ratios (INRs) without adverse (bleeding) effects these 
polymorphisms had a profound influence on dose requirements and time to 
reach therapeutic INRs.15,25 Despite numerous attempts to standardize the 
management of oral anticoagulant therapy, a high proportion of patients are 
still inadequately anticoagulated and the optimal means to initiate the therapy 
is still a matter of debate. It has been suggested that dosing algorithms 
incorporating genetics might outperform usual care. However, a major obstacle 
to the widespread adoption of genetic based coumarin dose modelling is that 
access to timely genetic testing is currently not widely available.26 
Nevertheless, even despite its limitations, prospective genotyping for CYP2C9 
and VKORC1 of patients taking oral anticoagulants has the clear potential to 
significantly optimize the safety of drug therapy and set a promising example of 
‘personalized’ medicine.10  
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Drugs, oxidative stress and pulmonary damage  
Beside anticoagulants, D-penicillamine, nitrofurantoin, amiodarone, 
propylthiouracil, cocaine, or sirolimus, and/or exposure to toxic agents such as 
trimellitic anhydride, insecticides, and pesticides may also cause bleeding 
complications including DAH events.27 It has been suggested that oxidative 
damage plays a role in the pathophysiology of various diseases, including DAH 
and pulmonary fibrosis.28,29 DAH is characterized by pulmonary alveolar cell 
death, inflammation, and hyaline membranes composed of fibrin and cellular 
debris.30 Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and 
frequently fatal form of ILD, characterized by impaired fibrinolysis and a 
complex pathogenesis.29,31,32 As a result of diffuse alveolar bleeding events iron 
is released in the lung. In turn this free toxic iron causes oxidative stress, 
inflammation, and finally irreversible damage or fibrosis.30,33 Moreover, people 
with VKORC1 and/or CYP2C9 variant alleles might have a predisposition for a 
greater risk of bleeding events in case they use oral anticoagulants, which 
might make them more susceptible to iron-catalysed toxicity caused by 
oxidants. This is important as anticoagulant therapy is considered to be an 
additional new strategy to treat IPF patients.34 In contrast, Thomassetti et al. 
did not find a beneficial effect of anticoagulants.35 It is tempting to speculate 
that an association with VKORC1 and/or CYP2C9 variant alleles might even be 
a risk factor for the development or exacerbation of IPF. Furthermore, it was 
accentuated that in DAH cases early recognition of the presence of one of the 
studied polymorphisms is important, because of a potential lethal outcome and 
the fact that simple vitamin K supplementation can be life-saving.36 Increased 
availability of vitamin K through daily supplementation, is expected to diminish 
the inhibitory activity and the relative day-to-day variability of coumarins and 
can significantly improve anticoagulation control in unstable patients.36,37  
Importance of various genetic variants  
It was emphasized that early recognition of the presence of certain 
polymorphisms is important.36,37 Not only in case of anticoagulant use, also in 
psychiatry, pharmacogenetic testing has become more common practice in the 
United States (US) with FDA approval of the AmpliChip CYP450 and CYP2D6 
and CYP2C19 testing helping patients with a history of excessive difficulties 
with antidepressants.38-40 This was also illustrated by the case described in 
chapter 5. Besides CYP and VKORC1 polymorphisms other genetic variants are 
also important. Two main immunosuppressive drugs that are often used in the 
treatment of severe ILD are methotrexate (MTX) and azathioprine. MTX is 
frequently used in the treatment of autoimmune diseases such as rheumatoid 
arthritis, psoriasis, Crohn’s disease, as well as in sarcoidosis. MTX toxicity and 
efficacy is associated with a number of polymorphic enzymes and testing for 
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variants was found to be predictive of response to and safety of MTX 
treatment.17,21,22,41 Moreover, when a patient develops an adverse drug 
reaction after starting MTX treatment, testing the C677T and A1298C variants 
in the methylenetetrahydrofolate reductase (MTHFR) gene involved in the MTX 
metabolism, should be considered.42 In case of an azathioprine indication, also 
used as treatment for certain ILDs including IPF, testing thiopurine 
methyltransferase (TPMT) variants involved in the azathioprine metabolism is 
advised before starting treatment.43-45 In the US, drug labels for azathioprine 
now include information on TPMT polymorphisms and recommend determining 
patients’ phenotype or genotype prior to drug treatment.46 
Sarcoidosis 
Sarcoidosis is a chronic granulomatous disorder of unknown cause with a highly 
variable course, characterized by activation of T-lymphocytes and 
macrophages. In an effort to determine the etiology of sarcoidosis the 
multicenter study A Case Control Etiologic Study of Sarcoidosis (ACCESS) was 
designed.47 One of the lessons learned from ACCESS was that genetic 
associations with sarcoidosis were observed and appeared to be stronger 
predictors of the course of sarcoidosis than environmental factors.48 The 
assumption that genes contribute to the etiology of sarcoidosis comes from the 
observation that prevalence and incidence rates of sarcoidosis are different 
between ethnic groups and that the disease tends to cluster in families. 
Interactions of exposures with genetic predispositions would have important 
implications for the understanding of immune responses as well as the 
pathogenesis of sarcoidosis.47 Prognostic factors of sarcoidosis are very 
important because certain obstacles confound the accurate prediction of the 
prognosis of sarcoidosis, such as the lack of reliable activity markers, the 
intensity level of granulomatous response, and the inability to differentiate the 
response from the dys-regulated repair process leading to fibrosis.47  
The role of genes in the etiology of sarcoidosis 
Association of sarcoidosis and class I and II HLA antigens is well known and in 
several studies the risk of progression of sarcoidosis, and the presence or 
absence of a polymorphism has been established.1,3,24,49,50 In addition to HLA 
types, co-stimulatory molecules of the immunoglobulin superfamily are also 
necessary to activate T-cells. The butyrophiline-like 2 (BTNL2) gene is located 
close to and in linkage with HLA-DRB1, which in turn is implicated in the 
etiology of sarcoidosis.51-54 Moreover, the presence of the BTNL2 16071A 
variant allele was recently associated with an increased risk of developing 
sarcoidosis.55-58 In T-helper cell 1 (Th1) dominated granulomatous diseases 
similar to sarcoidosis, an association between the presence of BTNL2 G16071A 
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and disease predisposition was found. This association was attributed to the 
strong linkage with HLA-DRB1/DQB1 haplotypes.54,59 Nevertheless, because of 
this strong linkage between BTNL2 and HLA-DRB1/DQB1, BTNL2 G16071A 
should be considered relevant to any immune-related disease associated with 
HLA-DRB1/DQB1.54 In the study presented in this thesis, the strong linkage 
between the BTNL2 16071A variant allele and HLA-DRB1*15 was confirmed. 
Another conclusion was that the presence of the BTNL2 A-allele was also 
associated with an increased risk of progressing to a persistent form of 
pulmonary sarcoidosis. Another SNP that was confirmed to influence 
sarcoidosis susceptibility is cyclooxegenase-2 (COX2) T8473C, however, no 
association with progression was found.60 Therefore, determining the BTNL2 
G16071A genotype even prior to the development of complaints, can be 
beneficial, for example when there is a family history of sarcoidosis.61 Not only 
to establish whether or not someone is more prone to develop sarcoidosis, but 
also whether there is an additional risk to progress to a more persistent form. 
Recently, strong evidence was found for the postulation that several SNPs in 
the vascular endothelial growth factor (VEGF) and its receptor genes VEGFR-1 
and VEGFR-2 also possessed the ability to predict predisposition and 
progression of sarcoidosis, but further studies are needed to evaluate the 
clinical relevance.62  
The influence of genes on the course of sarcoidosis 
Recently, it was found that serum amyloid A plays an important role in 
granuloma formation in sarcoidosis as well as tumor necrosis factor (TNF), 
interleukin-10 (IL-10), interferon-gamma (INF-γ), and Toll-like receptor 2 
(TLR2).63 In turn, these cytokines and enzymes not only influence the serum 
amyloid A production, but their expression can also be influenced by possible 
polymorphisms in their coding or non-coding sequence, and thus influence the 
cause or course of sarcoidosis.7,50 The potent pro-inflammatory cytokine TNF-
alpha (TNF-α) for instance plays a pivotal role in inflammatory and immune 
responses, and regulates and sustains granuloma formation in sarcoidosis.64 
Several SNPs are identified in the TNF-α gene and especially the variant 
A-allele of the TNF-α G-308A gene is associated with higher TNF-α serum 
levels and an acute course of sarcoidosis.65 The findings presented in chapter 7 
of this thesis demonstrate that it is sometimes beneficial to possess a variant 
allele (i.e. TNF-α -308A), opposed to not having a polymorphism, in the course 
of sarcoidosis.50 The risk of progressing to a more severe pulmonary 
involvement or persistent form of sarcoidosis was found to be higher in the 
absence of a TNF-α G-308A allelic variant, corroborating findings of other 
studies conducted on smaller populations.66,67 In line with this, bearing the 
HLA-DRB1*03 type also predicted a more favorable outcome, as was 
previously established in sarcoidosis patients with Löfgren’s syndrome, the 
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acute form of sarcoidosis with predominantly spontaneous remission.1,2,66,68 
What is more, both TNF-α G-308A and HLA-DRB1*03 typing appear to be 
interchangeable as far as the outcome or prediction of the course of sarcoidosis 
is concerned, consequently confirming the strong linkage between both 
genes.68,69  
The role of genes in therapeutic management 
Because of the strong linkage disequilibrium found between several genes and 
HLA-types, the choice of whether or not to test for a simple SNP (for example 
BTNL2 or TNF-α gene SNPs) or perform HLA typing appears to depend more on 
the availability of the technique or test. Conclusions drawn from studies 
presented in this thesis can be useful in furthering the clinical validation of 
applying genotyping in predicting the clinical course of sarcoidosis in individual 
patients and fine-tune disease management. Since available sarcoidosis 
therapies are not without risk and sometimes even toxic, patient care would 
benefit from the ability to predict the progression of the disease.70 Therefore, 
identifying those cases that might have a chance to develop a more severe 
manifestation of sarcoidosis is important and treatment aimed at avoiding 
irreversible damage can be started early.71 Furthermore, if the course of the 
disease has already progressed to severe or refractory sarcoidosis it would be 
of great clinical relevance to be able to select those cases who might benefit 
from a certain drug and who will not. For instance, when corticosteroids, most 
often the first drug of choice in sarcoidosis, are not effective, MTX might be 
considered. It has been beneficial in certain cases, however, it has a variety of 
clinical efficacies and toxicities, which are difficult to predict.22,72 Several reports 
have suggested that the use of pharmacogenetics might help to improve the 
understanding of drug efficacy and toxicity. However, studies in rheumatoid 
arthritis or psoriasis patients showed conflicting data whether or not these side 
effects were caused by the altered expression of genes by MTX.22,73,74 
 
Recently, anti-TNF-α therapy has proven to be useful in the treatment of 
refractory sarcoidosis. However, response to this therapy is not always as 
promising as expected.70,75 Moreover, it takes some time before the effect of 
these so-called biologicals is apparent, substantial side-effects are reported and 
additionally, this therapy is expensive. In refractory sarcoidosis, bearing a 
TNF-α G-308A variant allele appears to be a disadvantage. In previous studies 
conducted in rheumatoid arthritis patients not possessing a variant allele seem 
to respond to the therapy in contrast to variant allele carriers.76,77 Insight into 
the patient’s probable response might provide important information, especially 
for those patients, who very likely will not benefit from this anti-TNF-α therapy, 
and therefore should be treated with alternative medication without delay.  
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Directions for future research 
There is still a need for well designed prospective clinical trials that measure 
patient-oriented outcomes of selected genomic applications, and studies that 
evaluate the role of genomic variation in disease susceptibility, predicting 
prognosis, treatment response and in tailoring drug treatment for individual 
patients. These investigations are aimed to help to bridge the gap between 
‘personalized’ and ‘evidence-based’ medicine12  
 
In order to ascertain anticoagulation levels quicker and safer, without the risk 
of serious side effects and identify coumarin sensitive cases, genotyping for 
VKORC1, CYP2C9, and CYP2C19 polymorphisms would be a preferable cause of 
action. This genotyping should be performed ideally prior to oral anticoagulant 
therapy, but certainly in case of high and unstable or even overshot target 
INRs. A cost-effectiveness study, evaluating whether or not screening for 
VKORC1 and CYP2C9 polymorphisms prior to administering oral anticoagulant 
therapy is of clinical relevance, is therefore highly recommended.  
 
Furthermore, a prospective study to determine if, when variant alleles are 
present, simultaneous oral vitamin K supplementation can prevent diffuse 
alveolar hemorrhage (DAH) events is needed. Whether or not an association 
exists between CYP and VKORC1 polymorphisms and the development and/or 
progression of pulmonary fibrosis is another important issue for future studies. 
Hypothesizing that fibrosis could be associated with repeated episodes of 
diffuse alveolar damage to a certain extent is intriguing. Prospective clinical 
trials are needed to clarify the role of anticoagulant therapy and other alveolar 
bleeding initiating agents in the development of pulmonary fibrosis. Further 
investigations are also needed to assess if anticoagulant therapy is a friend or 
foe in the therapeutic strategies of pulmonary fibrosis. Therefore, it would be 
interesting to evaluate whether screening of patients before initiating 
anticoagulant therapy might be of clinical relevance.  
 
MTX, frequently used in sarcoidosis in combination with or without anti-TNF-α 
therapy, is also influenced by the presence of variant alleles. For that reason, a 
study into the influence of these polymorphisms on the efficiency and efficacy 
of this drug in sarcoidosis therapy should certainly be considered. Moreover, 
these studies might even give an answer to the question about which patients 
would benefit from MTX and for whom no advantage can be achieved or for 
whom the result will even be detrimental. It might be fascinating to develop a 
screening system based on both clinical and genetic information. 
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Next to the information about the progression of sarcoidosis, a patient’s TNF-α 
status or genetic make-up can also play a significant role in therapeutic disease 
management. Assessing a possible association in individual cases between the 
absence of a TNF-α -308A variant allele and being a responder or non-
responder to anti-TNF-α therapy would be of great clinical relevance. The 
results could provide important information about whether or not a patient 
would possibly benefit from anti-TNF-α therapy. Therefore, research should 
continue to depict the role of TNF genes in the immunogenetics and clinical 
management of sarcoidosis.  
 
The ability to identify individuals who are susceptible to adverse drug reactions, 
with the inclusion of both clinical and genetic risk stratification, may lead to a 
more accurate prevention of drug-induced damage and has the potential to 
reduce the personal and population costs of drug-related morbidity.78,79 The 
introduction of a genetic medical passport for each patient aimed to achieve a 
more appropriate individual pharmacotherapy seems promising in therapeutic 
drug monitoring. However, whether this might reduce the risk of side effects 
and related medical consumption needs to be evaluated. Collaboration between 
medical specialists, clinical pharmacists, pharmacologists and laboratory 
specialists will be necessary to accomplish individualize pharmacotherapy based 
on the pharmacogenetic profile.80  
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Verschillende acute en chronische longaandoeningen met variabele stadia van 
fibrose zijn beschreven en worden over het algemeen aangeduid als diffuse of 
interstitiële longaandoeningen (interstitial lung disease, ILD). De oorzaak van 
het ontstaan van ILD is veelal nog onbekend. Bij de meeste aandoeningen 
worden een genetische basis en omgevingsfactoren genoemd als mogelijke 
risicofactoren. Afgelopen jaren zijn er verschillende studies verricht die een 
associatie aantonen tussen  genetische polymorfismen of de aanwezigheid van 
bepaalde variant allelen, en het voorkomen en/of de progressie van ILD van 
onbekende oorsprong. Daarnaast gaat de zoektocht naar met name meer 
specifieke ‘markers’ nog steeds door.  
 
Het doel van de studies die in dit proefschrift worden beschreven, was om de 
klinische en prognostische waarde van genetische testen te evalueren. Als 
studiepopulatie werd een groep patiënten met door geneesmiddelen 
veroorzaakte ILD (drug-induced interstitial lung disease, DI-ILD), een groep 
patiënten met door orale antistolling veroorzaakte diffuse alveolaire bloedingen 
(diffuse alveolar hemorrhage, DAH) en een groep sarcoïdosepatiënten gebruikt, 
bekend bij het ild care team van het Maastrichts Universitair Medisch Centrum.  
 
De analyses in de studies beschreven in dit proefschrift werden uitgevoerd op 
volbloedmonsters van patiënten met door geneesmiddelen veroorzaakte ILD, 
idiopathische longfibrose (idiopathic pulmonary fibrosis, IPF) en 
sarcoïdosepatiënten. Sarcoïdose is een chronische inflammatoire 
multisysteemziekte, waarvan de oorzaak nog niet bekend is. Het verloop en de 
prognose van deze grillige aandoening kan erg variëren. Van de groep 
patiënten die een episode van diffuse alveolaire bloedingen doorgemaakt 
hadden werden de analyses op volbloedmonsters en cellen die in 
bronchoalveolaire lavage (BAL) vloeistof aanwezig waren gedaan. Van gezonde 
vrijwilligers (healthy volunteers, HV) werden volbloedmonsters en 
wangslijmvliesuitstrijkjes (buccal swab, BS) gebruikt voor de analyses.  
Het belang van het genotyperen van cytochroom P450 (CYP) enzymen (zoals 
CYP2D6, CYP2C9 en CYP2C19) en/of vitamine K epoxide reductase complex1 
(VKORC1) werd in de bovengenoemde populaties onderzocht. Daarnaast werd 
in sarcoïdose patiënten tumor necrose factor alfa -308 (TNF-α G-308A), 
butyrophiline-like 2 (BTNL2 G16071A) en humaan leukocytenantigeen (human 
leukocyte antigen, HLA) DRB1 en DQB1 getypeerd. 
 
In hoofstuk 1 wordt als inleiding een overzicht gegeven van de verschillende 
presentatievormen van interstitiële longaandoeningen. Speciale aandacht gaat 
uit naar door geneesmiddelen veroorzaakte ILD, diffuse alveolaire bloedingen 
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en sarcoïdose. Verder wordt het begrip polymorfisme en de manieren waarop 
deze kunnen worden bepaald verklaard. De in dit proefschrift gebruikte 
detectiemethode, de fluorescentie resonantie energie overdracht (fluorescence 
resonance energy transfer, FRET) wordt wat meer in detail besproken. 
 
In hoofdstuk 2 wordt de mogelijke rol van cytochroom P450 (CYP) enzymen 
in de pathogenese van interstitiële longaandoeningen, en in het bijzonder in 
door geneesmiddelen veroorzaakte ILD beschreven. De CYP enzymfamilie 
speelt een belangrijke rol in de metabolisatie van allerlei ingenomen of 
geïnhaleerde xenobiotische stoffen. Polymorfismen in deze CYP genen kunnen 
de metabole activiteit van de hieruit volgende enzymen beïnvloeden, en deze 
veranderde activiteit kan vervolgens leiden tot plaatselijke (toxische) reacties 
en weefselschade. Geneesmiddeltoxiciteit kan het gevolg zijn van geen of heel 
lage enzymactiviteit, in het bijzonder wanneer er geen andere metabole route 
beschikbaar is. Om toxische bijwerkingen te verhinderen wordt in het geval van 
een verlaagde enzymactiviteit een reductie van de voorgeschreven dosering of 
het gebruik van een alternatief geneesmiddel dat gemetaboliseerd wordt via 
een ander, niet aangetast (CYP) enzym, geadviseerd. Dit is vooral van belang 
wanneer er sprake is van meervoudig geneesmiddelengebruik. Daarom zou 
kennis over het CYP profiel van een patiënt voordat er een (bepaald) 
geneesmiddel wordt voorgeschreven van groot belang kunnen zijn en een 
manier om door geneesmiddelen veroorzaakte ILD en andere door 
geneesmiddelen geïnduceerde gevolgen te voorkomen. Verder kan het ook de 
ernstige bijwerkingen door ingeademde of ingenomen xenobiotische stoffen 
verklaren.  
 
Hoofdstuk 3 beschrijft een eenvoudige DNA isolatiemethode die gebruikt kan 
worden om monsters te bewerken alvorens polymorfismen te bepalen. Hoewel 
er diverse commerciële DNA isolatie kits beschikbaar zijn om genomisch DNA 
uit volbloedmonsters te isoleren, vergen deze procedures behoorlijk wat tijd en 
zijn over het algemeen ook behoorlijk kostbaar. Een alternatieve techniek zou 
de op een filteerpapier gespotte bloeddruppel (dried blood spot, DBS) 
monsterafname (zie Figuur A1) en een daaropvolgende simpele 
isolatiemethode zijn. De DNA isolatie wordt daarmee ook sneller, goedkoper en 
logistiek eenvoudiger.  
Deze gedroogde bloeddruppel DNA isolatiemethode bleek een goed alternatief 
voor commercieel verkrijgbare DNA isolatiekits en een zeer praktische methode 
om onderscheid te kunnen maken tussen verschillende genotypen. Dezelfde 
methode kan ook gebruikt worden om DNA uit wangslijmvliesuitstrijkjes (zie 
Figuur A2) te isoleren en geeft, naast goede DNA opbrengsten, totaal 
overeenkomende genotyperings resultaten vergeleken met monsters die met 
behulp van commerciële DNA isolatiekits geïsoleerd werden. Dit is een 
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praktische uitbreiding van de toepasbaarheid van deze snelle en eenvoudige 
DNA isolatiemethode. Zeker in combinatie met de niet-invasieve en 
patiëntvriendelijke wangslijmvliesuitstrijkjes monsterafname, bleek dit een 
goed alternatief ten opzichte van invasieve monsterafname methoden. 
 
   
 
 
 
 
 
 
 
 
 1                                                                  2 
 
Figuur A  (1) monstername van een gedroogde bloeddruppel, (2) monstername van wangslijmvlies 
met behulp van een wattenstokje. 
 
 
Door geneesmiddelen geïnduceerde longtoxiciteit vormt een nog steeds 
groeiend probleem. Het precieze ontstaansmechanisme van deze toxiciteit is 
veelal nog onbekend. Allerlei verschillende geneesmiddelen worden 
gemetaboliseerd door cytochroom P450 (CYP) enzymen.  
In hoofdstuk 4 wordt het onderzoek beschreven met de vraag of allel variatie 
in CYP polymorfe genen bijdraagt aan de tot nu toe onverklaarde toxiciteit en 
verschillen in het reageren op geneesmiddelen. Hiervoor werd een 
retrospectieve case-control studie uitgevoerd. De cases waren patiënten met 
door geneesmiddelen veroorzaakte interstitiële longaandoeningen. Daarnaast 
werden er twee controle groepen gebruikt: een groep gezonde vrijwilligers en 
een groep patiënten met idiopathische longfibrose. Het aantal mensen met één 
of meer variant CYP genen was duidelijk hoger in de door geneesmiddelen 
veroorzaakte ILD groep vergeleken met de gezonde vrijwilligers evenals van de 
bestudeerde longfibrosepatiënten. Bovendien werd er een significante 
associatie tussen het ontwikkelen van door geneesmiddelen veroorzaakte ILD 
en het bezitten van één of meer variant CYP genen gevonden. Door 
geneesmiddelen veroorzaakte ILD bleken geassocieerd met de aanwezigheid 
van tenminste één variant CYP allel. Deze studie ondersteunt het nut van het 
voorschrijven van geneesmiddelen na genotypering, de zogenaamde 
geïndividualiseerde geneeskunde, om zo efficiëntie, verdraagzaamheid en 
veiligheid van de voorgeschreven geneesmiddelen te verhogen. 
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De klinische relevantie van genotypering voor het initiëren van 
medicamenteuze behandeling met name in geval van gebruik van meerdere 
geneesmiddelen tegelijkertijd wordt geïllustreerd aan de hand van het 
patiëntenvoorbeeld beschreven in hoofdstuk 5. Het beter begrijpen van het 
mechanisme van geneesmiddelmetabolisme en eventuele interacties kan 
bijdragen tot het voorkomen of verminderen van bijwerkingen. De patiënte 
werd behandeld met onder andere venlafaxine i.v.m. een depressie en 
metoprolol i.v.m. hartritmestoornissen. Ondanks deze behandeling ging ze 
klinisch gezien achteruit i.p.v. vooruit. Bij opname in het ziekenhuis rees de 
verdenking op een overgevoeligheidsreactie (ADR) die toegeschreven zou 
kunnen worden aan het gebruik van venlafaxine en/of metoprolol. Er werden 
toxische waarden van venlafaxine gemeten en de actieve metaboliet (O-
desmethylvenlafaxine) was niet aantoonbaar. Na genotypering werd duidelijk 
dat patiënte een slechte metaboliseerder voor CYP2D6 ten gevolge van een 
polymorfisme in dit cytochroom P450 (CYP) gen bleek te zijn. Dit betekent dat 
de metabole activiteit van het corresponderende enzym negatief beïnvloed 
werd, waardoor serumconcentraties van de door het aangedane enzym te 
metaboliseren geneesmiddelen (venlafaxine en metoprolol) veranderden. 
Venlafaxine kon hierdoor niet worden omgezet naar de bijbehorende actieve 
metaboliet (O-desmethylvenlafaxine) en die was daarom niet aantoonbaar. Het 
gevolg was dat het doel waarvoor de venlafaxine werd voorgeschreven in het 
geheel niet werd bereikt en patiënte niet instaat was op de beoogde wijze te 
reageren op de voorgeschreven medicatie. De venlafaxine werd gestopt, een 
alternatieve therapie werd gestart en klinische toestand van de patiënte 
verbeterde aanzienlijk. Naast therapeutische geneesmiddelmonitoring, bleek 
het genotyperen van enkele belangrijke CYP enzymen van additionele waarde 
in het vinden van de verklaring waarom de patiënt ernstige bijwerkingen 
ontwikkelde. Daarnaast verschafte de genotypering inzicht in het waarom de 
patiënte geen therapeutisch effect bereikte van met name venlafaxine. Dit 
voorbeeld benadrukt het belang van zowel klinische als genetische 
risicostratificatie voor het starten van een behandeling. Dit kan uitermate 
behulpzaam zijn bij het nemen van het nemen van beslissingen betreffende 
welk geneesmiddel voorgeschreven kan worden, en tevens om een 
patiëntgerichte dosering vast te stellen. 
 
In hoofdstuk 6 wordt een studie bij patiënten met diffuse alveolaire 
bloedingen (DAH), een bloedingcomplicatie die kan optreden ten gevolge van 
onder andere orale antistollingstherapie, beschreven. De hypothese was dat bij 
patiënten die worden behandeld met coumarines deze complicatie geassocieerd 
zou kunnen worden met een polymorfisme in het vitamine K epoxide reductase 
complex1 (VKORC1) gen en de aanwezigheid van variant allelen in het 
cytochroom P450 gen CYP2C9, en in het geval van acenocoumarol gebruik ook 
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met CYP2C19 varianten. Retrospectief werden patiënten die coumarines 
gebruikten en tenminste één episode met diffuse alveolaire bloedingen hadden 
doorgemaakt over een periode van zeven jaar verzameld. Van de 173 
bevestigde gevallen van patiënten met diffuse alveolaire bloedingen gebruikten 
75 patiënten orale antistolling waarvan uiteindelijk 63 (84%) patiënten konden 
worden geïncludeerd aangezien er DNA monsters beschikbaar waren. Van deze 
monsters werden CYP2C9, CYP2C19 en VKORC1 single nucleotide 
polymorphismen (SNPs) gegenotypeerd. Bij 62 van de 63 bestudeerde 
patiënten was er of een VKORC1, of een CYP2C9 variant allel, of beiden 
aanwezig. Hieruit werd geconcludeerd dat het zinvol is om voorafgaand aan de 
behandeling met orale antistolling te genotyperen om met deze informatie 
zoveel mogelijk het risico op ernstige bijwerkingen, waaronder diffuse 
alveolaire bloedingen, te beperken. Om een veiligere en meer persoonlijke 
antistollingstherapie te garanderen wordt deze werkwijze reeds aanbevolen 
door de Amerikaanse federale Food and Drug Administration (FDA). 
 
De studie beschreven in hoofdstuk 7 werd uitgevoerd om te evalueren of er 
een verband bestaat tussen de aanwezigheid van tumor necrose factor alfa 
(TNF-α) polymorfismen en de prognose dan wel het verloop van sarcoïdose. In 
een retrospectieve case-control studie werd van 625 sarcoïdose patiënten 
TNF-α G-308A, TNF-α G-238A en lymphotoxin-α (LTA) gegenotypeerd. Deze 
patiënten werden onderverdeeld in een groep van 298 patiënten met 
persisterende sarcoïdose en 327 patiënten met niet-persisterende sarcoïdose. 
Niet-persisterende sarcoïdose werd gedefinieerd als patiënten die verbeterden 
naar of stabiel bleven met röntgenstadium 0 of I. Hierbij werd gebruik gemaakt 
van röntgenfoto’s en longfunctietestuitslagen na een periode van tenminste 
twee jaar na diagnosestelling. Het TNF-α -308A variant allel werd in 25.5% van 
de patiënten met persisterende sarcoïdose aangetroffen, vergeleken met 
44.0% voorkomen in patiënten met de niet-persisterende vorm. De gevonden 
data tonen dat, mede door de sterke associatie tussen TNF-α G-308A en HLA-
DRB1*03, de aanwezigheid van een TNF-α -308A variant allel geassocieerd kan 
worden met een gunstige prognose en dat een betrekkelijk eenvoudige 
bepaling van de TNF-α G-308A SNP bruikbaar is om het verloop van 
longsarcoïdose te voorspellen.  
 
In hoofdstuk 8 wordt een studie beschreven die de associatie tussen 
butyrophiline-like 2 (BTNL2) G16071A en de progressie van longsarcoïdose 
onderzoekt en de associatie met de prevalentie van de ziekte in 632 sarcoïdose 
patiënten bevestigd. Verder werd de samenhang tussen BTNL2 G16071A en 
specifieke HLA-DRB1 en HLA-DQB1 types onderzocht. Bij patiënten met 
persisterende sarcoïdose werd het BTNL2 16071A variant allel significant meer 
aangetroffen (92.4%) dan in patiënten met niet-persisterende sarcoïdose 
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(86.6%). Uit de resultaten van deze studie blijkt dat het bezitten van een 
BTNL2 16071A variant allel het risico op progressie van longsarcoïdose bijna 
verdubbeld. Dit verhoogde risico kan het gevolg zijn van de sterke link tussen 
BTNL2 G16071A en DRB1*15, waarvan de associatie tussen aanwezigheid en 
progressie naar een ernstigere en meer persistente vorm van longsarcoïdose 
bevestigd werd. Het werd verder duidelijk dat HLA-DRB1 typeren voldoende is, 
door het niet verkrijgen van extra informatie bij HLA-DQB1 typering. Of men 
uiteindelijk kiest voor een BTNL2 G16071A SNP bepaling of HLA-DRB1 typeren 
ligt meer aan de beschikbaarheid en/of uitvoerbaarheid van deze testen. 
 
De belangrijkste bevindingen beschreven in dit proefschrift worden besproken 
in hoofdstuk 9, evenals de hieruit voortkomende mogelijkheden voor 
toekomstig onderzoek. Ondanks het continue voortschrijdende inzicht 
aangaande het metabolisme van geneesmiddelen blijven er nog veel vragen 
open. Door continuering van het onderzoek naar de relatie tussen kliniek en 
genetische eigenschappen kunnen mogelijk in de toekomst een aantal 
antwoorden ingevuld worden. De genetische basis van sarcoïdose en de invloed 
van het genotype op het fenotype, ofwel de klinische presentatie, en het beloop 
is nog steeds onvoldoende opgehelderd. Het vergaren van verder inzicht in 
deze aspecten van de pathogenese van sarcoïdose zal een interessant en 
uitdagend thema vormen voor verder onderzoek. Met name onderzoek naar 
mogelijke onderscheidende factoren tussen zogenaamde responders en non-
responders op therapeutische interventies zal heel klinisch relevant en 
uiteindelijk kostenbesparend kunnen zijn. Op die manier kan dan in de 
toekomst een duidelijke beperking worden aangebracht in het voorschrijven 
van (dure) geneesmiddelen. 
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Appendix 
In the appendix drugs and other substances metabolized by and influencing 
(inhibit or induce) the most important CYP enzymes are listed. The drugs are 
subdivided into substrates, inhibitors, and inducers. The term substrate refers 
to a drug or other substance that is metabolized (activated or de-activated) by 
an enzyme. An inhibitor is a substance that inhibits the normal function of an 
enzyme and may result from non-competitive or competitive inhibition by a 
second drug or other substance, an effect that may occur rapidly. The result of 
non-competitive inhibition by the addition of a second agent is a slower 
metabolism of the first substance, higher plasma concentrations, and toxicity 
risk. In case of competitive inhibition, the metabolism of both substances can 
be reduced, resulting in higher than expected and possible toxic concentrations 
of both parent agents. An inducer is a substance that may result in increased 
CYP enzyme synthesis, faster drug metabolism, subtherapeutic drug 
concentrations and the risk for ineffective drug therapy. The promptness of the 
induction depends on the half-life of the inducing substance as well as the rate 
of synthesis of new enzymes.  
 
The drugs and other substances are alphabetically ordered by CYP enzyme. 
The list of substrates metabolized by a specific (affected) enzyme and possible 
present inducers and/or inhibitors might be helpful to prevent possible 
problems.  
 
This appendix is not comprehensive as new information is constantly being 
identified.1-11  
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Drugs and other substances metabolized by and influencing CYP enzymes. 
Substrates      
1A2  2C9  2C19  
Acetaminophen Paroxetine Aceclofenac Lornoxicam Acenocoumarol Primidone 
Aminophylline Pentazocine Acenocoumarol Losartan Alprazolam Progesterone 
Amitriptyline Perphenazine Acetaminophen Mefenaminic acid Amiodarone Proguanil 
Anagrelide Phenacetin Amitriptyline Meloxicam Amitriptyline Propranolol 
Bendamustine Pimozide Bosentan Mephenytoin Carisoprodol Rabeprazole 
Caffeine Pirfenidone Candesartan Mestranol Chloramphenicol Ranitidine 
Chlordiazepoxide Primaquine Cannabinol Mirtazapine Cilostazol Ritonavir 
Chlorpromazine Propafenone Carmustine Montelukast Citalopram R-Mephobarbital 
Cimetidine Propranolol Carvedilol Naproxen Clobazam R-Warfarin 
Cinacalcet Ramelteon Celecoxib Nateglinide Clomipramine Sertraline 
Citalopram Ranitidine Chloramphenicol Nicoumalone Clopidogrel S-Mephenytoin 
Clomipramine Rasagiline Chlorpheniramine Omeprazole Cyclophosphamide Temazepam 
Clopidogrel Riluzole Chlorporpamide Paclitaxel Desipramine Teniposide 
Clozapine Ritonavir Clomipramine Paroxetine Diazepam Thioridazine 
Cyclobenzaprine Ropinirole Clopidogrel Phenobarbital Diclofenac Tolbutamide 
Dacarbazine Ropivacaine Cotrimoxazol Phenytoin Divalproex Trimipramine 
Desipramine R-Warfarin Dapsone Pirfenidone Efavirenz Valproic acid 
Diazepam Sertraline Desogestrel Piroxicam Escitalopram Venlafaxine 
Duloxetine Tacrine Diazepam Ritonavir Esomeprazole Voriconazole 
Erlotinib Tamoxifen Diclofenac Rosiglitazone Flunitrazepam  
Estradiol Theophylline Dicoumarol R-Warfarin Fluoxetine  
Ethinyl estradiol Thioridazine Divalproex sodium Seratrodast Fluvoxamine  
Febuxostat Thiothixene Dronabinol Sertraline Formoterol  
Fluoxetine Tizanidine Efavirenz Sildenafil Hexobarbital  
Fluphenazine Toremifene Febuxostat Sulfamethoxazole Ibuprofen  
Flutamide Trifluoperazine Fluoxetine Sulfaphenazole Ifosfamide  
Fluvoxamine Verapamil Flurbiprofen Sulfinpyrazone Imipramine  
Frovatriptan Zileuton Fluvastatin Sulfonamides Indomethacin  
Haloperidol Ziprasidone Fluvoxamine Suprofen Lansoprazole  
Imipramine Zolmitriptan Formoterol S-Warfarin Loratidine  
Isotretinoin Zolpidem Glibenclamide Tamoxifen Mephenytoin  
Levobupivacaine Gliclazide Tenoxicam Mephobarbital  
Lidocaine Glimepiride Tertrahydrocannabinol Methsuximide  
Melatonin Glipizide Testosterone Moclobemide  
Mesoridazine Glyburide Tolbutamide Nelfinavir  
Methadone Hexobarbital Torsemide Nevirapine  
Mexiletine Ibuprofen Valdecoxib Nilutamide  
Mibrefradil Idarubicin Valproic acid Omeprazole  
Mirtazapine Imipramine Valsartan Pantoprazole  
Naproxen Indomethacin Vardenafil Paroxetine  
Nortriptyline Irbesartan Voriconazole Pentamidine  
Olanzapine Irinotecan Zafirlukast Phenobarbital  
Ondansetron Ketoprofen Zileuton Phenytoin  
Oxtriphylline Leflunomide Zolpidem Pirfenidone  
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Substrates   
2D6   
Acetaminophen Fentanyl Penbutolol
Alprenolol Flecainide Perhexiline
Amiodarone Flunarizine Perphenazine
Amitriptyline Fluoxetine Phenacetin
Amphetamine Fluphenazine Phenformin
Aripiprazole Fluvoxamine Pindolol
Atomoxetine Formoterol Pirfenidone
Benztropine Galantamine Procainamide
Bisoprolol Guanoxan Promethazine
Bufuralol Haloperidol Propafenone
Captopril Hydrocodone Propoxyphene
Carvedilol Hydrocortisone Propranolol
Cevimeline Hydroxyzine Pyrantel
Chlorpheniramine Idarubicin Quetiapine
Chlorpromazine Imipramine Quinidine
Chlorpropamide Indinavir Ranitidine
Cinacalcet Indoramin Ranolazine
Citalopram Labetalol Risperidone
Clemastine Lidocaine Ritonavir
Clomipramine Loratadine Ropivacaine
Clozapine Maprotiline Selegiline
Codeine MDMA (ecstasy) Sertindole
Cyclobenzaprine Meperidine Sertraline
Darifenacin Mequitazine Sparteine
Debrisoquine Methadone Tacrine
Delavirdine Methamphetamine Tamoxifen
Desipramine Methoxyamphetamine Tamsulosine
Dexfenfluramine Metoclopramide Thioridazine
Dextroamphetamine Metoprolol Timolol
Dextromethorphan Mexiletine Tolterodine
Diltiazem Minaprine Tramadol
Dimenhydrinate Mirtazapine Tranylcypromine
Dimethoxyamphetamine Moclobemide Trazodone
Diphenhydramine Morphine Trimipramine
Dolasetron Nebivolol Tripelennamine
Donepezil Nefazodone Tropisetron
Doxepin Nifedipine Venlafaxine
Doxorubicin Nisoldipine Yohimbine
Duloxetine Nortriptyline Zuclopenthixol
Encainide Olanzapine
Escitalopram Ondansetron
Ethylmorphine Oxycodone
Fenfluramine Paroxetine
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Substrates     
3A4-5        
Acetaminophen Cocaine Etonogestrel Loxapine Primaquine Tinidazole 
Alfentanil Codeine Etoposide Medroxyprogesterone Progesterone Tipranavir 
Alfuzosin Colchicine Exemestane Mefloquine Progestin Tolcapone 
Aliskiren Conjugated estrogens Felbamate Meloxicam Proguanil Tolterodine 
Almotriptan Cortisol Felodipine Meperidine Propafenone Toremifene 
Alprazolam Cyclobenzaprine Fentanyl Methadone Propoxyphene Tramadol 
Amiodarone Cyclophosphamide Fexofenadine Methsuximide Propranolol Trazodone 
Amitriptyline Cyclosporine Finasteride Methylprednisolone Quetiapine Tretinoin 
Amlodipine Cytarabine Fluconazole Methysergide Quinidine Triamcinolone 
Amprenavir Danazol Flunitrazepam Metoprolol Quinine Triazolam 
Anastrozole Dapsone Fluoxetine Mexiletine Rabeprazole Trimetrexate 
Aprepitant Darifenacin Flupenthixol Mibefradil Ramelteon Trimipramine 
Aranidipine Darunavir Flurazepam Miconazole Ranitidine Trofosfamide 
Aripriprazole Dasatinib Flutamide Midazolam Ranolazine Troleandomycin 
Astemizole Daunorubicin Fluticasone Mifepristone Rapamycin Valdecoxib 
Atazanavir Delavirdine Fluvestrant Mirtazapine Reboxetine Valproic acid 
Atorvastatin Desogestrel Fluvoxamine Mitotane Repaglinide Vardenafil 
Azithromycin Dexamethasone Fomepizole Modafinil Rifabutin Venlafaxine 
Bepridil Dextromethorphan Fosamprenavir Mometasone Rifampin Verapramil 
Bexarotene Diazepam Galantamine Montelukast Risperidone Vesnarinone 
Bicalutamide Diclofenac Gefitinib Nateglinide Ritonavir Vinblastine 
Bosentan Dihydroergotamine Gestodene Navelbine Rokitamycin Vincristine 
Bromocriptine Diltiazem Glyburide Nefazodone Ropinirole Vindesine 
Budesonide Dirithromycin Granisetron Nelfinavir R-Warfarin Vinorelbine 
Buprenorphine Disopyramide Halofantrine Nevirapine Salmeterol Voriconazole 
Buspirone Docetaxel Haloperidol Nicardipine Saquinavir Zaleplon 
Busulfan Dofetilide Hydrocannabinol Nifedipine Selegiline Zileuton 
Cabergoline Dolasetron Hydrocodone Nilotinib Seratrodast Ziprasidone 
Caffeine Domperidone Hydrocortisone Nimodipine Sertraline Zolpidem 
Cannabinoids Donepezil Ifosfamide Nisoldipine Sibutramine Zonisamide 
Carbamazepine Doxazosine Imatinib Nitrazepam Sildenafil Zopiclone 
Carvedilol Doxepin Imipramine Nitrendipine Simvastatin Zuclopenthixol 
Cerivastatin Doxorubicin Indinavir Nordazepam Sirolimus  
Cevimeline Doxycycline Irinotecan Norethindrone Solifenacin  
Chlordiazepoxide Dronabinol Isotretinoin Omeprazole Sorafenib  
Chloroquine Dutasteride Isradipine Onapristone Sparfloxacin  
Chlorpheniramine Ebastine Itraconazole Ondansetron Sufentanil  
Chlorpromazine Efavirenz Ketamine Oral contraceptives Sunitinib  
Cilnidipine Eletriptan Ketoconazole Oxybutynin Tacrolimus  
Cilostazol Enalapril Lamotrigine Oxycodone Tadalafil  
Cimetidine Eplerenone Lansoprazole Paclitaxel Tamoxifen  
Cinacalcet Ergots Lercanidipine Pantoprazole Tamsulosin  
Ciprofloxacin Erlotinib Letrozole Paroxetine Taxol  
Cisapride Erythromycin Levobupivacaine Pergolide Telithromycin  
Citalopram Escitalopram Levomethadyl Perphenazine Temazepam  
Clarithromycin Esomeprazole Lidocaine Phencyclidine Teniposide  
Clindamycin Estazolam Lilopristone Pimozide Terazosin  
Clobazam Estradiol Loperamide Pioglitazone Terfenadine  
Clomipramine Eszopiclone Lopinavir Pravastatin Testosterone  
Clonazepam Ethinyl estradiol Loratadine Praziquantel Theophylline  
Clopidogrel Ethosuximide Losartan Prednisolone Tiagabine  
Clozapine Ethylmorphine Lovastatin Prednisone Timolol  
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Inhibitors     
1A2  2C9  2C19 
Acyclovir Ritonavir Amiodarone Sulfaphenazole Amitriptyline 
Amiodarone Ropinirole Anastrozole Sulfinpyrazone Artemisinin 
Amitriptyline Sparfloxacin Atazanavir Sulfonamides Chloramphenicol 
Anastrozole St. John's Wort Benzbromarone Tacrine Cimetidine 
Atazanavir Tacrine Capecitabine Tamoxifen Citalopram 
Caffeine Tegaserod Chloramphenicol Teniposide Cocaine 
Cimetidine Ticlopidine Cimetidine Ticlopidine Delavirdine 
Ciprofloxacin Tocainide Clopidogrel Tipranavir Devil's Claw 
Citalopram Troleandomycin Cocaine Trimethoprim Efavirenz 
Clarithromycin Verapamil Cotrimoxazole Troglitazone Esomeprazole 
Diltiazem Zafirlukast Delavirdine Troleandomycin Felbamate 
Duloxetine Zileuton Devil's claw Valproic acid Fluconazole 
Echinacea  Diclofenac Voriconazole Fluoxetine 
Enoxacin  Disulfiram Wolfberry Fluvastatin 
Erythromycin  Efavirenz Zafirlukast Fluvoxamine 
Estradiol  Fenofibrate Zileutin Garlic
Ethinyl estradiol  Fluconazole Imipramine 
Famotidine  Fluorouracil Indomethacin 
Fluoxetine  Fluoxetine Interferon 
Fluphenazine  Flurbifprofen Isoniazid 
Flutamide  Fluvastatin Ketoconazole 
Fluvoxamine  Fluvoxamine Lansoprazole 
Furafylline  Garlic Letrozole 
Gatifloxacin  Gemfibrozil Modafinil 
Grapefruit (juice)  Grapefruit (juice) Norfluoxetine 
Imipramine  Imatinib Omeprazole 
Interferon  Isoniazid Oral contraceptives 
Isoniazid  Itraconazole Oxcarbazepine 
Ketoconazole  Ketoconazole Pantoprazole 
Levofloxacin  Ketoprofen Paroxetine 
Levonorgestrel  Leflunomide Pirfenidone 
Lidocaine  Lovastatin Probenicid 
Lomefloxacin  Methoxsalen Rabeprazole 
Methoxsalen  Metronidazole Ranitidine 
Mexiletine  Mexiletine Ritonavir 
Mibefradil  Modafinil Sertraline 
Moclobemide  Nalidixic acid St. John's Wort 
Moxifloxacin  Norethindrone Sulfaphenazole 
Nalidixic acid  Norfloxacin Telmisartan 
Nelfinavir  Omeprazole Ticlopidine 
Norethindrone  Oral contraceptives Tolbutamide 
Norfloxacin  Paroxetine Topiramate 
Ofloxacin  Phenylbutazone Tranylcypromine 
Omeprazole  Pirfenidone Troglitazone 
Oral contraceptives  Probenicid Valdecobix 
Paroxetine  Ranitidine Voriconazole 
Perphenazine  Ritonavir
Phenacetin  Rosuvastatin
Pirfenidone  Sertraline
Propafenone  St. John's Wort
Ranitidine  Stiripentol
Rifampin  Sulfamethoxazole
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Inhibitors     
2D6  3A4-5   
Amiodarone Moclobemide Acitretin Mibefradil
Amitriptyline Nefazodone Amiodarone Miconazole
Anti-histamine Norfloxacin Amprenavir Mifepristone
Aripiprazole Norfluoxetine Anastrozole Nafimidone
Black cohosh Orphenadrine Androstenedione Nefazodone
Black pepper Paroxetine Aprepitant Nelfinavir
Buproprion Perphenazine Atazanzvir Nevirapine
Cajuput Pimozide Black cohosh Nicardipine
Celecoxib Pomegranate Bromocriptine Nifedipine
Chloroquine Propafenone Cat's claw Norethindrone
Chlorpheniramine Propoxyphene Chloramphenicol Norfloxacin
Chlorpromazine Propranolol Chloroquine Norfluoxetine
Cimetidine Quinacrine Cimetidine Omeprazole
Cinacalcet Quinidine Ciprofloxacin Oral contraceptives
Cinnamon Quinine Cisapride Oxiconazole
Citalopram Ranitidine Clarithromycin Paroxetine
Clemastine Ranolazine Clomipramine Phenobarbital
Clomipramine Risperidone Clotrimazole Pimozide
Clove Ritonavir Cyclosporine Pirfenidone
Clozapine Sandalwood Dalfopristin Posaconazole
Cocaine Sertindole Danazol Prednisone
Darifenacin Sertraline Delavirdine Primaquine
Desipramine St. John's Wort Devil's claw Propofol
Diphenhydramine Tegaserod Diltiazem Propoxyphene
Doxepin Terbinafine Dithiocarbamate Quinidine
Doxorubicin Thioridazine Doxycycline Quinine
Duloxetine Ticlopidine Echinacea Quinupristin
Escitalopram Tipranavir Efavirenz Ranitidine
Febuxostat Tripelennamine Enoxacin Ranolazine
Fluoxetine Valproic acid Erythromycin Ritonavir
Fluphenazine Venlafaxine Ethinyl estradiol Roxithromycin
Fluvoxamine Vinblastine Ezetimibe Saquinavir
Ginger Vinorelbine Fluconazole Sertindole
Ginseng Yohimbine Fluoxetine Sertraline
Goldenseal  Fluvoxamine Sparfloxacin
Halofantrine  Garlic St. John's Wort
Haloperidol  Gestodene Star fruit
Hydroxychloroquine  Ginseng Tacrolimus
Hydroxyzine  Goldenseal Tamoxifen
Imatinib  Grapefruit (juice) Telithromycin
Imipramine  Haloperidol Troglitazone
Indinavir  Imatinib Troleandomycin
Lansoprazole  Indinavir Valproic acid
Levomepromazine  Isoniazid Venlafaxine
Lomustine  Itraconazole Verapamil
Lopinavir  Ketoconazole Voriconazole
Methadone  Khella Zafirlukast
Methotrimeprazine  Lopinavir Zileuton
Methylphenidate  Methadone
Metoclopramide  Methylprednisolone
Mibefradil  Methylprednisone
Midodrine  Metronidazole
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Inducers     
1A2 2C9 2C19 2D6 3A4-5 
beta-Naphthoflavone Aprepitant Artemisinin Dexamethasone Aminoglutethimide 
Barbituates Barbituates Barbiturates Rifampin Amprenavir 
Broccoli Bosentan Carbamazepine Aprepitant 
Brussel sprouts Carbamazepine Ginko Biloba Barbiturates 
Cabbage Cyclophosphamide Lopinavir Bosentan 
Caffeine Ethanol Norethindrone Butalbital 
Carbamazepine Ginseng Orphenadrine Cannabinoids 
Cauliflower Glipizide Phenobarbital Carbamazepine 
Charbroiled meats Ifosfamide Phenytoin Cisplatin 
Clotrimazole Pentobarbital Prednisone Clotrimazole 
Esomeprazole Phenobarbital Primidone Cyclophosphamine 
Griseofulvin Phenytoin Rifabutin Dexamethasone 
Insulin Primidone Rifampin Efavirenz 
Lansoprazole Rifabutin Ritonavir Ethosuximide 
Marijuana Rifampin St John's Wort Felbamate 
Mebendazole Rifapentine Valproic acid Garlic supplements 
Methylcholanthrene Ritonavir Ginseng 
Modafinil Secobarbital Glucocorticoids 
Moricizine St John's Wort Glutethimide 
Nafcillin Valproic acid Griseofulvin 
Nicotine  Ifosfamide 
Omeprazole  Lopinavir 
Phenobarbital  Methadone 
Phenytoin  Methylprednisolone 
Primidone  Modafinil 
Psoralen  Nafcillin 
Rifampin  Nevirapine 
Ritonavir  Oxcarbazepine 
St John's Wort  Pentobarbital 
Tobacco  Phenobarbital 
  Phenylbutazone 
  Phenytoin 
  Pioglitazone 
  Prednisone 
  Primidone 
  Rifabutin 
  Rifampin 
  Rifapentine 
  Ritonavir 
  St. John's Wort 
  Sulfinpyrazone 
  Topiramate 
  Troglitazone 
  Troleandomycin 
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Nou ben ik aan de leukste, meest gelezen, maar ook moeilijkste bladzijden 
aangekomen in dit proefschrift. Hoe ik ga voorkomen dat ik niemand vergeet is 
me nu nog een raadsel, maar ik ga een poging wagen. 
 
Allereerst mijn promotoren Prof. dr. Marjolein Drent en Prof. dr. Marja van 
Dieijen-Visser en co-promotor Dr. Otto Bekers.  
Beste Marjolein, ik heb door jou hoog leren springen en diep leren nadenken. 
Hoe jij je meer dan drukke bezigheden allemaal weet te combineren en te 
arrangeren, zodat je ook nog de tijd vond om mij te begeleiden, vind ik meer 
dan knap. Ik kon altijd bij je aankloppen en heb de afgelopen jaren ontzettend 
veel geleerd, waarin jij een heel groot aandeel had.  
Beste Marja, ondanks je meer dan drukke werkzaamheden kon ik altijd bij je 
binnenlopen voor advies en hulp. Dank je voor het feit dat je me deze 
mogelijkheid hebt geboden. Ik was alleen een beetje langzaam met het 
benutten ervan, maar na ongeveer 11 jaar aan het idee wennen en wetende 
dat jij ervan overtuigd was dat ik het aankon, is het er nu dan toch van 
gekomen. 
Otto, je zult het soms toch behoorlijk moeilijk gehad hebben met al die 
‘vrouwelijke hormonen’, maar je hebt je er meer dan dapper doorheen 
geslagen. Dank je voor je kalme manier van ‘procesbewaking’ en voor de altijd 
open deur.  
 
De leden van ‘mijn’ beoordelingscommissie, Prof. dr. Schrander-Stumpel, Prof. 
dr. Bast, Prof. dr. Bruggeman, Prof. dr. Camus en Dr. Ir. Ruven, dank u allen 
dat u de tijd en moeite hebt genomen voor een grondige en kritische 
manuscriptbeoordeling.  
Je tiens également à remercier Prof. dr. Camus pour le temps consacré au 
compte rendu approfondi et critique lors de la présentation de ma thèse. J'ai 
beaucoup apprécié votre présence, faisant partie du jury. 
 
Collega’s, ik ga een aantal met naam noemen en dat betekent niet dat de rest 
minder belangrijk is, maar ik moet voor sommigen het ‘lastigvallen’ een beetje 
meer goedmaken. Allereerst Petra: jij zat en zit nog steeds heel erg ‘in de 
gevarenzone’, dank je dat je me af en toe met humor weer ‘op de rit’ bracht. 
Voor het lezen en weer lezen van stukjes en zeker ook voor al het werk wat je 
me uit handen hebt genomen tijdens de afgelopen periode.  
Dan de collega’s in een straal van minder dan 10 meter, de mensen van ‘Lab D 
& co’. Beste Riet, Marlies, Gitte, Ludwine, Patricia, Rianne, Marie-Claire, Ellen, 
Kristel en Vincent: jullie hebben hopelijk niet al te veel geleden, dank jullie voor 
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het ‘meesleuren’ naar de koffie, het luisterend oor, de gezelligheid en ‘het komt 
goed’ op het juiste moment.  
Andere collega’s zaten er dan wel wat verder vanaf, maar toch is dit een mooi 
moment om jullie allemaal te bedanken voor de vele jaren van heel prettige 
samenwerking. Dit geldt trouwens niet alleen voor mijn directe collega’s van 
LCHE maar ook de mensen van LHLE & BTD, MMB en de GLI, die aan mij 
blootgesteld worden. Het feit dat ik na al die jaren, zei het met veel moeite, ’s 
morgens mijn bed uitkom om uiteindelijk toch met plezier naar mijn werk te 
gaan, zegt genoeg.  
 
Mijn medepromovendi Alma, Bianca, Judith en Leo: dank jullie voor het feit dat 
ik er ondanks de op een aantal fronten aanwezige verschillen toch bij hoorde 
en dat er af en toe geklaagd (die vervelende tijdschriften met hun rare 
voorwaarden), gebrainstormd (zou je dat niet zus of zo kunnen doen) en 
vooral gelachen kon worden.  
Alma, Bianca en Leo ik wens jullie heel veel succes bij het afronden van jullie 
promoties. Dat gaat zeker weten meer dan goed komen.  
Beste Judith, jij bent ons al voorgegaan met een mooie promotie, nog even en 
Nederland is een Klinisch Chemicus rijker. Dank je, ook voor je tips en adviezen 
wat betreft de ‘P’. 
Ook de onderzoekers en klinisch-chemici in opleiding die ik in de loop van de 
jaren de revue heb zien passeren of er momenteel voor ‘gaan’: Snjezana, Jart, 
Etienne, Jaap, Lenneke en Steven, dank jullie voor de fijne samenwerking.  
 
Dr. Patty Nelemans (J-R...), beste Patty, dank je voor al je hulp niet alleen bij 
het op een rijtje zetten en houden van de nullen en enen. Ook al zie ik ze soms 
nog steeds ‘vliegen’, door jouw deskundige adviezen gelukkig niet meer in de 
artikelen.  
 
Prof. dr. Marcel Tilanus en Dr. Christien Voorter enorm bedankt voor de heel 
prettige samenwerking en ondersteuning tijdens mijn onderzoek.  
Verder Eva, mijn aanspreekpunt op het lab weefseltypering, Fausto en alle 
anderen die ik extra werk heb bezorgd, enorm bedankt voor jullie hulp. 
 
Prof. dr. Cees Neef, Dr. Petra Kuijpers, Dr. Ger Koek en Dr. Guido Haenen, 
medeleden van de ‘CYP werkgroep’. Dank jullie voor de vele stimulerende en 
leerzame bijeenkomsten en hulp bij de totstandkoming van dit proefschrift. 
 
Dr. Marinus Kroonenburgh en Dr. Stefan Vöö, van de ‘Pettenclub’, Rémy 
Mostard (Do-Re-Mi, Dr. to be) en Dr. Roel Erckens, ‘het is maar een bolletje’. 
Dank jullie voor de ontzettend fijne en constructieve samenwerking, ik heb er 
al heel wat van opgestoken en ik verheug me op toekomstige ‘projecten’. 
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Dr. Kitty Linssen, kamergenote tijdens mijn eerste congres, dank je voor je 
steun en gezelligheid tijdens mijn ‘eerste grote optreden’. En zeker ook voor je 
hulp bij een deel van het onderzoek in dit proefschrift. 
 
Dr. Johan de Vries en Dr. Robert op den Buijsch, medeschuldig aan het feit dat 
dit boekje er nu is. Johan door me te begeleiden bij mijn eerste stappen op het 
pad van de DNA analyse en Robert, door me een flinke ‘duw’ te geven en me 
te laten beloven dat ik ‘ermee door zou gaan’. Beste Robert, ook bedankt voor 
het feit dat ik een promotie al eens van heel dichtbij heb mogen meemaken 
doordat ik het genoegen had om bij jou paranimf te mogen zijn. 
 
Mijn paranimfen Marianne Vrijsen en Mr. Ramona Batta: geweldig om te weten 
dat jullie dit samen met mij willen ‘doorstaan’.  
Leef Ramoon, als rechtgeaarde deurwaarder legde jij meteen beslag op deze 
positie en dat was al één zorg minder.  
Lieve Marianne (Sch...), als langjarige vriendin en collega kan jij het in geval 
van nood zo van mij overnemen (geintje), dat is een pak van mijn hart. 
 
Marjon Elfferich en Tiny Wouters, dank zij jullie kom ik goed beslagen ten ijs.  
Marjon, ik hoop dat al het ‘koken en klaarstomen’ je niet al te veel ‘jaren van je 
leven’ heeft gekost. Naast heel nuttig was het ook altijd heel gezellig, waarvoor 
dank. 
Tiny, dank zij jou ziet het eindresultaat er perfect uit.  
 
Alle vrienden/vriendinnen die er vooral het afgelopen jaar voor hebben gezorgd 
dat ik niet helemaal aan mijn computer vastgroeide. Dank jullie voor de 
uitnodigingen, gezelligheid, afleiding en vriendschap. 
 
En tenslotte maar zeker niet in de laatste plaats mijn ouders (Ha T...). Zonder 
jullie onvoorwaardelijke steun en stimulering zonder enige vorm van dwang, 
was ik nooit zover gekomen. Dit hebben we toch maar mooi samen voor elkaar 
gekregen. 
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